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Abstract 
There is a clinical need for effective alternative skin replacements to autografts, allografts and 
xenografts.  In this thesis a bi-layer skin graft was developed by encapsulation of fibroblasts 
in calcium-alginate hydrogel and culture of keratinocytes on the surface.  Initially, the use of 
5% and 2% w/v alginate hydrogels were investigated.  Both scaffolds maintained fibroblast 
viability for at least 150 days encapsulation and caused reversible mitotic and catabolic 
inhibition, as assessed by fluorescent staining, immunochemistry and the thiazolyl blue assay.  
Sustained expression of angiogenic factors such as vascular endothelial growth factor, 
interleukin 6 and nerve growth factor were seen by fibroblasts encapsulated in both scaffolds, 
by reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked 
immunosorbent assay.  Histological staining demonstrated that following degradation of the 
scaffolds, fibroblasts secreted ECM to facilitate dermal repair.  Comparison of degradation of 
the scaffolds over time by measuring release of calcium, and changes in rheological 
properties, morphology and mass, indicated that 5% w/v alginate hydrogel degraded more 
slowly and was preferable to 2% w/v alginate hydrogel.  Fibroblasts encapsulated in 5% w/v 
alginate hydrogel were shown to express keratinocyte growth factor by RT-PCR, to support 
keratinocyte proliferation and differentiation, and keratinocytes cultured on the 5% w/v 
alginate hydrogel surface were seen to form multi-layered epidermal structures by histology, 
immunostaining and RT-PCR.    
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1. Introduction 
There has been a consistent increase in the mean life expectancy of the population of the 
developed world over the past century.  Healthy life expectancy, however, has not increased 
concurrently.  As a result we are living a larger proportion of our lives in poor health 
(Christensen et al. 2009) and there is a growing demand for the replacement of diseased and 
damaged tissues (Langer & Vacanti 1993) including skin (Falanga 1993).  Skin can be lost 
due to infection, trauma or disease (MacNeil 2007). Effective wound healing is essential to 
enable maintenance of homeostasis and to prevent penetration of infectious agents (Elias 
2007; Menon & Kligman 2009).  Skin can undergo spontaneous repair following damage, 
provided the affected area is less than 4cm in diameter (Herndon et al. 1989) and there is no 
underlying genetic abnormality or disease affecting wound healing (MacNeil 2007).  In cases 
where wounds do not spontaneously heal, surgical replacement of the skin must be 
performed.   
 
While autografts remain the ‗gold standard‘ in skin replacement (Ben-Bassat et al. 2001), 
alternative treatments are necessary where there is inadequate donor site availability 
(Gajiwala & Gajiwala 2004) or underlying conditions affecting healing of secondary wounds 
produced by harvesting of autografts.  Furthermore, tissue harvest and transplantation are 
associated with undesirable consequences such as the risk and expense of surgery, additional 
infection at the secondary wound site and rejection of the transplanted tissue (Atiyeh et al. 
2005; Clark et al. 2007; Sahota et al. 2004).  Alternatively, wound coverage can be provided 
by the use of allografts or xenografts, but these grafts are associated with disease 
transmission and immune rejection, making them only suitable as a temporary wound 
covering (Leon-Villapalos et al. 2010; Sahota et al. 2004).  For this reason, there is a need for 
synthetic alternatives.   
 
Skin is a complex tissue consisting of two main anatomically distinct regions known as the 
epidermis and the dermis.  Following the establishments for the culkture of keratiocytes in 
vitro (Rheinwald & Green 1975a), the first tissue engineered (TE) skin consisted of a 
cultured epithelial autograft (CEA), with no dermal component which was developed in 1975 
(Rheinwald & Green 1975b), and since then a number of CEAs have become commercially 
available.  CEAs are designed to provide epidermal replacement to facilitate restoration of the 
barrier function of skin to prevent penetration of foreign materials and prevent heat and water 
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loss from the body (Gibbs & Ponec 2000; Liu et al 2007). CEAs have, however, been 
associated with various problems due to lack of a dermal component, including lack of take/ 
blistering, fragility, scarring and extensive wound contraction (Meana et al. 1998b).  This has 
lead to the development of dermal grafts, which can be applied in conjunction with a CEA, 
and bi-layer composite grafts with both a dermal and epidermal components.  Restoration of 
the dermal layer is essential (Caissie et al. 2006; Metcalfe & Ferguson 2007) since the dermis 
provides skin with mechanical integrity (Metcalfe & Ferguson 2007) and facilitates 
adherence of the epidermis to the body surface (Rennekampff et al. 1997).    
 
At present, however, there are no commercially available composite grafts consisting of 
dermal and epidermal components together in one grafting stage that can provide permanent 
autologous skin replacement for full-thickness wounds (Ikada 2006).  Furthermore, almost all 
the commercially available grafts with a dermal component include animal or human derived 
products such as collagen, glycosaminoglycans (GAGs) or deepidermalised dermis (DED), 
which can result in immunological responses and disease transmission.  Alternative scaffold 
materials, from non-animal sources should be sought (MacNeil 2007). 
 
In order that successful healing of full thickness wounds is achieved, it has been shown that 
the presence of both keratinocytes and fibroblasts is beneficial (Maas-Szabowski et al. 
2000;Witte & Kao 2005).  The aim of this project was to develop a composite bi-layer graft 
using a fibroblast/ keratinocyte co-culture with an alginate hydrogel scaffold.  Alginate is a 
polysaccharide derived from algae which has shown great promise within the field of 
regenerative medicine, including the immuno-isolation of mammalian cells for the sustained 
release of therapeutic molecules (Bazou et al. 2008; Calafiore et al. 2006; Gao et al. 2005; 
Jen  et a.l 1996; Soon-Shiong 1999), as a wound dressing (Balakrishnan et al. 2006; Boateng 
et al. 2008; Chiu et al. 2008; Lansdown 2002b), and also within tissue engineering (Augst et 
al 2006).   Alginate is US Food and Drug Administration (FDA) approved for use in food and 
for many types of medical applications including use as a wound dressing and haemostatic 
agent.    
 
In this thesis, the use of alginate hydrogel as a scaffold for the localized delivery of a 
fibroblast/ keratinocyte co-culture to engineer a skin bi-layer in vivo has been investigated.  
The construct should be delivered to the wound site and become integrated into the host 
tissue (Langer & Vacanti 1993).  The potential of the tissue engineered bi-layer to become 
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successful integrated, including the regeneration of the dermal tissue by fibroblast 
proliferation, extracellular matrix deposition and vascularisation, and to facilitate epidermal 
regeneration was investigated.   
 
In order that epidermal and dermal replacement is achieved, the scaffold should maintain the 
viability of encapsulated fibroblasts for extended periods of time.  In order that the fibroblasts 
in the dermal layer remain viable, the metabolic demand of the encapsulated fibroblasts in the 
avascular graft should be low, and the fibroblasts should secrete angiogenic factors such as 
vascular endothelial growth factor (VEGF), nerve growth factor (NGF) and interleukin-6 (IL-
6) to promote vascular in-growth.  To achieve epidermal replacement the fibroblasts in the 
dermal layer should be mitotically inhibited so that they do not over grow the keratinocytes in 
the co-culture.    The fibroblasts should also secrete factors such as keratinocyte growth factor 
(KGF) to support the proliferation and differentiation of keratinocytes in order that they can 
produce a stratified epidermal layer. The scaffold should also degrade in a controlled manner 
in order that cells remain immobilized at the site of implantation, where they can secrete 
ECM to replace the degrading scaffold material to achieve dermal regeneration.   
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2. Skin structure, functions and wounds 
Skin is a complex structure consisting of multiple layer and cell types, which performs a 
number of functions.  Skin wounds can occur as a result of disease, trauma, infection or 
injury.  In order that the structure and function of skin is restored, it is essential that 
successful wound healing occurs.  In this chapter, the structure and functions of skin are 
summarised, along with causes of skin wounds and the wound healing cascade. 
 
2.1 Skin structure 
The skin is a physiologically and anatomically specialised boundary lamina essential to life.  
The skin typically occupies almost two square metres of surface area, and accounts for 8% of 
the body‘s mass, making it the largest organ in the body.  The thickness of skin varies widely 
depending on the part of the body in which it is found.  For example, on the eyelids it is less 
than 0.5mm thick, whereas on the middle of the upper back it is more than 5mm thick, but, 
characteristically it is 1-2mm thick (Gray 1987; Carola et al 1990).  
 
Skin is structurally complex and highly specialised, consisting of two intimately associated 
main layers called the epidermis, which is the outermost layer of keratinised squamous 
epithelial tissue, and the dermis, or corium, a thicker layer of connective tissue beneath the 
epidermis. Certain appendages to skin such as hair follicles and sweat glands span both the 
epidermis and the dermis, and penetrate into the subcutaneous adipose tissue below the 
dermis (Alberts et al 2002; Carola et al. 1990).  The general architecture of skin is illustrated 
in Figure 2.1.  
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Figure 2.1: Illustration showing the main components of skin (MacNeil 2007).  The skin 
comprises of two main layers called the epidermis and the dermis, which are separated 
by a basement membrane.  Below the dermis there is a subcutaneous fatty layer. 
 
2.1.1. Variation in Skin Structure 
The appearance and function of specific areas of the integuement can vary due to variations 
in the activity, frequency and types of glands, or size, distribution and shape of hairs and their 
follicles. In addition, the skin may vary due to local variations in thickness, mechanical 
strength, degree of keratinisation, pigmentation or vascularity.  The appearance and structure 
of skin is not only due to genetics, but may also be affected by normal hormonal changes, 
age, state of health and other factors (Gray 1987).   
 
Skin can be classified either as thin, hairy (hirsute) skin, which constitutes the majority of the 
body‘s surface, or, thick, hairless (glabrous) skin, which covers the palms, soles and flexor 
surfaces of the digits (Gray 1987). 
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2.1.2. Epidermis 
The outermost layer of skin, called the epidermis composes of keratinised stratified squamus 
epithelium.  It contains no blood vessels, and as a result it is usually possible to rub off dead 
cells of the epidermis without bleeding (Carola et al. 1990). The epidermis comprises mainly 
of keratinocytes, but also contains other cell types such as Langerhans cells and melanocytes 
(Alberts et al. 2002).  Human epidermis thickness varies in thickness from 50µm on the 
eyelids to 1.5mm on the palms and soles (So et al. 1998). 
 
2.1.2.1. Epidermal appendages 
The epidermis and epidermal appendages together are known as the integument.  Certain 
appendages to skin such as hairs, hair follicles, glands and nails span both the epidermis and 
the dermis (Alberts et al. 2002).  These structures are formed by the in-growth or other 
modifications of the epidermis (Gray 1987).   
 
2.1.2.2. Epidermal strata 
In epidermal tissue there is a continuous replacement of keratinocytes at the surface from the 
base layer of mitotic cells (Fuchs 2007).  The rate of replacement is typically between 45 to 
75 days, although this can vary due to body position, epidermal thickness, and degree of skin 
abrasion, time of day, hormonal changes, age and many other factors.  In particular, certain 
pathological conditions may alter the rate of replacement as, for example, in psoriasis where 
the rate is as little as 8 days, and thus the keratinocytes do not fully differentiate before 
reaching the surface (Gray 1987).  
 
As keratinocyte stem cells differentiate and move up through the epidermal strata they 
undergo progressive changes in shape and content, eventually transforming from polygonal 
living cells to dead, flattened squames full of keratin. Traditionally, the term epidermal 
keratinisation applies to the final stage of keratinocyte differentiation in which cells are 
converted to tough, cornified squames.  Cells of the epidermis, however, have a varied and 
changeable pattern of keratin filament chemistry which changes as keratinocytes mature.  
Keratins of the basal stem cells are different to those of young keatinocytes and it is only in 
the upper layers of the stratum spinulosum that the final types of keratin filament begin to 
emerge.  The classic process of epidermal keratinisation, therefore, only describes the final 
stages of maturation in which dead squames fill with keratin and other proteins such as 
involucrin are formed (Gray 1987).  
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The epidermis is usually divided into a number of strata which each represent a different 
stage in keratinocyte maturation.  In glabrous skin, the epidermis is thick and comprises of 
five layers or strata.  The strata from superficial to deep are the stratum corneum, stratum 
lucidum, stratum granulosum (granular layer), stratum spinosum (spinous layer) and stratum 
basale.  In hairy skin, however, the stratum lucidum is absent (Carola et al. 1990), and only 
four strata are found as illustrated in Figure 2.2.               
 
Figure 2.2:  General architecture of the epidermis of hairy skin (Fuchs 2008) showing 
the different strata representing keratinocytes at different stages of differentiation.  The 
basal layer (stratum basal) lies upon the basement membrane, and above the basal layer 
there are the spinous and granular layers (stratum spinulosum and stratum 
granulosum, respectively) which together are known as the suprabasal layers.  In 
glabrous skin a stratum lucidum is present above the granular layer.  Finally, the 
stratum corneum forms the surface of the epidermis. 
 
2.1.2.2.1. Stratum corneum 
The stratum corneum is the horny, cornified layer of the epidermis, which as previously 
mentioned, is the outermost layer of epidermal tissue.  It is a flat, relatively thick layer of 
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dead cells arranged in parallel rows.  The cells in the corneum are constantly shed through 
normal abrasion, and are replaced by new cells formed by cell division and pushed up from 
the germinative layers below, which take on the function of the cells they replace (Carola et 
al. 1990).  Depending on the location of the skin, this layer can vary from only a few cells 
thick, as in the scalp, to more than 50 cells thick.  The cells are compact and contain high 
concentrations of keratin filaments each about 8-10nm thick, often lying parallel and 8nm 
apart, and embedded in another protein, filaggrin.  Disulphide bond formation appears to 
stabilize this protein complex.  A protein envelope, consisting of a number of cross-liked, 
chemically inert proteins including keratolinin and involucrin coats the internal surface of the 
cell membrane of the cells in this layer (Fuchs 2008; Gray 1987). 
 
2.1.2.2.2. Stratum lucidum 
The stratum lucidum consists of flat, translucent layers of dead cells that contain the protein 
eleidin.  This protein is thought to be a transitional substance between the soft keratin found 
in the corneum, and the precursor of soft keratin, keratohyaline, of the stratum granulosum.  
The lucidum only appears in glabrous skin, where it acts as a protective shield against the 
ultraviolet rays of the sun, thus preventing sunburn to these areas (Carola et al. 1990).   
 
2.1.2.2.3. Stratum granulosum 
The stratum granulosum is usually two to four cells thick and lies just below the lucidum.  
The cells of this layer contain keratohyaline crystals.  The layer initiates the process of 
keratinisation, associated with the dying process of cells (Carola et al. 1990). 
 
2.1.2.2.4. Stratum spinosum 
The stratum spinosum is composed of several layers of mature keratinocytes known as 
polyhedral cells that have delicate ‗spines‘ protruding from their surfaces, thus these cells are 
sometimes called ―prickle cells‖.  The spine-like projections interlock with each other helping 
to give support to this binding layer.  Cells of the spinosum layer grow and divide and new 
cells that are formed here are pushed to the surface to replace the cornified cells of the 
stratum cornium (Carola et al.1990). 
 
2.1.2.2.5. Stratum basale 
The stratum basale rests on the basement membrane next to the dermis, and usually includes 
only a single layer of cells of columnar or cuboid appearance.  Like the stratum spinosa, it too 
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is capable of undergoing cell division to produce new cells to replace those being sheared off 
in the exposed corneum layer (Carola et al. 1990).  A population of stem cells found in this 
layer divide and differentiate, then move up and apart through the stratum spinulosum‘s 
lower region before ceasing mitotic activity (Fuchs 2009).  Structurally the cells of the 
stratum basale are heterologous as they comprise both stem cells and keratinocytes in various 
stages of early maturation, as well as non-keratinocytes, such as melanocytes and Langerhans 
cells (Gray 1987).   
 
2.1.3. Basement membrane 
Under physiological conditions the epithelium is connected to the basement membrane, a 
specialised sheet-like ECM that forms an interface to mesenchymal tissues.  Epithelial cells 
require adherence to a matrix for regular growth (Eckhart et al. 2003; Inoue et al. 2005). 
 
The basement membrane of the epidermis consists of a basal lamina, about 80nm thick, to 
which all the cells of the stratum basale are attached, and on the dermal side, a reticular 
lamina which grades into the connective tissue of the dermis.  The basal lamina of the skin 
consists of a lamina lucida lying close to the epidermal cell bases, and a deeper lamina densa.  
The lamina lucida is occupied by various macromolecules which gives this layer a finely 
granular or filamentous appearance.  These macromolecules include heparan sulphate 
proteoglycan, laminin and a protein which is unique to skin called pemphigoid antigen.  The 
lamina densa includes a network of type IV collagen molecules, a glycoprotein called 
epidermolysis bullosa acquisita antigen, fibronectin and various proteoglycans.  Whilst the 
lamina lucida is strongly adherent to the overlying epidermal cell membrane, the meshwork 
of the lamina densa may limit the passage of macromolecules from the dermis to the 
epidermis.  The basal lamina may also suppress the differentiation of keratinocytes in the 
stratum basale and regulate other cellular activities in the epidermis.  A major function of the 
whole basement membrane is to mechanically stabilize the epidermis (Gray 1987).  
 
2.1.4. Dermis 
The dermis lies beneath the epidermis and constitutes the majority of skin.  The cellular 
components of dermis include fibroblasts, endothelial cells, smooth muscle cells, and mast 
cells, but the bulk of dermis is made of extracellular matrix (ECM) (Supp & Boyce 2005b).  
The ECM consists of irregular, moderately dense, soft connective tissue consisting of an 
interwoven collagenous meshwork, mainly comprising of collagen type I, containing various 
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amounts of elastin fibres, proteoglycans, fibronectin, blood vessels, lymphatic vessels and 
nerves (Gray 1987).   
 
The dermis comprises of two ill-defined layers, which are the thin papillary or subepithelial 
layer, which lies directly below the epidemis, and the deeper, thicker layer, called the 
reticular layer.  Overall, the dermis is highly flexible and reliant, but when it is stretched 
beyond its limits, collagenous and elastic fibres can be torn resulting in ―stretch marks‖ from 
the repaired scar tissue (Carola et al. 1990). 
 
2.1.4.1. Papillary layer 
The papillary layer consists of fairly loosely packed connective tissue, with thin bundles of 
collagenous fibres.  Papillae (tiny, finger-like projections) join this layer to the epidermis, 
through their indigitation with recesses in the epidermis to form dermo-epidermal junctions at 
their interfaces. Most of these papillae contain loops of capillaries that nourish the epidermis, 
and others have special nerve endings called corpuscles of touch (Meissner‘s corpuscles), that 
serve as sensitive touch receptors.  In the glabrous skin, double rows of papillae produce 
ridges that help to keep the skin from tearing and improve the grip on surfaces.  The 
overlying epidermis follows the corrugated contours of the underlying dermis, and therefore, 
the double rows of papillae produces distinct fingerprint patterns on the finger pads (Carola et 
al. 1990). 
 
The layer is specialised to provide mechanical anchorage, metabolic support and trophic 
maintenance to the overlying epidermal tissue.  Another function of the layer is to house a 
rich network of sensory nerve endings and blood vessels (Gray 1987).  
 
2.1.4.2. Reticular layer 
This is a netlike layer which is made up of dense connective tissue, with coarse collagenous 
fibres and fibre bundles that criss-cross to form a strong and elastic network. The collagenous 
fibres appear to be randomly organised, however, they are arranged so that different 
directional patterns can be found in each area of the body.  The resulting lines of tension over 
the body are known as cleavage or Langer‘s lines.  The deepest region of the reticular layer 
contains smooth muscle fibres, especially in the genital and nipple area and at the base of hair 
follicles (Carola et al. 1990) 
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2.2. Skin functions 
The skin performs a wide range of protective, perceptive, and regulatory functions. In 
addition, skin also has good frictional properties, assisting locomotion and manipulation by 
its texture. Skin‘s role in providing a protective barrier is, however, most critical for survival. 
Within limits, the skin is a most effective barrier against microbial invasion and dehydration, 
and also against mechanical, chemical, osmotic, thermal and photic damage (Gray 1987; 
Carola et al. 2005).    
 
2.2.1. Protection from water loss and infection 
The skin acts as a stretchable protective barrier that prevents the entry of harmful 
microorganisms and foreign material into the body.  It also functions to prevent water loss 
from the body.  These functions are a result of the layered sheets of epithelial tissue and a 
nearly waterproof layer of soft keratin in the stratum corneum (Gray 1987; Presland 2009).  
The skin is, however, not just a passive barrier, but actively defends the body against disease.  
This is a result of Langerhans cells present in skin (Menon & Kligman 2009).   
 
Langerhans cells can be recognised easily by the presence of Langerhans bodies, which are 
elongated vacuoles.  These cells are regularly scattered throughout the epidermis and are 
derived from bone marrow cells and continuously renewed.  The cell bodies of the 
Langerhans cells are situated in the base of the stratum spinulosum, whilst their extensively 
branched dendrites sit between the surrounding cells.  Langerhans cells have many features in 
common with the connective tissue macrophages, including that they are both derived from 
bone marrow cells and are both thought to be involved in cellular defence, particularly in 
detecting, binding and presenting antigens to T-cells as part of their immune mechanism in 
the skin.  Such a system appears to be important in cell-mediated immunity to epidermal viral 
infections, in the elimination of epidermal cancers and many other defensive responses 
(Asahina & Tamaki 2006).  Langerhans cells may also play a role in the regulation of cell 
division, which is suggested by their closes relation with mitotic epidermal basal cells (Carola 
et al. 1990).  
 
2.2.2. Temperature regulation and excretion 
The skin can act as a sheet of insulation to retain body heat.  To assist in the cooling of the 
body, dense beds of blood vessels in the dermis dilate to allow heat loss through increased 
radiation of heat from the blood.  To assist in heat retention, these vessels can constrict to 
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reduce radiation (Gray 1987; Carola et al. 1990). Furthermore, since the skin is slightly 
permeable due to the presence of pores, which are the endings of ducts in the skins surface, 
skin can also regulate body temperature through the opening and closing of pores and 
perspiration.  These pores allow both the entry of some chemicals and the escape of sweat 
from sweat glands.  The excretion of sweat and its subsequent evaporation causes cooling of 
the body.  Perspiration also allows the excretion of small amounts of waste products such as 
urea and up to 1 gram of waste nitrogen every hour (Carola et al. 1990).  
 
2.2.3. Synthesis 
Although most of the UV rays are screened out by the skin, it is necessary for the skin to 
permit the entry of a small amount, which are used to convert the chemical 7-
dehydrocholesterol, in the skin, to viamin D3 or cholecalciferol.  Vitamin D is essential for 
the proper growth of bones and teeth. A lack of UV and thus, vitamin D, impairs the 
absorption of calcium from the intestine into the blood stream (Carola et al. 1990). 
 
2.2.4. Sensory reception and transduction 
Sensory detection is a critical function of skin (Clark et al, 2007).  The skin contains sensory 
receptors for heat, pain, cold, touch, and pressure, making it an important sensory organ.  The 
many nerve endings that are present keep us responsive to environmental dangers, and also 
allow us to make adjustments to maintain homeostasis (Carola et al. 1990). 
 
The exact mechanisms of sensory transduction are as yet poorly understood, but some cells 
involved or thought to be involved in sensory perception have been identified.  Merkel cells 
play a role in sensory transduction.  They are only present in glabrous skin, where they lie at 
the base of the epidermis, usually protruding from there into the dermis.  They form the 
terminal attachment of certain mechanoreceptive cutaneous nerve endings.  Merkel cells are 
elliptical in shape, and from their apical surface several cytoplasmic spikes arise, which insert 
among the epidermal cells.   Hair cells are also known to be involved in cutaneous sense and, 
keratinocytes are thought to be involved in detection of physical and chemical stimuli 
(Lumpkin & Caterina 2007). 
 
2.2.5. Protection form ultraviolet (UV) radiation 
UV protection is provided by melanocytes which produce a dark pigment called melanin.  
Melanocytes have rounded cell bodies which are usually located in the deepest part of the 
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stratum basale in contact with the basal lamina, where they extend their long extensively 
branched dendrites under and around neighbouring cells reaching deep into the stratum 
spinulosum.  Melanin is found in all areas of the skin, but is more concentrated in certain 
areas such as the armpits and external genitals, and significantly less concentrated in the 
palms and soles (Carola et al. 1990).  
 
Melanin is packaged ino melanosomes and delivered to keratinocytes in the basal layer.  
Melanosomes are oblong, membrane-bound, rounded bodies which contain the dark pigment, 
eumelanin.  There are also more spherical bodies called phaeomelanosomes which contain a 
reddish yellow pigment phaeomelanin, and are mostly found in reddish hair.  The shape and 
form of these bodies changes with melanosome maturation Pigment is constantly lost from 
the epithelium as the basal keratinocytes divide and migrate, and are shed from the skin‘s 
surface, so a continuous production of melanosomes is needed (Lin & Fisher 2007).  
 
If too much UV light penetrates the skin, due to inadequate protection, then the radiation may 
cause acute damage and cell death in epidermal cells, as in sunburn.  Alternatively, after 
chronic exposure, epidermal neoplasms may occur because of damage to the basal cell DNA 
resulting in squamous cell carcinoma.  This occurs because UVB rays can kill some of skin 
cells and damage others, so that normal secretions are temporarily stopped, increasing the 
risk of skin cancer and mutations by affecting the genetic material of cells and cause the 
immune system to falter.  UV rays can also damage enzymes and cell membranes and 
interfere with cell metabolism.  If tissue destruction is extensive, then toxic waste products 
and other resulting debris can enter the blood stream and produce a fever, associated with sun 
stroke (Carola et al. 1990). 
 
The main function of melanin is to screen the harmful UV rays to protect the nucleus and its 
genetic material in particular.   Extra protection is provided when the melanin is darkened by 
the sun and transferred to the outer layers of the skin, thus causing these layers to become less 
sensitive to the sun (Carola et al. 1990). 
 
Due to genetic differences, darker races have slightly more melanocytes but the differences in 
the appearance of skin between races are generally reflected by the number and types of 
melanosomes present. In darker races, more melanin is produced and the melanin is 
distributed more widely beyond the stratum basale, into the higher strata of the epidermisn.  
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Various hormones can alter melanization, including melanocyte stimulating homone (MSH), 
oestrogens and progesterones as well as age and various pathological conditions (Lin & 
Fisher 2007; Carola et al. 1990). 
 
2.3. Clinical need for skin replacement 
Keratinocytes and fibroblasts present in skin can repair minor wounds caused by trauma or 
surgery in healthy individuals.  If the wound is, however, too large to allow spontaneous 
healing, or there is an underlying condition which prevents adequate healing, skin graft 
materials may be used to restore functional integrity and prevent fibrous tissue in-growth. 
The sections below describe the diseases, both congenital and acquired, and traumas which 
can necessitate a skin graft.   
 
2.3.1. Diseases and congenital skin disorders 
A number of diseases exist whereby treatment requires the excision of affected skin or can 
irreversibly damage skin so that without skin grafting the likelihood of chronic wounds is 
markedly increased. Some frequently encountered diseases are summarised in this section. 
 
2.3.1.1. Necrolysis 
Toxic Epidermal Necrosis (TEN or Lyell‘s syndrome) and Stevens Johnson Syndrome (SJS) 
are rare acute dermatological diseases characterised by epidermal necrosis and mucal 
erosions (Lyell 1956), with extensive loss of contact between the epidermis and dermis and 
massive keratinocyte apoptosis (Abe et al. 2003; Paul et al. 1996).  More than 10% of the 
total skin can be lost in TEN, and more than 30% in SJS.  The conditions are thought to result 
mainly from severe adverse drug reaction or, in some cases, bacterial infection (Nassif et al. 
2004). 
 
2.3.1.2.Graft-Versus-Host Disease (GVHD) 
GVHD can develop as a result of allogeneic bone marrow transplantation as a consequence of 
tissue damage induced by cytotoxic T-cells (Lippens et al. 2009).  The skin is one of the main 
organs in which the condition manifests, and large areas of skin can be lost due to apoptosis 
of keratinocytes (Gilliam et al. 1996). 
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2.3.1.3.Pemphigus diseases 
Pemphigus Diseases are autoimmune blistering diseases characterised by the presence of 
autoantibodies against structural proteins of the intracellular junctions.  An example of a 
pemphigus disease is Pemphigus Vulgaris (Lippens et al. 2009). This excessive blistering can 
result in significant skin loss. 
 
2.3.1.4. Giant congenital epidermal melanocytic nevi 
Giant congenital epidermal melanocytic nevi can cover more than 50% total body surface 
area (TBSA) and can significantly increase the patient‘s lifetime risk of developing a 
melanoma if they are left untreated.  Melanoma can develop because some of these nevi have 
the potential to become malignant, particularly if they are exposed to stresses such as 
excessive abrasion or excessive sunlight (Arneja & Gosain 2009).  It is, therefore, often 
considered desirable to remove the affected skin, thus resulting in the need for a graft. 
 
2.3.1.5. Skin cancer  
Epidermal tumours are divided into melanoma and non-melanoma skin cancers, resulting 
from over-growth of melanocytes or keratinocytes respectively.  The most common skin 
cancers are basal cell carcinomas, which are non-melanoma skin cancers resulting from the 
overgrowth of basal keratinocytes due to acquisition of mutations.  The treatment of tumours 
associated with skin usually involves complete resection of the affected tissue. Often, this 
procedure results in the formation of a wound that must be filled by a grafting material 
(Lippens et al. 2009). 
 
2.3.1.6. Epidermal Bullosa (EB) 
EB is a group of congenital genetic disorders characterised by erosions and blistering of the 
epidermis and can result in significant skin loss (Nagy & McGrath 2010; Supp & Boyce 
2005). 
 
2.3.2. Trauma 
Trauma as a result of road-traffic accidents, chemical and thermal burns, or inter-personal 
violence contributes massively to hospital admissions in the UK, and can all result in 
significant skin loss.  The most common cause of skin loss, however, is thermal injury.  
Burns can be classified as first, second or third degree, and these classifications are 
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summarised in Table 2.1.  Where burns are third degree, they require a graft (Atiyeh et al. 
2005; Boucard et al. 2007; Mann & Heimbach 1996; Wood et al. 2006).   
 
Table 2.1: Classification of burns. 
Classification Description 
First-degree (superficial) burns Burns affect only the epidermis, or outer layer of 
skin. The burn site is red, painful, dry, and with 
no blisters. Mild sunburn is an example. Long-
term tissue damage is rare and usually consists 
of an increase or decrease in the skin colour. 
Second-degree (partial thickness) burns Second-degree burns involve the epidermis and 
part of the dermis layer of skin. The burn site 
appears red, blistered, and may be swollen and 
painful. 
Third-degree (full thickness) burns Burns destroy the epidermis and dermis. Third-
degree burns may also damage the underlying 
bones, muscles, and tendons. The burn site 
appears white or charred. There is no sensation 
in the area since the nerve endings are 
destroyed. 
 
2.3.3. Chronic wounds 
Chronic wounds do not usually affect a large surface area but are still of high medical and 
economic impact because they have a high incidence in the general population in the 
developed world, and generally require grafting to promote healing.  Chronic wounds are 
characterised by excessive and prolonged inflammation and a lack of progression to re-
epithelialisation as a result of poor vascularisation of the affected area.  They usually occur 
due to diabetes, pressure and venus stasis (Bannasch et al. 2000; Clark et al. 2007; Supp & 
Boyce 2005b).  Since chronic wounds do not heal following cleaning and dressing of the 
wounds, and their incidence is so much higher in the developed world compared with burn 
injuries, in practise, these wounds are more likely to be treated with TE skin than burn 
injuries (Kirsner et al. 2009). 
 
2.4. Wound healing 
Wound healing is a complex process involving clot formation, inflammation, re-
epthelialisation and tissue remodelling (Martin 1997).  The main stages of wound healing are 
summarised in Table 2.2. 
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Table 2.2.  The main stages in the wound healing cascade. 
Stage Details 
Fibrin Clot Formation 
 
Day 0 
Fibrinogen in blood released from damaged blood vessels is cleaved to fibrin by 
thrombin and a clot forms (Martin 1997).  Platelets are embedded in the fibrin mesh, 
which start to degranulate to release growth factors and cytokines (Babensee et al. 
1998). 
Inflammation 
 
Day 0+ 
Neutrophils and monocytes are attracted to the wound by chemoattractants.  
Neutrophils serve to remove foreign material and bacteria from the wound and 
express pro-inflammatory cytokines which activate local keratinocytes and 
fibroblasts.  Monocytes become activated macrophages and phagocytose any 
contaminating microorganisms, cell/ matrix debris and necrotic tissue and express 
more growth factors and cytokines (Babensee et al. 1998). 
Reepithelialisation 
 
Day 0+ 
 
 
Keratinocytes secrete collagenase to allow detachment from the underlying ECM 
allowing migration over the wound surface from the leading edges of the wound.  
Keratinocytes behind the actively migrating cells proliferate and subsequently also 
migrate. Epidermal cells then revert to their normal phenotype and attach to the 
basement membrane and underlying dermis (Singer & Clark 1999).  
Wound Contraction 
 
Day 3+ 
Fibroblasts in the dermis assume a myofibroblasts phenotype and draw the wound 
edges together by connective tissue compaction (Martin 1997).  It has also been 
demonstrated that keratinocytes contribute to the matrix contraction (MacNeil 2007). 
Granulation Tissue 
Formation 
Day 4+ 
Fibroblasts are recruited to the wound site and secrete fibronectin-rich ECM, until the 
space is filled.  Blood vessels and macrophages also move into the space (Singer & 
Clark 1999). 
Matrix Remodelling 
 
Day 7+ 
Fibrinolytic enzymes such as plasmin are expressed by cells in the clot to facilitate 
degradation of the clot.  Matrix metalloproteins (MMPs) are also expressed by 
macrophages, epidermal cells, endothelial cells and fibroblasts.  MMPs faciliatate 
cleavage of collagens in the extracellular matrix of both the dermis and the basal 
membrane (Martin 1997).  Cells undergo apoptosis (Desmouliere et al. 1995) and the 
provisional fibronectin-rich ECM is replaced with collagenous matrix.  A scar forms 
(Singer & Clark 1999). 
 
2.5. Conclusion 
Skin is a complex structure which performs a variety of functions, most importantly 
prevention of infection and water loss by provision of a barrier to the external environment.  
Skin can be lost due to disease, trauma or surgery and due to the complex nature of skin, the 
healing process is complex.  Where wounds do not heal spontaneously, there is a need for 
technologies to promote wound healing via the wound healing cascade, to restore the barrier 
function of the skin. 
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3. Skin Repair Technology 
In order to promote healing in ‗difficult wounds‘ various approaches have been taken.  The 
gold standard in skin replacement remains the autograft, however, if the affected area is very 
large, or there is an underlying condition that prevents healing of secondary wounds, 
alternative strategies must be taken.  Other approaches that have been investigated include the 
use of allografts or xenografts, dressings, growth factors, and tissue engineering.  If an 
approach is to be successful, then the complete structure and function of native skin should be 
restored. 
 
3.1. Skin grafting 
3.1.1. Autograft skin 
An autologous skin graft, or autograft, is harvested from one site in a patient and placed in 
another. The autograft remains the most frequently used grafting material since it is 
recognised by the body as self and so does not elicit an adverse immunological reaction.  
Most frequently, the skin is harvested from the thigh, unless this is the affected area.   
Disadvantages associated with autograft skin are limited availability, and donor site 
morbidity and scarring (Atiyeh et al. 2005). 
 
3.1.2. Allograft skin 
Allograft skin is harvested from a member of the same species prior to placement. Use of 
allograft skin is limited by limited supply the risk of disease transmission, eventual immune 
rejection and difficulties associated with its storage (Babensee et al. 1998; Vuola & Pipping 
2002).  The immunogenic response to allograft material can be reduced by removing the 
epidermis, and using only the viable allodermis (Tanner et al. 1964).  Allogenic skin 
substitutes act as temporary skin substitutes and can allow early-resurfacing of burn wounds, 
but allografts often have little effective ‗take‘ (adherence to the wound bed and 
vascularisation) compared with autografts  (Nanchahal et al. 2002). 
 
3.1.3. Xenograft skin  
Xenografts are harvested from one species and implanted into another. The use of most 
xenograft tissues is excluded because of a vigorous immune response on implantation leading 
to a high failure rate (Babensee et al. 1998; Garfein et al. 2003).  By removing the epithelium 
of the skin and fixing it, it is possible to reduce the extent of the immune response, but this 
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also reduces the bioactivity of the skin.  The readily available supply of xenografting 
materials mean that the problems associated with supply are reduced but concerns over the 
risk of viral transfer from animal to human (Enoch et al. 2005) limit the use of xenografting.   
 
3.1.4. Amniotic membranes 
Amniotic membranes have been used since 1910 (Rejzek et al. 2001).  They provide 
temporary wound coverage, since they cannot become integrated into the host tissue due to 
their allogenic source.  They do, however, allow early healing including epithelialisation, 
under the amniotic membrane, in superficial wounds but they are not suitable for the 
treatment of deep burns since the membrane disintegrates faster than epithelialisation occurs 
(Atiyeh et al. 2005). 
 
3.1.5. Acellular porcine small intestinal submucosa (SIS) 
SIS is an FDA-approved xenogenic scaffold for skin tissue repair.  It allows tissue in-growth 
and degrades in vivo.  The success of SIS has been attributed to its ECM proteins and 
glycosaminoglycans, and the cytokines and growth factors that are retained within the matrix 
(Ratner & Bryant 2004) such as vascular endothelial growth factor (Hodde et al. 2001), 
transforming growth factor β1 (TGFβ1), and basic fibroblast growth factor (Voytik Harbin et 
al. 1997). 
 
3.2. Wound dressings 
Traditionally, dressings such as natural or synthetic bandages, cotton wool, lint and gauzes all 
with varying degrees of absorbency were used for the management of wounds. Their primary 
function was to keep the wound dry by allowing evaporation of wound exudates and 
preventing entry of harmful bacteria into the wound. It has now been shown however, that 
having a warm moist wound environment achieves more rapid and successful wound healing. 
Modern wound dressings, therefore, are designed to create and maintain a moist environment 
around the wound and include hydrocolloids, calcium-alginate sponges and hydrogels.  
Alginate-based dressings include Contreet-H, Seasorb and Algisite M (Paddle-Ledinek et al. 
2006).  The vast array of modern dressings available are reviewed by Paddle-Ledinek et al. 
(2006) and Boateng et al. (2008). 
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3.3. Growth factors and cytokines 
A variety of growth factors and cytokines are involved in wound healing, including, 
epidermal growth factor (EGF) (Spiekstra et al. 2007), platelet derived growth factor (PDGF) 
(Greenhalgh 1996), transforming growth factor (TGF-β1) (Puolakkainen et al. 1995), insulin-
like growth factor (IGF-1), human growth hormone (Steenfos 1994) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Mann et al. 2006).  Growth factors and 
cytokines can mediate healing through the stimulation of angiogenesis, cellular proliferation, 
differentiation and migration, and modification of extracellular matrix metabolism and 
inflammation (Boateng et al. 2008; Gu et al. 2004).  The effect of localized application of 
some growth factors and cytokines on wound healing has been investigated.   
 
Direct application  of heparin-binding epidermal growth factor (HB-EGF), EGF, GM-CSF, 
PDGF and keratinocyte growth factor-2/ fibroblast growth factor -10 (KGF-2/ FGF-10) have 
been seen to accelerate healing (Cribbs et al. 1998; da Costa et al. 1999; Gaches et al. 1998; 
Jimenez & Rampy 1999; Mann et al. 2006; Marchese et al. 2001; Rees et al. 1999).  The 
different growth factors have been seen to enhance different aspects of wound healing.  KGF-
2 has been seen to increase collagen accumulation, strength of wounds and thickness of the 
epithelium (Jimenez & Rampy 1999), and to induce proliferation and differentiation of 
human primary cultured keratinocytes (Brown et al. 1988; Marchese et al. 2001).  GM-CSF 
has been shown to stimulate keratinocyte proliferation, formation of granulation tissue and 
vascularisation (Mann et al. 2001a), and has been used successfully in the treatment of ulcers 
(da Costa et al. 1999; Stagno et al. 1999; Voskaridou et al. 1999) and amputation wounds 
(Gaches et al. 1998).  It has been reported that EGF stimulated epidermal regeneration in 
partial thickness incisions (Boateng et al. 2008; Brown et al. 1988).   
 
Other approaches to localized delivery of growth factors have been taken, including injection 
and controlled release from wound dressings.  Basic fibroblast growth factor/ fibroblast 
growth factor-2 (bFGF/ FGF-2) injected into the dermis of wound margins in full-thickness 
wounds in humans has been shown reduce scar formation (Ono et al. 2007).  Dressings which 
have been seen to enhance wound healing are hydrogel dressing containing transforming 
growth factor-β1 (TGF-β1) (Puolakkainen et al. 1995), collagen film containing human 
growth hormone (Maeda et al. 2001), alginate hydrogel dressing containing vascular 
endothelial growth factor (VEGF) (Gu et al. 2004), and polyurethane and collagen film 
dressings containing EGF (Grzybowski et al. 1999; Park et al. 2004).  
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3.4. Tissue engineering 
Many skin substitutes have been developed over the last 30 years because the use of 
autografting is limited.    Engineered skin may also be used for in vitro applications, to 
provide a platform for the evaluation of the behavior of new chemical entities in drug and 
cosmetic development (Faller et al. 2002; Faller & Bracher 2002; Hoffmann et al. 2003; 
Hoffmann et al. 2005; Khetani & Bhatia 2006; Pu & Bernstein 1995; Souto et al. 2006), and 
as disease models (Jean et al. 2009) and aging models (Pageon et al. 2008).  For grafting 
purposes, the ideal skin replacement should promote faster and better healing (Clark et al. 
2007), including enhanced wound closure and reduced scar formation (Nolte et al. 2008).  At 
present, no engineered skin substitute can replace all of the functions performed by intact 
human skin (Ikada 2006; Supp & Boyce 2005).   
 
3.4.1. Epidermal grafts 
Since the restoration of barrier function of the skin is often seen as the main priority in wound 
repair (MacNeil 2007), the first TE skin simply involved the replacement of the epidermis 
using autologous keratinocytes.  This involved the culture and differentiation of autologous 
keratinocytes in vitro to form cultured epithelial autografts (CEA) (Rheinwald & Green 
1975b).  TE of CEAs was made possible by the establishment of methods for cultivation of 
keratinocytes in vitro with the support of lethally irradiated 3T3 (transformed murine 
fibroblast) cells in the 1970s (Rheinwald & Green 1975a; Rheinwald & Green 1977), which 
can allow expansion of enough keratinocytes to culture 2m
2
 of epidermis from a 2cm
2
 biopsy 
(Pomahac et al. 1998).  CEAs were first reported in the treatment of major burns in 1981 
(Burke et al. 1981; Wood et al. 2006b), but have been more frequently used in the treatment 
of chronic wounds (Chern et al. 2009).  Since the development of the first CEA (Rheinwald 
& Green 1975b) a number of similar products have been developed, some of which contain 
pure keratinocyte cultures, and others containing a co-culture of melanocytes and 
keratinocytes (Green et al. 1979; Mak et al. 1991; Pu & Bernstein 1995).   It has been 
recognized that although only autologous keratinocytes can be sustained and provide 
permanent wound coverage, epidermal grafts composed of allogenic keratinocytes can 
provide temporary wound coverage.  Allogenic epidermal grafts serve as biologically active 
dressings, secreting growth factors and cytokines that enhance wound healing (Phillips & 
Gilchrest 1991) and is gradually replaced with recipient cells (Gielen et al. 1987).  Epidermal 
grafts can be difficult to handle and to address this problem, keratinocyte sprays have been 
developed.  It has been shown that spraying keratinocytes has no adverse effect on cell 
22 
 
viability and that the keratinocytes retain their ability to stratify and form an epidermal layer 
(Duncan et al. 2005; Navarro et al. 2000).  Epidermal replacements are, however, not ideal 
skin substitutes as the lack of dermis results in contracture, difficulty in take/ blistering, scar 
formation and long-term fragility (Donati et al. 1992; Kirsner et al. 1998; Meana et al. 1998a; 
Still et al. 1994; Wood et al. 2006b).  The effectiveness of epidermal grafts varies, with some 
studies reporting no appreciable benefit to burn healing (Cuono et al. 1986), whilst some 
studies reported success rates of around 70% in the treatment of chronic wounds (Limat et al. 
2003: Poskitt et al. 1987), in terms of restoration of the epidermal barrier layer. Some 
epidermal replacements which are commercially available or being developed are 
summarized in Tables 3.1 and 3.2, respectively. 
 
Table 3.1:  Commercially available tissue engineered epidermal replacements. 
Skin 
Substitute  
Description 
Epicel 
CEA formed from keratinocytes cultured on a petrolatum gauze support 
(Supp & Boyce 2005; Wright et al. 1998). 
Epidex 
CEA formed from keratinocytes isolated from outer root sheath of scalp 
hair follicles on a silicone membrane support (Supp & Boyce 2005; 
Tausche et al. 2003). 
Transcell and 
MySkin 
Keratinocyte CEAs on plasma acrylic acid/octa-1,7-diene copolymer 
supports (Higham et al. 2003; Hernon et al. 2006; Moustafa et al. 2007). 
CellSpray Allogenic keratinocyte suspension spray (Navarro et al. 2000). 
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Table 3.2:  Tissue engineered epidermal replacements being developed. 
 
  
Reference Description 
Pu & Bernstein 1995 
Keratinocyte CEA cultured on a nylon mesh 
microporous membrane support coated in collagen.  
Horch et al. 2000 
Undifferentiated keratinocytes cultured on the surface 
of a collagen membrane.   
Horch et al. 1998 
Undifferentiated keratinocytes suspended in a fibrin 
sealant biomatrix.   
Liu et al. 2006a 
Autologous keratinocytes cultured on porcine gelatin 
microcarriers.   The microcarriers were first seeded 
with autologous dermal fibroblasts, which secreted 
ECM, and are then killed prior to seeding with 
keratinocytes. 
Voigt et al. 1999 
Collagen-coated dextran microcarriers seeded with 
keratinocytes.  
Kamolz et al. 2006 
CEA formed from keratinocytes derived from 
differentiation of umbilical cord blood stem cells 
cultured on fibrin gels. 
Wood et al. 2007 
Duncan et al. 2005 
Keratinocyte suspension sprays.   
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3.4.2. Tissue engineered substitutes with a dermal component  
The presence of dermis has been shown to support faster re-epithelialisation, better take of 
epithelial grafts, inhibit wound contraction and improve aesthetic outcome (Kangesu et al. 
1993; Leigh et al. 1993; Navsaria et al. 1994).   
 
Most dermal analogues contain a scaffold, which can be used to control and guide wound 
healing, act as a transplantation vehicle or to provide controlled, localized release of growth 
factors and cytokines (Babensee et al. 1998).  Initially, de-epidermalised dermis (DED) and 
collagen-based scaffolds were investigated as scaffolds for dermal replacement (Bell et 
al.1979; Regnier et al. 1981).  Since then, collagen scaffolds have been extensively used as 
analogues of the ECM of the dermis, either in their acellular form or seeded with fibroblasts 
(Bell et al. 1979; Hafemann et al. 1999; Helary et al. 2010; Powell & Boyce 2006a; Powell et 
al.  2008).   Collagen based scaffolds have a number of limitations for tissue engineering skin 
including excessive contraction (Hafemann et al. 1999; Sahota et al. 2003), poor 
vascularisation, blistering and scar formation (Garcia et al. 2008; Sahota et al. 2004).  Poor 
mechanical properties and rapid degradation rates are the biggest problem associated with 
collagen scaffolds as this can cause graft instability and difficult handling (Garcia et al. 
2008).  It has been reported that non-crosslinked collagen sponges degrade in vivo within 
three days (Powell & Boyce 2006), and therefore the scaffold degrades much faster than 
dermal tissue forms.  Approaches have been taken to develop collagen-based TE skin 
matrices with more favorable mechanical properties and degradation characteristics, such as 
cross-linking with transglutaminase (Garcia et al. 2008) or chemicals like EDC (1-ethyl-3-3-
dimethylaminopropylcarbodiimide hydrochloride) (Powell & Boyce 2006).  Chemical cross-
linking of collagen has, however, been shown to reduce chemo-attraction and cellular 
proliferation and differentiation (Ruszczak 2003).   
 
Collagen scaffolds also present the problem of disease transmission (Alisky 2004) and ethical 
issues due to their animal source.  As a result, other scaffold materials have been investigated 
for tissue engineering skin, such as fibrin (Cox et al. 2004), which can be derived from the 
patient‘s own blood, and non-animal derived materials. Fibrin scaffolds, however, also 
degrade rapidly, and thus may not be the ideal scaffold material for tissue engineering skin.  
Polyglactin is another material which has been investigated as a scaffold for dermal 
replacement, and is the material used in Dermagraft.  The scaffold has been shown to degrade 
in vivo within 15 days (Cooper et al. 1991), which although longer than collagen based 
25 
 
materials, still may be too fast, and may be the reason that although reduced, scar formation 
and wound contraction still occur with Dermagaft treatment (Hansbrough et al. 1993).  
Furthermore, as dermagraft degrades in vivo, the wound pH is altered (Pomahac et al. 1998), 
which may have an adverse effect on keratinocytes and fibroblasts.  This may be why when 
Dermagraft was seeded with fibroblasts and covered with keratinocytes, only half the grafts 
were seen to be successful in an in vivo study (Hansbrough et al. 1993). 
 
A number of TE dermal and bi-layer skin replacements are now commercially available, and 
these are summarized in Tables 3.3 and 3.4 respectively.  Since no commercially available 
product can allow perfect skin regeneration, there is still much research in this area (Ikada 
2006; MacNeil 2007; Supp & Boyce 2005).  Some of the dermal and bi-layer skin 
replacements under development are summarized in Tables 3.5 and 3.6, respectively. 
 
Table 3.3:  Commercially available dermal substitutes. 
Dermal skin 
Substitute  
Description 
Dermagraft 
Neonatal human fibroblasts seeded into bioabsorbable polyglactin mesh 
scaffold.  Extracellular matrix produced in the mesh by the cells (Cooper et 
al. 1991;Marston et al. 2003). 
Alloderm Acellular human dermis (Wainwright 1995). 
Graftjacket Acellular human dermis (Brigido et al. 2004). 
Oasis Porcine small intestine submucosa (Niezgola et al. 2005). 
SkinTemp 
Spongy type I collagen/nylon composite matrix for temporary wound 
coverage (Kolenik et al. 1999). 
Promogran 
Acellular material consisting of 55wt% collagen and 45wt% oxidised 
regenerated cellulose (Ruszczak 2003;Veves et al. 2002).   
Permacol Acellular porcine dermis (van der Veen et al. 2010). 
Tiscover 
Acellular human dermis with autologous fibroblasts (van der Veen et al. 
2010). 
Glyaderm Acellular human dermis (Pirayesh et al. 2008). 
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Table 3.4:  Commerically available bi-layer skin analogues. 
Bi-layer Skin 
Substitute  
Description 
OrCel 
Dermal layer of type I bovine collagen sponge seeded with allogeneic 
fibroblasts.  Allogeneic keratinocytes cultured on the non-macroporous 
surface of the collagen sponge.  Absorbable and permanent (Lipkin et al. 
2003). 
BioBrane 
Aceullar, flexible cell adherent substrate to be used as a temporary dressing 
to promote wound coverage.  Dermal layer of collagen and nylon covered 
with a layer of semi-permeable silicone to prevent water loss and allow gas 
exchange, with an.  It has a three year shelf-life (Phillips et al. 1994;Tavis et 
al. 1980).  Biobrane has been successfully used to treat burns (Purdue et al. 
1987). 
TransCyte 
A temporary substitute composed of neonatal keratinocytes cultured in a 
nylon mesh coated with porcine dermal collagen, which is bonded to a 
silicone membrane (Kumar et al. 2004). 
Integra 
Acellular, cell adherant dressing (Kremer et al. 2000).  Dermal component is 
a glutaraldehyde cross-linked insoluble bovine collagen and 
glycosaminoglycan composite.  This is covered by a silicone epidermal layer 
which is removed once the graft has ‗taken‘.   
Apligraft 
(formerly 
Graftskin) 
Dermal component is compised of bovine type I collagen mixed with 
allogenic dermal fibroblasts.  Allogenic keratinocytes are seeded on the 
upper surface (Falabella et al. 1999;Falabella et al. 2000;Greenberg et al. 
2003).  The epidermal component is lost either due to chronic rejection or 
terminal differentiation of all keratinocytes (Mansbridge 2009).   
Laserskin 
A pliable hyaluronic acid-derived dermal matrix seeded (after production) 
with non-proliferating dermal fibroblasts (feeder layer) and autologous 
keratinocyctes (Lam et al. 1999). 
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Table 3.5:  Dermal skin substitutes under development. 
 
  
Reference Description 
Fleischmajer et al. 1993; 
Slivka et al. 1993 
Human neonatal foreskin fibroblasts grown on a nylon mesh 
and induced to deposit collagen matrix. 
Heimbach et al. 1988; 
Yannas & Burke 1980 
Acellular collagen sponge. 
Chau et al. 2005 
Transglutamine cross-linked collagen gel with human dermal 
fibroblasts seeded on the surface. 
Chen et al. 2000 
Collagen microsponges in the pores of a polylactin mesh 
seeded with human dermal fibroblasts. 
Gorodetsky et al. 1999 Fibrin microbeads surface-seeded with fibroblasts.   
Cox et al. 2004 Human dermal fibroblasts encapsulated in fibrin gel.  
Garcia et al. 2008 
Acellular transglutaminase cross-linked and freeze-dried 
collagen sponge.   
Blackwood et al. 2008 
Acellular electrospun poly(D,L)-lactide-co-glycolide (PLGA) 
polymer scaffolds. 
Sun et al. 2005 
Electrospun polystyrene scaffold seeded with human 
keratinocytes, fibroblasts and endothelial cells.  This is a TE 
skin which could be used for in vitro testing, but is not designed 
for in vivo applications due to the non-degradable nature of the 
scaffold material. 
28 
 
Table 3.6:  Tissue engineered skin bi-layers under development. 
 
  
Reference Description 
Boyce et al. 1995 
Collagen-glycosaminoglycan substrate containing autologous 
fibroblasts with keratinocytes cultured on the surface. 
Souto et al. 2006 
Human fibroblasts in a bovine collagen type I matrix with a 
melanocyte/ keratinocyte co-culture on the surface.  
Powell & Boyce 
2006 
EDC cross-linked collagen sponge seeded with human dermal 
fibroblasts and human keratinocytes. 
Cuono et al. 1986 DED seeded with cultured keratinocytes 
Rehder et al. 2004 DED seeded with melanocytes and keratinocytes. 
Golinski et al. 2009 
Matriderm® collagen/ elastin scaffold seeded with fibroblasts and 
keratinocytes. 
Lee et al. 2006 
ECM scaffold secreted by in vitro cultured dermal fibroblasts,   
surface-seeded with keratinocytes.   
Kim et al. 2005 
Poly(lactide-co-glycolide) biodegradable microspheres seeded with 
either keratinocytes of fibroblasts for co-transplantation.   
El Ghalbzouri et al. 
2004 
Biodegradable co-polymer of PEGT/PBT seeded with fibroblasts to 
create the dermal layer, then seeded with a CEA cultured on a 
membrane. 
Maas-Szabowski et 
al. 2000 
Gamma-irradiated post-mitotic fibroblasts or normal fibroblasts 
encapsulated in collagen gel and seeded with keratinocytes.   
Stark et al. 1999 Collagen gel populated with fibroblasts and seeded with keratinocytes.   
Hafemann et al. 
1999 
70% collagen/ 30% elastin porcine membrane dermal analogue seeded 
with autologous keratinocytes.   
Meana et al. 1998b 
Fibroblasts encapsulated in fibrin gel and keratinocytes cultured on the 
surface.   
Bannasch et al. 2008 Keratinocytes encapsulated in fibrin and seeded onto Alloderm DED. 
Boyce 2004 Dermal component synergistic to Integra seeded with keratinocytes.   
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3.4.3.  Factors affecting clinical uptake of skin substitutes 
In order to ensure clinical uptake of a skin substitute it is important to consider the key 
strengths and limitations of the product.  Clinicians often express the desire for an ‗off the 
shelf‘ product which can be easily stored for extended periods of time until needed 
(Shevchenko et al. 2010).  Such products are limited to acellular dermal analogues such as 
SkinTemp, Permacol, Tiscover, Glyaderm and Alloderm, which are summarised in Table 3.3.  
Although these products can offer enhanced wound healing, the inclusion of cells has been 
shown to enhance wound healing by the secretion of growth factors and cytokines (Philips & 
Gilchrist 1991; Marston et al. 2003).  Furthermore, where large full thickness wounds are 
incurred where the hair follicles are lost, there is a need to provide keratinocytes to restore the 
epidermal layer, since the epidermis cannot be restored by the migration and differentiation 
of stem cells in the hair follicle (Fuchs 2007), and migration of keratinocytes from the wound 
margins is often insufficient.  In addition, it has been shown that the presence of fibroblasts 
enhances the formation of a basement membrane (Smola et al.1998) increasing the adhesion 
of the new epidermis to the underlying tissue.  This indicates the benefit of inclusion of both 
keratinocytes and fibroblasts in the production of a skin substitute.  Another key 
consideration in choice of treatment is the associated cost.   Cadavaric allograft is one of the 
cheapest skin substitutes, and is available from not-for-profit skin banks at a cost of around 
60p/cm
2
.  Cell-seeded scaffolds are more expensive, due to high amount of skilled labour 
associated with their production.  For example, Transcyte and Dermagraft, which both 
contain fibroblasts, cost £7.87/cm
2
 and £7.14/cm
2
, respectively.  Apligraft is approximately 
twice the pice of Dermagraft and Transcyte, probably dues to the inclusion of both fibroblasts 
and keratinocytes in this product (Jones et al. 2002).  The high cost of the material is, 
however, not necessarily associated with an increased cost of overall treatment.  The cost of 
the overall treatment should also take into account costs associated with outpatient visits, 
homecare, dressing materials and debridement as well as many other indirect costs, which are 
often reuced when more expensive skin substiues are used (Langer & Rogowski 2009). 
 
3.5.  Conclusion 
The development of a skin substitute that could perform all the functions of native skin would 
be beneficial in the clinical setting for the treatment of large and chronic wounds.  There are a 
number of epidermal replacements commercially available and under development, but for 
the treatment of full thickness wounds, affecting both the epidermis and the dermis, a bi-layer 
replacement is required for optimal wound healing.  The scaffold should degrade at the rate 
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of new tissue formation and should promote tissue in-growth, vascularisation, innervation 
and re-epithelialisation.  In addition, the scaffold should be from a non-animal source to 
avoid disease transmission, and should also elicit no adverse immune response.   
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4. Biopolymer hydrogel encapsulation in tissue engineering 
There is a current trend in tissue engineering towards the delivery of cells within the material 
matrix in order to expedite healing (Kretlow et al. 2009).  Much of this work has involved the 
use of sponge-like scaffold materials exhibiting interconnected porosity (Rosa et al. 2008).  
Although within such structures, the cells are arranged spatially in three dimensions with 
respect to one another, they still attach to a two dimensional surface and as such do not 
exhibit a phenotype that would be expected in native tissue.  Since cell phenotype is critical 
to correct healing of the damaged tissue, a number of workers have attempted to deliver cells 
within a matrix that is more akin to the extracellular matrix (ECM) than sponge-like 
polymers.  The structure of hydrogels is morphologically similar to that of the ECM of soft 
tissues (Bokharia et al. 2005) due to the high water content and soft consistency of hydrogels 
(Ratner et al. 1976).  Hydrogels, therefore enable tencapsulated cell populations to exhibit 
phenotypes more similar to those in vivo than when the cells are grown in monolayer culture 
(Abbott 2003).  Cell encapsulation in biopolymer hydrogels was initially investigated for the 
treatment of diseases by the sustained release of therapeutic molecules, secreted by the 
encapsulated cells, and later, for tissue engineering.   In this chapter the use of different 
commonly used biopolymer hydrogels used in cell encapsulation are described, along with 
the major advantages and disadvantages of each material. 
 
4.1. Biopolymer gels 
A vast range of different hydrogel based materials are available with contrasting chemistries 
which may or may not allow cell attachment (Lee & Mooney 2001).  A basic overview of a 
selection of biopolymers utilised for mammalian cell encapsulation in regenerative is given in 
Table 4.1.   
 
It is essential that materials used in regenerative medicine are able to exist in the body 
without damaging adjacent cells or leading to significant scarring or otherwise elicit 
undesirable effects such as excessive inflammation or carcinogenesis (Lee & Mooney 2001).  
Most biopolymer hydrogels are considered to be suitable for implantation due to the high 
water content and the minimal mechanical irritation inflicted on surrounding tissue, due to the 
soft, elastic properties of these hydrogels (Peppas et al. 2000).  In contrast, synthetic 
hydrogels frequently display undesirable effects when implanted (Lee & Mooney 2001). 
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Table 4.1: Biopolymer gels used for cell encapsulation and tissue regeneration and their 
key features. 
Biopolymer Protein/ 
Polysachharide 
Source Gelation 
method 
Mechanism 
of 
degradation 
Cell 
adhesivity 
Agarose Polysaccharide 
 
Seaweed Thermal  Non-
degradable 
Low 
Alginate Ionotropic 
cross-linking 
Ion exchange 
Carageenan Thermal and 
ionic cross-
linking 
Ion exchange 
and 
enzymatic 
degradation 
Gellan Bacteria Thermal or 
ionotropic 
cross-linking 
Thermal or 
ion exchange 
High 
Chitosan Crustaceans 
and fungi 
Ionotrophic or 
covalent 
Ion exchange 
of stable 
Dextran Bacteria Physical, 
Chemical 
cross-linking 
or radical 
polymerization 
Phagocytosis  Low 
Collagen Protein Animal/ 
human 
Neutralisation Enzymatic 
cleavage  
High 
Fibrin Proteolytic 
cleavage 
Gelatin Thermal 
Hyaluron Polysaccharide Chemical 
cross-linking 
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4.1.1. Alginate 
Alginate is a polysaccharide isolated from brown algae which has been used with great 
success as a wound dressing (Augst et al. 2006) and as a food additive.  On dissolution in an 
aqueous medium, monovalent alginate salts form hydrocolloids, which gel ionotropically 
following the addition of multivalent cations such as Ca
2+
, Ba
2+
 
and Sr
2+
.  Alginate is formed 
from polysaccharides derived from a range of seaweeds found world-wide and consists of a 
mixture of D-mannuronic acid (M) and L-guluronic acid (G) residues  (Lee & Mooney 2001).  
The ratio of M to G blocks can vary significantly depending upon the source of the raw 
materials used in alginate manufacture. Since hydrogel formation occurs following 
electrostatic interaction between the carboxylic moieties on the G blocks of alginate and 
multivalent cations, hydrogel stiffness can be influenced by varying M to G ratios (Wang et 
al. 2003), the properties of main polymer chains/cross-linking molecules (i.e. molecular 
weight and chain stiffness) (Treloar 1975), and concentrations of the binding cations 
(Mancini et al. 1999). The simplest method for tailoring the mechanical properties exhibited 
by the alginate, however, is to vary the concentration of alginate in solution (Kong et al. 
2002).  Alginate itself has limited interaction with the majority of mammalian cells due to its 
hydrophilic character, which promotes limited protein adsorption (Lee & Mooney 2001) and 
also the lack of cell adhesion ligands in the alginate itself.  Cell adhesion to alginate gels can 
be increased by covalently modifying the polymer with molecules such as the tri-amino 
peptide, Arginine–glycine–aspartic acid (RGD) (Rowley & Mooney 2002).   
 
4.1.2. Fibrin 
Fibrin gels occur widely in the human body following injury and are important in 
haemostasis (Janmey et al. 2009).  They have, therefore, been used as a sealant and an 
adhesive in surgery (Lee & Mooney 2001).  Fibrin gels form following the cleavage of 
fibrinogen by thrombin to expose regions on the fibrin molecules that interact allowing self 
assembly of protofibrils which aggregate and lengthen.  At certain points in the fibrin 
network, branching occurs, which increases the volume of the gel.  The presence of RGD 
motifs within the fibrin network allow cell adhesion and binding of a range of important 
growth factors.  In the presence of mammalian cells, however, fibrin can degrade rapidly due 
to the localised secretion of proteolytic enzymes (Ye et al. 2000).  To overcome this problem, 
fibrin degradation inhibitors and fibrin stabilisers, such as aprotinin, factor XIII and ε-amino-
n-caproic acid, have been added to the gels to maintain the structure over longer time periods 
(Mol et al. 2005; Park et al. 2005; Ye et al. 2000). Furthermore, the importance of sufficient 
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thrombin and calcium to prevent excessive degradation has been reported (Eyrich et al. 
2007).  A main advantage of fibrin gels is that they can be formed from the patients‘ own 
blood so that no inflammatory response would be expected.  Also, no toxic degradation 
products should occur following degradation.   The limited mechanical strength of fibrin gels 
has, however, limited use in clinical applications (Lee & Mooney 2001).   
 
4.1.3. Collagen 
Collagen is the most abundant form of protein in humans, constituting 30% of all protein 
found in the body and is the main component of ECMs of skin, bone, cartilage, tendon and 
ligament (Lee & Mooney 2001).  There are twenty nine different forms of collagen found in 
the body, the most ubiquitous which is type I collagen, which comprises triple α-helices, 
which in the correct environmental conditions self assemble to form a fibrillar structure 
(Pachence 1996).  The self assembling tendencies of type I collagen have led to it being used 
as a hydrogel for use in tissue engineering.  Rat tail collagen, for example, may be dispersed 
in acidic medium which, when neutralised in culture, forms gels which have been widely 
used in regenerative medicine since they allow good cell adhesion.  The two major 
limitations of these collagen based scaffolds are their weak nature and their extensive 
contraction by encapsulated cells.  One group has sought to address both of these drawbacks 
by plastic compression of the collagen gel immediately after its formation (Brown et al. 
2005).  Alternatively, collagen can be chemically cross-linked using glutaraldehyde (Rault et 
al. 1996) or diphenylphosphoryl azide (Marinucci et al. 2003) to improve its physical 
strength, but this still results in relatively weak gels, and the gels can be potentially 
immunogenic (Pulapura & Kohn 1992), and toxic due to the release of cross-linking agents 
with time in culture (Speer et al. 1980; Cooke et al. 1983).  The rapid cell-mediated 
degradation of collagen gels can also be problematic.  To address this problem Chau et al. 
(2005) investigated the use of transglutimase as a cross-linker and Powell and Boyce (2006) 
have proposed the use of 1-ethyl-3-3-dimethylaminopropylcarbodiimide hydrochloride 
(EDC) as a cross-linker.  Both these methods have been demonstrated to reduce cell-mediated 
degradation. 
 
4.1.4. Gelatin 
Gelatin is formed from the hydrolysation of collagen, in which the natural triple helix 
structure of collagen is broken into single strands (Lee & Mooney 2001).  Two different 
forms of gelatin with different isoelectric points can be formed depending on the 
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hydrolysation protocol.  Gelatin dissolves in water at 60°C then gels as the solution cools to 
room temperature (Young et al. 2005).  Due to its ease of manipulation, biodegradable nature 
and low price, gelatin is widely used in pharmaceutical and medical applications in wound 
dressings, artificial organs and as a temporary scaffold for damaged tissues (Zandi et al. 
2007; Ikada and Tabata 1996; Miyoshi et al. 2005).  As with collagen gels, however, the 
weakness of gelatin gels has proved problematic in tissue engineering applications (Lee & 
Mooney 2001).  A number of approaches have been taken to improve mechanical properties 
of gelatin gels such as carbodiimide cross-linking, which has been shown to be successful 
(Kuijpers et al. 1999). 
 
4.1.5. Hyaluronic acid 
Hyaluronan (HA), a glycosaminoglycan (GAG), is a carbohydrate found throughout the body 
in the ECM of a number of tissues, including skin and cartilage.  HA is a linear polymer of 
glucuronic acid N-acetylglucosamine disaccharide, which binds cells, either directly through 
the cell surface receptors CD44, receptor for hyaluronan mediated motility (RHAMM) and 
intracellular adhesion molecule-1 (ICAM-1), or via cell adhesion to HA-binding proteins 
known as hyaladherins (Chen & Abatangelo 1999).  Colloids of HA can be gelled by prior 
chemical modification of hyaluronan with thiols, methacrylates or tyramines, or can be cross-
linked in-situ using formaldehyde or divinyl sulphone.  One of the key advantages of using 
HA gels for tissue engineering is that their degradation can be mediated by hyaluronidase, an 
enzyme secreted by a multitude of mammalian cell types (Peppas et al. 2006).  The main 
disadvantages associated with HA gels are their typically low mechanical properties 
compared with native tissues and that if the HA is not thoroughly purified, it has the potential 
to transmit disease, elicit immune response and carry endotoxins (Liu et al. 1999).  These 
disadvantages have limited the use of HA gels in tissue engineering applications. 
 
4.1.6. Agarose  
Agarose is a marine algal polysaccharide which can be formed into a gel that once heated to 
90°C forms a polymer solution.  When the temperature of this solution is lowered to room 
temperature gelation will occur, which is reversible upon re-heating (Wong & Mooney 1997).  
Agarose is used widely in molecular biology and since it is well accepted following 
implantation it has been evaluated for immunoisolation purposes (Lahooti & Sefton 2000b).  
The pore size and mechanical properties of agarose gels can easily be tailored by varying 
agarose concentration (Lee & Mooney 2001).  The non-degradable nature of the gel, 
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however, means that it has not been widely used in tissue engineering since scaffold materials 
used in tissue engineering applications should degrade over time to allow space for 
accumulation of new tissue. 
 
4.1.7. Dextran 
Dextrans are colloidal, hydrophilic, water-soluble polysachharides synthesised by bacteria.  
Since dextran hydrogels do not affect cell viability, they have been used for many years as 
carrier systems for a variety of therapeutic agents, including antibiotics, anticancer drugs and 
peptides (Imren et al. 2010; Hennink et al. 1996; Hennink et al. 1997; Franssen et al. 1997; 
Franssen et al. 1999a; Franssen et al. 1999b).  Several approaches to preparing dextran 
hydrogels have been adopted, including chemical cross-linking with N,N'-
methylenebisacrylamide, epichlorohydrin or glutaraldehyde (Imren et al. 2010) or physically 
crosslinked by oligo lactic acid stereocomplexes (Bos et al. 2005).   Generally, dextran 
hydrogels are seen to degrade very slowly, limiting their applications within tissue 
engineering.  Recently, however, dextran methacrylate esters have been prepared by treating 
dextran with glycidyl methacrylate (van Dijk-Wolthuis et al. 1995). Varying building units 
and methacrylate offers the possibility to adjust the cross-linking density and may prove an 
effective method to tailor the degradation of the dextran to the requirements of cell 
cultivation scaffolds (Moller et al. 2007; de Groot et al. 2001).  Furthermore, although the 
cell adhesivity of dextran is limited, RGD molecules can be incorporated into the scaffold in 
order to increase cell adhesion (Ferriera et al. 2007; Massia & Stark 2001). 
 
4.1.8. Chitosan 
Chitosan is an amino polysaccharide (Kumar 2000) prepared by N-deacetylation of chitin, the 
structural element in the exoskeleton of crustaceans (crabs, shrimp, etc.) and cell walls of 
fungi.  Chitosan forms hydrogels by ionic cross-linking (Chenite et al. 2000), chemical cross-
linking with glutaraldehyde (Mi et al. 2000), or by UV irradiation (Ono et al. 2000).  
Chitosan has found many biomedical applications, including tissue engineering, due to its 
low toxicity, structural similarity to natural glycosaminoglycans, and degradation by enzymes 
such as chitosanase and lysozyme (Singh & Ray 2000). Since chitosan is positively charged it 
promotes good mammalian cell adhesion, which is often desirable in tissue engineering 
applications (Lee & Mooney 2001). 
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4.1.9. Gellan  
Gellan gum is a FDA-approved food additive and has been widely exploited in food and 
pharmaceutical industries (Gong et al. 2009).  It is a linear extracellular polysaccharide of 
around 50,000 residues produced by the bacterium Pseudomonas elodea (Grasdalen & 
Smidsrod 1987; Miyamoto et al. 2001).  Gellan may be considered a preferable choice of 
scaffold material for tissue engineering because bacterial fermentation can be easilly 
controlled and offers products of reproducible physical and chemical properties (Abramovic 
& Klofurator 2006).  Both an acetylated and non-acylated form of the polysaccharide are 
available which form thermoreversible gels.  The mechanical properties of the thermally 
gelled gels can easily be varied by controlling the degree of acylation, from soft and elastic 
for the acetylated form to hard and brittle for the fully deacetylated polysaccharide 
(Abramovic & Klofurator 2006), although only the fully deacetylated form is commercially 
available.  Thermal gelation of unmodified gellan, however, occurs above 42°C, thus making 
it unsuitable for cell encapsulation.  It has recently been reported, however, that oxidative 
cleavage of the gellan backbones can reduce the gelation temperature (Gong et al. 2009).  
Gelation can also occur ionically with both monovalent and divalent cations (Fialho et al. 
2008; Tang et al. 1996).  Gellan adsorbs fibronectin (Miyamoto et al. 2002), which has 
specific binding sites for molecules such as heparin and integrin on the cell surface, therefore 
allowing cell adhesion (Hynes 1990), which is often desirable in tissue engineering 
applications. 
 
4.1.10.  Carageenan 
There are three forms of carrageenan, known as iota, kappa and lamda, of which the first two 
can form hydrogels by ionic cross-linking.  Gelation of these carrageenans is thought to occur 
by the simultaneous intra-molecular chain ordering and chain association in the presence of 
gel-promoting cations (Smidsrod & Grasdalen 1982).  Carageenan hydrogels degrade in vivo, 
and there is evidence from studies performed on rats, guinea pigs and monkeys which 
indicates that degraded carrageenan (poligeenan) may cause ulcerations in the gastro-
intestinal tract and gastro-intestinal cancer.  Therefore the investigation into the use of 
carageenan in regenerative medicine has been limited (Tobacman 2001). 
 
4.2. Tissue engineering 
Cell encapsulation in biopolymer hydrogels was initially investigated for immunoisolation of 
cells producing therapeutic proteins for treatment of diseases.  Some of these studies are 
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summarised in Table 4.2. More recently, encapsulation of mammalian cells has been used in 
the regeneration of an array of different tissues.  Table 4.3 summarises a broad cross section 
of the literature covering tissues from the majority of the body.   
 
Table 4.2:  Biopolymer gel cell encapsulation for treatment of diseases with non-
autologous cells. 
Biopolymer Gel Encapsulated cell 
type 
Secreted 
therapeutic 
protein 
Disease 
Treatment 
References 
Agarose Islet cells Insulin Diabetes Gazda et al. 2007; 
Kobayashi et al. 2003 
 Kidney cells Hepatic 
Lipase 
Hyperlipidemia Lahooti & Sefton 2000a 
 Fibroblasts Alkaline 
phosphatase 
Osteoporosis Lahooti & Sefton 2000b 
Alginate Fibroblasts VEGF Cardiovascular disease Keshaw et al. 2005 
 Kidneys cells Endostatin Brain tumour Joki et al. 2001;  
Read et al.  2001a;  
Read et al. 2001b 
 Myoblasts Human factor 
IX 
Haeophilia Hortelano et al. 1996 
 Fibroblasts Human factor 
IX 
Haemophilia Liu et al. 1993 
 Fibroblasts Human 
growth 
hormone 
Dwarfism Chang et al. 1994 
 Islet cells  
Insulin 
 
Diabetes 
Calafiore et al. 2006; Soon-
Shiong et al. 1994; Soon-
Shiong 1999; Zimmermann 
et al. 2007  
Collagen Fibroblasts Alkaline 
phosphatase 
Osteoporosis Lahooti & Sefton 2000c 
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Table 4.3:  A summary of key references from the current literature describing cell 
encapsulation for the regeneration of a number of tissues. 
Biopolymer gel Encapsulated cell type Engineered 
tissue 
Reference 
Agarose MSCs Cartilage Pelaez et al. 2009 
Alginate Dorsal root ganglia Neural Bellamkonda et al. 1995 
Chondrocyctes Cartilage Choi et al. 2006;  Hong et al.. 2007 
MSCs Bone Smith et al. 2007a;  Wang et al. 2003 
Osteoblasts Bone Kong et al. 2003 
Hepatocytes Liver Khattak et al. 2007 
Neural progenitor cells Neural Zielinski & Aebischer 1994 
Chitosan Chondrocyctes Cartilage Hong et al. 2007 
Fibroblasts Neural Zielinski & Aebischer 1994 
Dextran ESCs Blood vessel Ferreira et al. 2007 
Collagen Myofibroblasts Skeletal muscle Cheema et al. 2003 
Fibroblasts Dermis Brown et al. 1998; Brown et al.. 2005; Chau et al.2005; 
Nazhat et al. 2006; Marenzana et al. 2006 
Fibroblasts Ligament Murray et al. 2006; Cacou et al. 2000 
Fibroblasts Tendon Marenzana et al. 2006 
Chondrocyctes Cartilage Hoshikawa et al. 2006 
Osteosarcoma cells Bone Bitar et al. 2007 
Fibrin Myofibroblasts Cardiac muscle Ye et al. 2000; Birla et al. 2005 
Myofibroblasts Blood vessel Mol et al. 2005 
Smooth muscle cells Blood vessel Grassl et al. 2003 
Fibroblasts Dermis Tuan et al. 1996; Brown et al. 1993; Meana et al. 1998; 
Cox et al. 2004 
Fibroblasts Ligament Chun et al. 2003 
Keratinocytes Epidermis Bannasch et al. 2000; Bannasch et al. 2008 
Chondrocytes Cartilage Park et al. 2005; Eyrich et al. 2007; Mesa et al. 2006 
MSCs Bone Catelas et al. 2006; Hou et al. 2008 
Hepatocytes Liver Bruns et al. 2005 
Dorsal root ganglia Neural Herbert et al. 1998 
Urethral cells Urethra Bach et al. 2001 
Keratocytes Corneal stroma Alaminos et al. 2006 
Gelatin Chondrocyctes Cartilage Hoshikawa et al. 2006 
Hepatocytes Liver Wang et al. 2006 
Gellan Chondrocytes Cartilage Gong et al. 2009 
BMSCs Bone Smith et al. 2007b 
Hylauronic acid Chondrocytes Cartilage Chung 2008 
Dorsal root ganglia Neural Horn et al. 2007 
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4.2.1. Musculoskeletal tissue engineering 
During embryogenesis musculoskeletal tissue develops from the mesoderm.  Mesenchymal 
stem cells (MSCs) differentiate to form the individual musculoskeletal tissues, which include 
muscle, cartilage, bone, tendons and ligaments.  The musculoskeletal system enables 
locomotion and with the ageing population, novel approaches to regenerate parts of the 
musculoskeletal system and therefore restore patient mobility are gaining increasing 
attention. 
 
4.2.1.1.  Muscle 
In musculogenesis MSCs differentiate to myoblasts, the muscle cell precursors, which further 
differentiate and fuse to form multinucleated myotubes.  These myotubes mature into 
myofibres which bundle to form skeletal muscle (Berendse et al. 2003).  Encapsulated 
skeletal myoblasts have been shown to remain viable and differentiate to form myotubules in 
collagen gel when mechanical conditioning is used after 7 days culture in vitro. Cell 
alignment was shown to occur uniaxially in the direction of applied tension (Cheema et al. 
2003). 
 
4.2.1.2.  Cartilage 
Cartilage is found in joints and prevents bone to bone contact.  The tissue consists of mainly 
chondrocyctes and an ECM containing collagens type I and II, and aggregan (Sterodimas et 
al. 2009).  A large amount of research has focussed on tissue engineering cartilage by the 
encapsulation of chondrocyctes in a variety of hydrogels including fibrin, collagen, chitosan 
and alginate.  Chondrocyctes encapsulated in fibrin gels have been maintained for five weeks 
in vitro (Park et al. 2005).  Park et al. (2005) also showed that addition of HA gel to the fibrin 
gel may be beneficial since after four weeks in vivo culture the degree of contraction was 
reduced and ECM production was higher in fibrin/ HA gels when compared with pure fibrin 
gels.  Chondrocyctes encapsulated in pure HA gels have been evaluated both in vivo up to 12 
weeks and in vitro up to two weeks post-encapsulation.  The constructs were shown to 
maintain, or increase, in size and encapsulated chondrocyctes were shown to deposit ECM 
both in vivo and in vitro. The amount of ECM produced was also shown to be enhanced 
under mechanical loading (Chung et al. 2008). 
 
Chondrocyctes encapsulated in collagen and gelatin gels were shown to produce cartilage 
specific matrix over 21 days in vitro culture.  The collagen gel was shown to contract after 
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one day and an increase in cell number was observed throughout the first 7 days.  The viable 
cell number however, fell gradually over the subsequent 14 days culture.  In contrast, the 
viability of chondrocyctes encapsulated in gelatin hydrogels was maintained, with no 
significant change in cell number (Hoshikawa et al. 2006).  Maintaining the viability of 
encapsulated chondrocytes can be problematic due to insufficient perfusion of scaffolds of 
large volume.  The addition of microchannels to polymeric gels has been proven to maintain 
the viability and function of alginate encapsulated chondrocytes (Choi et al. 2007), and this 
may prove effective for other polymeric gels.     
 
Recently, the use of low molecular weight gellan to encapsulate chondrocytes by thermal 
gelation has been investigated.  The gels, which were monitored up to 150 days in vivo, were 
shown to retain chondrocyte viability, support extracellular matrix (ECM) secretion and 
maintain normal chondrocyte phenotype, demonstrating that gellan is a potential and 
promising material for chondrocyte encapsulation to tissue engineer cartilage (Gong et al. 
2009). 
 
4.2.1.3.  Ligament and tendon 
Ligaments and tendons are rich in fibroblasts which secrete ECM containing collagen type I/ 
III, elastin and proteoglycans (Carvalho et al. 2000; Chan and Leong 2008; Cheema et al. 
2007; Cleary et al. 1967). Collagen and fibrin gel encapsulation of fibroblasts have been 
shown to have promise for tissue engineering of tendons and ligaments.  Marenzana et al. 
(2006) showed that tendon fibroblasts encapsulated in collagen gels attached, spread and 
were orientated in the parallel to the long axis of the collagen fibrils.  The fibroblasts 
produced tensile forces and remodelled the matrix (Marenzana et al. 2006).  Ligament 
fibroblasts encapsulated in collagen gels proliferated and secreted further collagen up to day 
14, then maintained the collagen level and cell number for a further 7 days culture.  Gel 
contraction was shown to occur over the 21 days culture (Murray et al. 2006).  Similarly, 
ligament fibroblasts encapsulated in fibrin gels have been shown to proliferate, contract the 
gel and secrete ECM (Chun et al. 2003).  Cacou et al. (2000) showed that mechanical loading 
of collagen gels encapsulating ligament fibroblasts may be beneficial in creation of tissue 
engineered ligaments, since loading increases the metabolic rate of ligament fibroblasts 
(Amiel et al. 1983) and results in an increase in the gel‘s structural stiffness after 11 days of 
cyclic loading. 
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4.2.1.4. Bone 
Bone tissue consists mainly of osteoblast secreted mineralised ECM containing collagen type 
1, collagen type IV, fibronectin and heparan sulphate (Narayanan et al. 2009; Williams et al. 
1989).  Fibrin gel encapsulation has been investigated as an approach for bone tissue 
engineering.  Where MSCs have been used, their osteogenic differentiation is measured by 
expression of alkaline phosphatase (ALP), osteopontin, bone sialoprotein (BSP), and 
osteocalcin.  MSCs encapsulated in fibrin gel have been shown to proliferate, but at a slower 
rate than in monolayer culture.  Encapsulation was seen to enhance osteogenic differentiation 
and ECM production, compared with monolayer culture.  Mineralised tissue was seen to 
accumulate in the pores that formed in the fibrin gel, which were surrounded by numerous 
cells (Hou et al. 2008).  Catelas et al. (2006) also showed that MSCs encapsulated in fibrin 
gels proliferate, show osteogenic differentiation, and secrete mineralised tissue.  They, 
however, observed that the MSCs did not fully differentiate to mature osteoblasts within the 
28 days of in vitro culture.  The potential of gellan hydrogels to tissue engineer bone by the 
encapsulation of bone marrow stromal cells has also been reported.  The gellan samples were 
shown to gel in the presence of the millimolar concentrations of cations present in cell culture 
media, which allowed for the maintainence of excellent cell viability within the samples.  The 
encapsulated cells were seen to remain viable for at least 21 days encapsulation and 
appreciable mechanical integrity was maintained throughout this period, although some 
degradation was observed.  This degradation should leave space for new tissue formation, 
although the synthesis of ECM was not measured (Smith et al. 2007b). 
 
4.2.2. Skin 
For tissue engineering skin fibrin has been used to encapsulate both fibroblasts, to develop a 
dermal analogue (Cox et al. 2004; Meana et al. 1998) and keratinocytes to create an 
epidermal analogue (Bannasch et al. 2000; Bannash et al. 2008).  Encapsulated human 
neonatal fibroblasts were shown to proliferate within the fibrin matrix, but also allow for the 
stratification of the co-cultured human neonatal keratinocytes on the surface of the gel both in 
vivo and in vitro (Meana et al. 1998).  Fibrin encapsulated porcine keratinocytes applied to 
the surface of Alloderm® were shown to produce a continuous epithelium with a cornified 
layer and basement membrane after four weeks in vivo (Bannasch et al. 2008). 
 
Brown and co-workers have investigated the use of collagen gels for the encapsulation of 
human dermal fibroblasts in order to tissue engineer the dermis of skin (Brown et al.1998; 
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Brown et al. 2005).  Initial work investigated the potential of mechanical loading of these 
collagen gels to induce matrix contraction and ECM accumulation (Brown et al. 1998).  Later 
work, however, focused on the use of plastic compressed collagen gels.  The compression 
was only seen to reduce cell viability of encapsulated human dermal fibroblasts by 10% as 
long as the gel did not become desiccated (Brown et al. 2005).  A concern when increasing 
the collagen content of the hydrogel is that diffusion of nutrients and waste products through 
the scaffold would not be sufficient to maintain cell viability over extended periods of time.  
To address this problem Nazhat et al. (2007) incorporated micro-channels into the gels using 
soluble phosphate glass fibres and after 24 hours the cell viability of encapsulated fibroblasts 
was seen to be greater than 80%. 
 
4.2.3. Neural tissue 
Chronic neurological diseases and physical injuries can result in loss of neuronal cell bodies, 
axons and associated glial support.  Since the central nervous system has limited or no 
capacity to replace the lost neurons, there is a significant interest in the engineering of neural 
tissue (Nisbet et al. 2008).  One of the major challenges facing researchers in this area is 
stimulation of guided axonal extension (Norman 2009).  To this end, Horn et al. (2007) 
encapsulated chick dorsal ganglia in HA and fibrin gels which were both evaluated in vitro.  
Both gels were shown to support neurites within the first 60h, but after 192h neurite length 
was seen to be 50% higher in HA gels when compared with the fibrin gels.   Despite this, 
when the neurons encapsulated in the HA gels were implanted, there was no restoration of 
spinal cord function.  Herbert et al. (1998) also investigated the use of fibrin gels for neural 
tissue engineering.  Encapsulated chick dorsal root ganglia were successfully maintained in 
the hydrogels and displayed neurite outgrowth.  Bellamkonda et al. (1995) showed that PC12 
neural progenitor cells and chick dorsal ganglia encapsulated in agarose also produced 
neurites of 900µm in length after four days in culture. 
 
Another approach to neural regeneration is the localised and sustained release of nerve 
growth factor (NGF) to stimulate neural differentiation of precursor cells.  For example, 
Zielinski & Aebischer (1994) have shown that a genetically modified fibroblast cell line 
provided sustained release of NGF during encapsulation in chitosan hydrogels.  The amount 
of NGF secreted was sufficient to induce the differentiation of co-cultured neural progenitor 
PC12 cells.  The limitation of this approach, however, was that fibroblasts were seen to 
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aggregate during the course of the study and after two weeks which resulted in necrosis in the 
centre of the aggregates. 
 
4.2.4. Liver 
Hepatic tissue is formed of hepatocytes which are organized into a polarized epithelium with 
distinct apical and basal domains (Dunn et al. 1989).  Hepatocytes have a high metabolic 
activity and produce many liver specific molecules such as urea, amino acids, glycogen and 
bile.  The successful tissue engineering of liver is often assessed by measuring the secretion 
of these liver specific products.   
 
Hepatocytes encapsulated in fibrin maintained viability over the first three days culture in 
vivo, but thereafter showed significant loss despite the maintenance of an even distribution of 
cells.   Neotissue formation, however, was observed with good integration into the host tissue 
after 7 days in vivo as well as maintained liver specific function and phenotype in viable cells 
(Bruns et al. 2005).  In order to maintain encapsulating hepatocytes viability and function 
various approaches have been taken to facilitate the diffusion of nutrients within hydrogels.  
For example, the incorporation of micro-channels into gelatin hydrogels was shown to 
maintain 90% viability and metabolic activity of the encapsulated hepatocytes after 45 days 
in vitro culture (Wang et al. 2006).  Similarly Khattak et al. (2007) have shown that 
perfluorocarbon incorporation improved metabolic activity and viability of encapsulated 
hepatocytes cultured in vitro for two weeks. 
 
4.2.5. Cardiovascular tissue  
The cardiovascular network is essential to maintaining the viability and functions of all living 
tissues.  The network can become obstructed of damaged due to disease or injury and thus 
efforts towards the tissue engineering of blood vessels and cardiac tissue are being made 
(Stegemann et al. 2007).  In order to engineer vascular tissue, myofibroblasts have been 
encapsulated in fibrin gels (Mol et al. 2005; Ye et al. 2000) and viability maintained for up to 
six weeks in vitro and the cells were also seen to proliferate and secrete collagen.  Smooth 
muscle cells have also been encapsulated in fibrin gels in order to produce an arterial media 
equivalent.  After three weeks in vitro culture the arterial equivalent was seen to have a 95% 
reduction in volume and was shown to accumulate collagen, which was aligned in the 
circumferential direction of the tubular structure.  The accumulation of collagen and the gel 
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contraction was associated with an increase in ultimate tensile strength of the construct 
(Grassl et al. 2003).  
 
Dextran hydrogel has also been investigated as a scaffold for tissue engineering blood 
vessels.  Ferriera et al. (2007) showed that human embryonic stem cells (ESCs) encapsulated 
in photocrosslinked dextran-methacrylate hydrogels survived for at least 10 days in vitro.  
The cells were encapsulated as aggregates as this was seen to promote better cell viability 
compared with monodispersed cells.  They found that the encapsulated cells displayed 
enhanced vascular differentiation compared to embyoid bodies formed in 2D culture.  The 
encapsulated cells, as compared with monolayers, were reported to have increased expression 
of the VEGF receptor, KDF, a marker of vascular differentiation, and reduced expression of 
markers of differentiation to other undesired cell types such as hepatocytes and neurons.  
During the study, however, no blood vessels were actually formed within the hydrogel, 
perhaps due to study being only 10 days long.   
 
Cardiac tissue has successfully been engineered in vivo by encapsulation of neonatal cardiac 
myocytes in fibrin gel within a silicon chamber implanted near an artery to maintain cell 
viability.  After three weeks the implant was found to be viable with large amounts of muscle 
tissue which contracted in response to electrical stimulation and had neovascularisation 
throughout (Birla et al. 2005). 
 
4.2.6. Urethral tissue 
The urethra is a tube which connects the urinary bladder to the outside of the body.  The 
tissue consists of an epithelial layer lining the lumen of the tube, and a thicker muscular layer.   
Damage or loss of the urethra can occur due to congenital defects, acquired disorders and 
injury.  Since only a small quantity of genitourinary tissue or mucosa is available for grafting, 
and other sources of tissue often show significant complications, there has been an interest in 
tissue engineering of the urethra (Magnan et al. 2009). 
 
Bach et al. (2001) have investigated the encapsulation of primary autologous urothelial cells 
in fibrin gel for the tissue engineering urethral tissue.  The encapsulated cells were applied to 
the surface of a pre-fabricated capsule tube in vivo and after 14 days histological and 
immuno-staining revealed that viable epithelial tissue similar to the native tissue had formed.  
The cells were reported to have proliferated, orientated appropriately, adhered and become 
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confluent.   In addition, the fibrin was reported to have fully degraded and been replaced by 
connective tissue.  After 28 days in vivo dense fibrous tissue was seen to have formed and 
vascular proliferation was evident as well as a mild inflammatory response.  This indicates 
that fibrin encapsulation of urothelial cells may be suitable for tissue engineering the urethra.  
It is possible that cell encapsulation in other biopolymers may also be suitable, but at present 
there appears to be limited research in this area. 
 
4.3. Conclusion 
The most widely used biopolymeric hydrogels in tissue regeneration have been summarised.  
Researchers have studied a variety of factors including cell viability, growth, matrix 
production and differentiation.  It is clear is that alginate, collagen, fibrin, gellan, chitosan, 
hyaluronic acid, and gelatin all show promise as materials for the encapsulation of cells for 
tissue engineering.  Alginate in particular shows great potential for the encapsulation of 
mammalian cells in regenerative medicine due to its ready availability, low cost, low 
immunogeneity, FDA-approval for medical applications, non-animal source, ease of gelation, 
relatively slow degradation, and proven support of cell viability and function of a variety of 
encapsulated cells.  Alginate hydrogel was, therefore, chosen as the scaffold material for the 
encapsulation of fibroblasts in order to produce the dermal layer of the tissue engineered skin. 
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5. Methods and materials 
5.1.   Fibroblasts 
NIH 3T3 murine fibroblasts were obtained from LGC (Middlesex, UK).   
 
5.1.1. Fibroblast culture 
FCM was prepared by supplementing high glucose Dulbecco‘s modified Eagle‘s medium 
(DMEM) (Sigma, UK) with 10% v/v foetal bovine serum (FBS) (PAA, Somerset, UK), 1% 
v/v penicillin-streptomycin (P/S), 2.25% v/v 1M 4-(2-hydroxyethyl)-1 piperazineethane-
sulfonic acid (HEPES) and 2% v/v L-glutamine.  All cultures were maintained at 37ºC with 
5% CO2 and 100% relative humidity and media was changed three times weekly. 
 
5.2. Alginate hydrogel preparation 
Alginate hydrocolloid solutions of either 2% or 5% w/v concentration were made by 
gradually dissolving low viscosity (20-40 centipoise (cps) for 2% w/v at 25°C, (Sigma UK, 
Cat number 180947, lot 08620BJ, MW 102000-209000, M:G ratio 1.56) sodium-alginate in 
double distilled water on a heated stirrer plate.  All hydrocolloids and other solutions required 
for gel preparation were sterilised by autoclaving for 2h at 121°C and 1bar. 
 
NIH 3T3 cells (LGC, Middlesex, UK), passaged at least twice after storage in liquid nitrogen 
and pelleted by centrifugation at 167 x g (1000rpm) for 3min, were  suspended at a density of 
7.5x10
5 
cells/ml of alginate hydrocolloid.  The alginate/3T3 dispersion or acellular alginate 
hydrocolloid was added dropwise into a bath of 100mM CaCl2 (Sigma, UK) and left to 
incubate at 37ºC for 2h to form cross linked spheres of 3.0±0.2 mm diameter.  To form 
alginate discs, the hydrocolloids were used to cover the surface of a petridish, on which 
silicone disc shaped molds were placed, and immersed in 100mM CaCl2 for 3h to allow for 
complete cross-linking of the alginate.  The displacement of alginate by calcium chloride was 
prevented by covering the alginate hydrocolloid with a layer of filter paper impregnated with 
100mM CaCl2.  After incubation in CaCl2 the samples were washed three times in DMEM 
before culture in FCM.  Cells were released from alginate hydrogel by incubation of the gel 
in 100mM tri-sodium citrate (Sigma, UK) solution for 2h at 37ºC. 
 
Alginic acid is a linear polymer composed of α-L-guluronic acid (G) and β-D-mannuronic 
acid (M) units in varying proportions and sequential arrangements. Calcium cations are 
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thought to electrostatically bind with the alginate, preferentially to the poly-guluronic acid 
units (GG) in a planar two-dimensional manner, producing the so-called ―egg-box‖ structure, 
where the negatively-charged carboxyl groups are accessible due to the epimerization of the 
fifth carbon (Park et al. 1993). 
 
5.3. Live/ dead staining 
Samples were immersed in 0.2µg/ml Calcein acetoxymethylester (Calcein-AM) for 15min 
and 2.5µg/ml Propidium Iodide (PI) (Invitrogen, Paisley, UK) for 5min in supplemented 
DMEM at 37ºC to stain live cells green and dead cells red, respectively, when visualised at 
490nm using fluorescence microscopy with a mercury light source.  Propdium Iodide and 
Calcein-AM were stored at -20°C until required.  PI was diluted in water to a concentration 
of 100ug/ml and Calcein-AM was diluted in DMSO to a concentration of 50µg/ml to form 
stock solutions which were stored at 4°C in darkness.  Calcein-AM is highly lipophilic and 
cell membrane permeable. Calcein-AM itself is not a fluorescent molecule, but the calcein 
generated from Calcein-AM by esterases in the cytoplasm of viable cells emits strong green 
fluorescence, and therefore, Calcein-AM only stains viable cells. PI is a nuclei staining dye 
which cannot pass through a viable cell membrane. It reaches the nucleus by passing through 
disordered areas of dead cell membrane, and intercalates with the DNA double helix of the 
cell to emit red fluorescence and therefore, only stains dead cells. Since both calcein and PI-
DNA can be excited at 490nm, simultaneous monitoring of viable and dead cells is possible 
with a fluorescence microscope.  The excitation maxima and emission of calcein and DNA-PI 
are 495nm and 535nm, respectively. 
 
5.4. Trypan blue exclusion/ haemocytometer counts 
In order to ascertain cell number using an improved Neubauer haemocytometer (Beckman 
Coulter Ltd, UK), cells were centrifuged at 167 x g (1000rpm) for 3min and resuspended in a 
small volume of culture medium then mixed 1:1 with a 0.2% w/v solution of trypan blue in 
phosphate buffered saline (PBS, NaCl 138mM; KCl 27mM, pH 7.4 at 25 °C, Sigma, UK).  
The Haemocytometer was then viewed under a light microscope and the number of blue 
(dead) and non-stained (viable) cells counted and used to ascertain the viable cell number 
according to the method described by Butler (2004).  The method is based on the principle 
that live cells possess intact membranes that exclude trypan blue, whereas dead cells do not, 
and therefore viable cells will have a clear cytoplasm whereas non-viable cells will have a 
blue cytoplasm. 
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5.5. Thiazolyl blue (MTT) assay 
3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) is a yellow water-
soluble molecule which readily passes through cell membranes and into the mitochondria.  
MTT is reduced to water-insoluble blue crystals of formazan by mitochondrial succinate 
dehydrogenase.  When cells are solubilised with isopropanol the formazan is released and 
solubilised.  
 
5.5.1. MTT assay for growth 
A stock solution of sterile-filtered 5mg/ml MTT (Sigma, UK) in phosphate buffered saline 
was prepared and stored at 4°C in darkness.  The MTT stock was added to supplemented 
DMEM at a concentration of 10% v/v.  600µl samples of alginate/ 3T3 beads were removed 
from the media, carefully washed in DMEM and immersed in the resulting 10% solution of 
MTT for 18h.  Monolayer cultures of fibroblasts were plated at a density of 4.4×10
5
 cells/ 
well in 6 well plates.  These monolayers were either 1) with no pre-treatment, 2) treated with 
100mM calcium chloride for 2h at 37ºC, 3) treated with 100mM tri-sodium citrate for 2h at 
37ºC, 4) in the presence of a piece of alginate suspended above the cell monolayer in a 
Thincert TM well insert (Greiner, Stonehouse, UK) or 5) released from an alginate hydrogel 
by immersion of the alginate hydrogel in 100mM tri-sodium citrate for 2h at 37ºC.  The MTT 
solution was then removed and replaced with 100mM HCl in isopropanol to lyse the cells and 
left for 2.5h at 37°C to allow the formazan produced to dissolve and diffuse out of the 
alginate.  The optical absorbance of the solution at 620nm was measured using a 
spectrophotometer (Cecil, Cambridge, UK).  The amount of formazan produced by cellular 
reduction of MTT was determined from the absorbance at 620nm according to a calibration 
of different cell concentrations in alginate or in monolayer culture as determined by counting 
using a haemocytometer and the absorbance at 620nm after application of the MTT assay. 
 
5.5.2. MTT assay for mitochondrial activity 
500µl samples of alginate/ 3T3 beads or 3.75×10
5
 monolayer cultured fibroblasts/ well in 6 
well plates were immersed in 10% MTT reagent (v/v) and the amount of formazan produced 
was assessed by spectrophotometer as described above.  Measurements were made hourly so 
that the metabolic activity of fibroblasts under different conditions could be compared.   
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5.6. Measuring mitochondrial membrane potential  
It has been suggested that the ability of 5,5',6,6'-tetrachloro-1,1',3,3'tetra-
ethylbenzimidazolylcarbocyanine iodide (JC-1) to probe the membrane potential depends on 
the reversible formation of aggregates (Reers et al. 1995).  The JC-1 monomers, which 
fluoresce green, should accumulate within the aqueous matrix space resulting in formation of 
aggragates, which fluoresce red, once the critical concentration of monomers has been 
reached (Reers et al. 1991).  De-energising conditions such as metabolic inhibition applied to 
the cells reduce the aggregate emission and increase the monomer emission (Dilisa et al. 
1995).  
 
Encapsulated or monolayer cultures of 3T3 fibroblasts were immersed in FCM containing 
1µm/ml JC-1 (Invitrogen, UK).  The samples were then incubated at 37ºC in the dark for 
15min.   The green and red fluorescence at 490nm were visualized using a fluorescence 
microscope with a mercury lamp.  The amount of green and red fluorescence seen in different 
samples after 15min was used as an indicator of metabolic activity under different conditions. 
 
5.7. Determining alginate degradation by change in mass 
500µl samples of alginate beads were prepared and immersed in 4ml of FCM.  The alginate 
hydrogel masses were assessed at various time points after in vitro culture.  Masses were 
measured before and after degradation in a vacuum freeze-drier (Edwards, EF03, Sussex, 
UK) for 16h.  500µl samples were removed from culture, blotted carefully on paper towels to 
remove excess surface moisture then weighed on a top pan balance.  Samples were measured 
in triplicate and the mean and standard deviation for each data point were shown. 
 
5.8. Inductively coupled plasma - mass spectroscopy (ICP-MS) 
1ml samples of alginate beads were prepared and immersed in 4ml of FCM.  Media was 
changed three times weekly then left unchanged for four days prior to removal of media for 
analysis of calcium, phosphate, potassium and sodium ion content using ICP-MS (Varian, 
Darmstadt, Germany) against standard solutions of 50ppm and 100ppm (Merck, Darmstadt, 
Germany).  Samples were performed in triplicate and mean values±SD shown. 
 
The sample is pumped into a nebulizer, where it is converted into a fine aerosol with argon 
gas. The fine droplets of the aerosol are separated from larger droplets using a spray chamber. 
The fine aerosol then emerges from the exit tube of the spray chamber and is transported into 
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the plasma torch via a sample injector, where the gas is ionized.  When the ionized gas is 
seeded with a source of electrons from a high-voltage spark, it forms a plasma discharge with 
a temperature of 500-800K.  Once the ions are produced in the plasma, they and directed into 
the mass spectrometer and electrostatically focused to the detector.  Analyte ions of a 
particular mass-to-charge ratio (m/z) are allowed through to the detector whilst all the non-
analyte ions are filtered out.  The ions are sampled and an ion detector converts the ions into 
an electrical signal. This electronic signal is then processed by the data handling system in the 
conventional way and converted into analyte concentration using ICP-MS calibration 
standards (Becker 2007).  
 
5.9. Rheology 
The word ‗Rheology‘ comes from the Greek word ‗Rheo‘, meaning to flow, and can be 
defined as the relationship between stress and strain within a material as a function of time, 
temperature, frequency etc.  Stress is the force per unit area acting on a sample and is 
measured in Pascals (Pa).  Strain is the resulting fractional deformation and therefore is a 
dimensionless ratio. 
 
According to their mechanical properties, materials can superficially be classified as either 
solids or liquids.  These two extremes of behavior correspond to a perfect (Hookean) solid or 
a perfect (Newtonian) liquid.  In Hookean solids, such as a steel rod, stress (ζ) is proportional 
to strain (γ) and independant of the rate of strain or oscillatory frequency (Clark & Ross-
Murphy 2009).  For Newtonian liquids, stress is proportional to the rate of strain but 
independent of strain itself.  Most materials, including gels, are referred to as viscoelastic 
materials meaning they display some solid (elastic) behaviour and some liquid (viscous 
behaviour). 
 
5.9.1. Small deformation oscillatory rheology  
Most modern rheometers employ oscillatory shear, with controlled stress.  In the simplest 
form, a small sinusoidal strain wave is applied to the top surface of a gel and the resultant 
stress transmitted through the sample is measured.  In general, the stress and strain waves 
vary in both phase and amplitude, but using phase resolution the in-phase and 90° out-of-
phase components can be extracted.  G′ is the storage or elastic modulus given as a ratio of 
in-phase stress divided by strain, and G″ is the loss modulus, the ratio of out-of phase stress 
to strain (Clark & Ross-Murphy 2009).  G′ is a measure of the energy stored in the material 
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and indicates solid or elastic behaviour.  G″ characterises the liquid or viscous behaviour 
(Zandi et al. 2007).  Combination of both parameters provides important information on 
viscoelastic behaviour of polymer gels.  Viscoelastic solids have a finite G ′, with a value 
usually well above (5-50×) that of the G″, at all frequencies.  G′ and G″ may also show an 
apparent increase with strain, although this is more difficult to generalise (Clark & Ross-
Murphy 2009). 
 
5.9.2. Mechanical spectroscopy 
From the G′ and G″ values the complex viscosity, can be calculated as follows: 
Firstly, the complex modulus, G*, is given by: 
 
G*=           (1) 
 
And the ratio: 
 
 =tan(δ) where δ = the phase angle       (2) 
 
And finally, the comple viscosity, η*, is given by: 
 
η*=  where ω= the oscillatory shear frequency given by 2π × frequency in Hertz. (3) 
 
5.9.3. Monitoring gel degradation by small deformation oscillatory rheology 
The degradation of 2% and 5% w/v acellular and fibroblast encapsulating alginate hydrogel 
discs of 20mm diameter and 5mm height were monitored by capturing images of the discs 
after 28 days in vitro culture (Canon Powershot GS, Surrey, UK) and by performing small 
deformation oscillatory rheology at days 1, 7, 14, 21 and 28.  For both 2% and 5% w/v 
alginate hydrogels the effect of cell culture media on alginate degradation was assessed by 
comparing acellular samples incubated in FCM with acellular samples incubated in water.  
The effect of encapsulated cells on degradation was assessed by comparing acellular samples 
and cell-encapsulating samples incubated in culture media.  All cultures were maintained at 
37ºC with 5% CO2 and 100% relative humidity and media or water was changed three times 
weekly.  Samples were trimmed to size where necessary using a razor blade to obtain samples 
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of 20mm diameter with planar surfaces.  Measurements were taken in the linear viscoelastic 
region using parallel plate geometry 20mm mounted on a Bohlin CVO Rheometer (Malvern 
Instruments, UK) fitted with Peltier plate thermal control. The plate gap corresponded to 
sample thickness.  Measurements of storage modulus (G′), loss modulus (G′′) and dynamic 
viscosity (η*) were taken at frequencies from 1rad/s to 100rad/s to ascertain mechanical 
spectra  of the gels at an isotherm of 37°C and at a fixed strain of 0.5%.  Measurements were 
performed in triplicate and mean values shown.  Comparisons of G′, G′′ and η* were made at 
a frequency of 6rad/s.  
 
5.10. Keratinocytes 
Primary keratinocytes were isolated from neonatal rats.   Primary cultures were established 
by sacrificing one to two day old neonatal rats by cervical dislocation.  The rats were kept on 
ice prior to tissue dissection to minimise tissue deterioration.  After cleaning by bathing in a 
concentrated solution of iodine dissolved in 70% ethanol followed by washing in 70% 
ethanol and then sterile double distilled water, the bodies were placed on a polystyrene board 
and immobilised by needles through the extremities of the limbs.  The skin was then cut away 
using dissection scissors and excess fatty tissue and dermis cut away before placing the skin 
dermis-down on 0.25% trypsin-0.1% EDTA (ethylenediaminetetraacetic acid).  The skin was 
left for 18h at 4°C on the trypsin-EDTA then using forceps the epidermis was mechanically 
separated from the dermis.  The epidermal layer was then minced and placed in FCM with a 
magnetic stirrer bar and placed upon a stirrer plate at approx. 100rpm (16.7 x g) for 30min at 
4ºC.   The stirring releases cells from the epidermal sheet.  The suspension was then strained 
through a tea-strainer so that released cells passed through and the cornified layers of the 
epidermis did not.  The cell suspension was then seeded onto fibroblast feeder layers at a 
density of approx. 3-5×10
5 
cells/ T75. 
 
5.10.1. Keratinocyte culture 
Keratinocyte culture medium (KCM) consisting of 3:1 DMEM:Ham‘s F12 (Sigma, UK)  
supplemented with 50mM hydrocortisone, 10µg/ml insulin, 25ng/ml EGF, 10% v/v FBS 
(PAA), 1% v/v P/S, 2.25% v/v HEPES and 2% v/v L-glutamine was used for the expansion 
of keratinocyte cultures. 
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To discourage primary fibroblast over-growth, the media was removed and replaced with 
0.02% w/v EDTA in PBS.  The cells were then incubated for 30sec at 37°C and aspirated 
vigorously to detach fibroblasts and leave the keratinocytes attached. 
 
3T3 feeder layers were prepared by incubating 3T3 monolayers in a 4µg/ml solution of 
Mitomycin C (Sigma, UK) in FCM.  The solution was removed, then cells were washed three 
times in PBS before being trypsinised in trypsin-EDTA for approx 3-5min at 37°C, 
centrifuged at 1000rpm (167 x g) for 3min, counted and used for support of keratinocyte 
cultures. Approx. 1×10
6 
feeder cells were seeded into T75 flasks for use as feeder layers. 
 
5.10.2. Epidermal analogue culture 
In order to tissue engineer epidermal analogues keratinocytes were seeded onto the surface of 
either alginate/ 3T3 dermal analogues or Thincert TM 6 well plate inserts with pores of 
0.4µm diameter (Greiner Bio One, UK) at a density of 2×10
5 
cells/cm
2
.  Where Thincerts 
were used, a 3T3 feeder layer was present on the base of the multiwall dish below. The 
keratinocytes were cultured for 7 days in KCM on these surfaces before being raised to the 
air-liquid (A/L) interface and cultured in 3:1 DMEM:Ham‘s F12 supplemented with 10% 
FBS (PAA), 1% v/v P/S, 2.25% v/v HEPES and 2% v/v L-glutamine to allow for 
stratification of the keratinocytes.  All keratinocyte cultures were maintained at 37ºC with 5% 
CO2 and 100% relative humidity. 
 
5.11. Endothelial cells (ECs) 
Immortalised mouse coronary ECs were a gift from Prof. Gerard Nash (University of 
Birmingham Medical School).  Endothelial cell culture medium (ECCM) was composed of 
Medium 199 with L-glutamine (Invitrogen, UK)  supplemented with 20% foetal bovine 
serum (PAA, UK), 1µg/ml mouse hydrocortisone, 10ng/ml mouse EGF, 1% v/v p/s, 1% v/v 
Fungizone (Gibco, UK) and 2.25% v/v HEPES.  EC cultures were maintained at 37ºC with 
5% CO2 and 100% relative humidity and media was changed three times weekly. 
 
5.11.1. EC migration assay  
The ability of the dermal analogue to induce migration of ECs was investigated.  7.5×10
5
 ECs 
were plated onto 6 well tissue culture (TC) treated transwell support with 8µm diameter pores 
(Fisher Scientific, UK).  These supports were placed in deep-well 6 well plates which were 
seeded with 7ml of 2% or 5% w/v fibroblast encapsulating/ acellular alginate to which 14ml 
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ECCM was added.  This medium was left unchanged throughout the course of the study.  At 
different time points, EC cells present on the underside of the transwell supports (which had 
migrated through the pores in the transwell supports) were were removed with a cell scraper 
and suspended in PBS. The number of cells was then determined by counting on a 
haemocytometer.  Samples were performed in triplicate and mean±SD values are shown. 
 
5.11.2. EC proliferation assay 
The ability of the dermal analogue to induce proliferation of ECs was investigated.  2.5×10
5
 
ECs were plated onto 6 well TC treated transwell support (Fisher Scientific, UK) with 0.4µm 
diameter pores.  These supports were placed in 6 well plates which were seeded with of 2% 
or 5% w/v fibroblast encapsulating/ acellular alginate, as for the EC migration experiments.  
This media was left unchanged throughout the course of the study. At different time points, 
the number of EC cells present was determined by counting on a haemocytometer, after 
trypsinisation in trypsin-EDTA fro approx. 3-5min at 37°C.  Samples were cultured in ECCM 
which was changed three times weekly.  Measurements were performed in triplicate and 
mean±SD values are shown.  
 
5.12. VEGF enzyme-linked immunosorbent assay (ELISA) 
ELISA is an immunoassay technique involving the reaction of antigen and antibody in vitro.  
ELISA is a sensitive and specific assay for the detection and quantitation of antigens or 
antibodies.  The ELISA kit used employs the quantitative sandwich enzyme immunoassay 
technique. A polyclonal antibody specific for mouse VEGF is pre-coated onto a microplate. 
Any mouse VEGF present is bound by the immobilized antibody and after washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for mouse VEGF is 
added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution is added to the wells. The enzyme reaction yields a blue product that turns 
yellow when the Stop Solution is added. The intensity of the colour measured is in proportion 
to the amount of mouse VEGF bound in the initial step. The VEGF concentrations are then 
read off the standard curve according to the absorbance at 450nm. 
 
The amount of VEGF secreted by 3T3 fibroblast monolyers and 3T3s encapsulated in 2% and 
5% w/v alginate hydrogels was determined by VEGF ELISA (R&D Research Systems, 
Abingdon, UK).  3T3 monolayers were seeded at a density of 4.4×10
5
/ well of a 6 well plate, 
and 1ml samples of alginate containing 7.5×10
5
/ml were used.  Samples were cultured in 4ml 
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FCM which was changed three times weekly and left unchanged for three days before 
sampling.  Media samples were collected and stored at -20°C for up to four weeks before 
assaying, in accordance with the manufacturer‘s instructions.  Measurements were performed 
in triplicate and mean±SD values are shown. 
 
5.13. Subculture and freezing  
Phosphate buffered saline (PBS) was obtained for Sigma (UK) and used to wash monolayer 
cultures.  0.25% w/v trypsin/ 0.1% EDTA was obtained from Sigma (UK) and used for 
detachment of cultured cells on tissue culture flasks to prepare cell suspensions for sub-
culture or freezing.  10% v/v DMSO (dimethyl sulfoxide) in FCM or KCM was used to 
protect cells during frozen storage, by preventing the formation of ice crystals.    Fibroblasts 
and ECs were split 1:6 and keratinocytes 1:2 for passaging.   All cells were generally frozen 
at a density of 1×10
6
 cells/ml. Cell densities for seeding were measured using a 
haemocytometer. 
 
5.14. Histology and immunostaining 
5.14.1. Histological Stains 
Once tissue sections or cells are firmly attached to glass microscope slides, various staining 
methodologies can be applied to visualize cell and tissue structure and composition.  
Visualization is facilitated by the application of dyes, the deposition of heavy metals and the 
use of chemical reactions  
 
The staining procedure most commonly used is the haematoxylin and eosin (H&E) method 
which demonstrates the general architecture of tissue.  The haematoxylin stains the cell nuclei 
and other negatively charged structures such as alginate blue-black while the eosin stains cell 
cytoplasm and most connective tissue fibres in varying shades of pink, orange and red 
(Gamble & Wilson 2002).  H&E staining was performed using a Shandon Linistain GLX 
Random Access Stainer (Thermo Scientific, UK).  Samples were heated to 60°C for 4.5min, 
then immersed in xylene for 1min, IMS 99 (Genta Medical, UK) for 40sec, 95% IMS 99 for 
40sec, rinsed in tap water for 20sec, immersed in Gill‘s III Haematoxylin (Surgipath Europe 
Ltd, UK) for 2.5min, rinsed in tap water for 20sec, immersed in 0.3% w/v acetic acid (Merck 
Ltd, UK) in distilled water for 20sec, 0.3% HCl (Genta Medical, UK) in 70% IMS 99, rinsed 
in water for 20sec, immersed in Scott‘s tap water substitute (Surgipath Europe Ltd, UK) for 
40sec, washed in tap water for 20sec, immersed in Eosin (Surgipath Europe Ltd, UK) diluted 
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1:1 with 70% IMS 199 for 20sec, rinsed in tap water for 20sec, immersed in IMS 199 for 
1min and zylene for 50sec.  Following this the samples were held in xylene for up to 4h 
before application of cover slips. 
 
Collagens are the most abundant component of most tissue ECM including the dermis of 
skin.  Collagens stain strongly with acid dyes due to the affinity of the cationic groups of the 
proteins for the anionic reactive groups of the acid dyes.  Van Gieson is a compound solution 
of acid dyes, developed in 1899, which can be used to selectively stain collagen red/pink and 
other tissues yellow.  The cell nuclei are again stained blue-black by the use of haematoxylin.   
For HVG staining, samples were taken down to water and stain with 1% w/v celestin blue 
(Merck Ltd, UK) for 5min, then drained and stained with Mayer‘s haematoxylin (Merck Ltd, 
UK) for 5min, rinsed in tap water, rapidly differentiated with 1% w/v hydrochloric acid 
(Merck Ltd, UK) in 70% IMS 99 (Genta Medical, UK), washed in tap water for 5min, then 
rinsed in distilled water.  Samples were then stained with Van Gieson‘s working solution (9 
parts saturated aqueous picric acid (Merck Ltd, UK): 1 part 1% w/v aqueous acid fuchsin 
(Merck Ltd, UK)) for 3min, rinsed rapidly in 100% IMS 99 then immersed in xylene for up 
to 4h before application of cover slips. 
 
5.14.2. Immunochemistry 
Immunocytochemistry (ICC) refers to the staining of cell monolayers whereas 
immunohistochemistry (IHC) refers to the staining of tissue sections.  IHC and ICC are 
techniques used to identify cellular and tissue constituents (antigens) by means of antigen-
antibody interactions.  The site of antibody binding is either identified by direct labeling or 
the use of a secondary labeling method.  An advantage of an indirect method, such as the 
peroxidase-anti-peroxidase (PAP) method, is that it gives increased staining when compared 
with direct methods.  In the PAP method a specific region of an antigen of interest, known as 
an epitope, is recognized by the primary antibody.  A PAP complex then binds to the primary 
antibody which is labeled with horse raddish peroxidase.  This enzyme is the most commonly 
used label in ICC and IHC, and when incubated with the chromogen 3,3'-diaminobenzidine 
(DAB) it produces a stable, non-soluble, brown coloured reaction end-product which can be 
visualised by light microscopy (Miller 2002).   IHC and ICC are useful for ascertaining semi-
quantitatively the level of gene expression and the distribution of a protein in a sample.    
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5.14.3. Sample preparations 
10% v/v formal-saline was prepared by dissolving 10ml 40% w/v formaldehyde (Sigma, UK) 
in 90ml 0.85% w/v saline solution (Sigma, UK).  This was used to fix 3D samples for 24h at 
room temperature.  Acetone was obtained form Sigma, UK and used to fix cell monolayers 
for 30min at room temperature. 
 
3D samples were transferred to CellSafe biopsy inserts (CellPath Ltd, Newtown, UK) and 
placed in cassettes (CellPath Ltd, UK).  They were automatically processed by progressive 
dehydration in graded ethanol then immersed in xylene using a Citadel 1000 Tissue Processor 
(Thermo Scientific Inc, UK).  Samples were then transferred to liquid paraffin (Tissue-Tek 
III Embedding Wax (polymer added), Sakura, UK) and embedded in paraffin using a Tissue-
Tek TEC Tissue Embedding Console System (Sakura, UK). 
 
Antibodies, dilutions and suppliers are displayed in Table 5.1.  Haematoxyllins, eosin, and 
other stains for histology were obtained from Surgipath Europe Ltd, UK. 
 
Table 5.1: Antibodies used in Immunohistological and immunocytochemical 
experiments. 
Antibody Supplier Dilution 
Used 
Antigen Retrieval Method 
Proliferating cell nuclear 
Antigen (PCNA) 
Dako 
(Cambridgeshire, 
UK) 
1/10 N/A 
Pan Cytokeratin (PanK) Sigma (Poole, UK) 1/400 30min in trypsin at room 
temperature. 
 
Embedded samples were cooled to 5°C in a refrigerator then placed on ice before 5μm 
sections were cut using a microtome (Leica RM 2035, Bucks, UK) and attached to glass 
slides for histology or Superfrost Plus glass slides (Laboratory Sales Limited, Rochdale, UK) 
for immunohistochemistry (IHC) .  Slides were dried at 56°C for 2h for IHC and for 45min at 
60°C for histology.  The wax was then removed from the sections by immersion of the slides 
in xylene then samples were progressively rehydrated through graded ethanol.  For IHC, all 
samples were labelled according to the peroxidase-anti-peroxidase (PAP) method, for which 
no antigen retrieval was necessary, and counterstained with Mayer‘s Haematoxylin 
(Surgipath Europe Ltd, Peterborough, UK).  Coverslips were then mounted on the slides 
using Xam (BDH Laboratory Supplies, Poole, UK) and viewed with a light microscope. The 
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images were then corrected using Image J software (NIH, Maryland, USA) to remove any 
uneven illumination from the image. 
 
5.15. Semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) 
RNeasy mini kits (Qiagen, UK) and DNase kits (Qiagen, UK) were used to extract sample 
RNA.  For lysis buffer preparation, beta-mercaptoethanol (Promega, UK), a reducing agent 
used for nuclease inhibition, was added to the RLT buffer (supplied in the RNeasy kit at a 
ratio of 1/100 (v/v). RNA isolation was performed according to the instructions in the Qiagen 
RNeasy mini kit.  mRNA quality and quantity were evaluated and quantified using a 
spectrophotometer (BioPhotometer, Eppendorf, UK) and by electrophoresis using a 1% w/v 
agarose gel, prepared by dissolving agarose in Tris Acetate EDTA (TAE) buffer.  3µl of 
stock solution of 10mg/ml ethidium bromide (Promega, UK) were added to 120ml gel 
solution to allow visualisation of bands on the gel when exposed to fluorescent light.  The gel 
was poured into a mold and combs placed in the gel to create the wells and left for around 
20min at room temperature until the gel solidified.  The gel was immersed in TAE buffer in 
the electrophoresis tank.  HyperLadder IV (Bioline, UK) was loaded onto the gel to provide 
molecular weight markers.  Cell lysates and mRNA samples were stored at -20°C and -80°C 
respectively to prevent sample degradation, and both were kept on crushed ice throughout the 
experiments. 
 
Omniscript reverse transcriptase, oligo dT primer (0.5ug/ml) and RNase inhibitor (40units/ul) 
from Promega (UK) were used for reverse transcription of mRNA to complementary DNA 
(cDNA) according to the instructions in the Omniscript kit handbook.  Montage PCR 
centrifugal filters (Millipore, UK) were applied to purify the cDNA.  The cDNA and mRNA 
quality and quantity were evaluated using a spectrophotometer (BioPhotometer, Eppendorf, 
UK) and by running samples on a 1.5% w/v agarose electrophoresis gel with ethidium 
bromide.  Mastercycler thermal cycler (Eppendorf, UK) and REDTaq® ReadyMix
TM
 PCR 
reaction mixture was used to amplify the cDNA according to the manufacturer‘s instructions.   
The PCR program was as follows; 94 °C for 5 min, denature the template at 94°C for 20sec, 
anneal primers at 60°C for 20sec, Extension at 72°C for 20sec, 72°C for 10min.  30 cycles 
were performed then samples were then held at 4ºC.  All primers were designed using Primer 
3 and obtained from Invitrogen, UK. The primers used are summarised in Table 5.2.  The 
expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was normalised between 
samples in each set, so that the relative expression of genes of interest could be established.  
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GAPDH was used for normalisation since it a house keeping gene and the expression of 
GAPDH should be relatively constant and, therefore, be proportional to cell number. 
 
The cDNA samples were stored at -20°C at kept on crushed ice throughout the experiments 
to inhibit nuclease activity.  All solutions and samples were prepared using RNase-free water 
and nuclease free plastic ware (Appleton Woods, UK).  The plastic ware was autoclaved 
before use and care was taken not to introduce contaminants to the plastic ware throughout 
the experiments.  Electrophoresis tanks and combs were cleaned with detergent and rinsed 
thoroughly in double distilled water between uses.   
 
Table 5.2:  Primers used for semi-quantitative RT-PCR experiments. 
Primer  Gene Primers (Forward(F) and Reverse (R)) Product 
length 
(bps) 
rGAPDH Rat GAPDH F-CCCATCACCATCTTCCAGGAG  
R-GCTGAACGGGAAGCTCACTGG 
227 
rINV Rat involucrin F-AAGTCCCCAGAGCCAGAACT  
R-TGTGAGTCATCCAGCTCCTG 
308 
rK5 Rat cytokeratin 5 F-AGTGTGCCAACCTCCAGAAT  
R-AGCCATAGCCAATGTTGCTT 
318 
rK10 Rat cytokeratin 10 F-TCACCACAGAAATCGACAGC  
R-GGGTTATTTGCAGGTTTCCA 
360 
rK1 Rat cytokeratin 1 F-CCCACCACACCATTAGCTCT  
R-GCGCTCCGTAAAAGACACTC 
369 
mKGF Mouse keratinocyte 
growth factor 
F-GATCAAGCCCCACACAAACT   
R-TGCTAGTCATGGTGTCAGCC 
611 
mIL-6 Mouse interleukin 6 F-CCGGAGAGGAGACTTCACAG  
R-GGAAATTGGGGTAGGAAGGA 
339 
mVEGF Mouse vascular 
endothelial growth 
factor 
F-CTGCTCTGGGTCCACTGG 
R-CACCGGGTTGGCTTGTCACAT 
431, 
563, 635 
mFGF-2 Mouse fibroblast 
growth factor - 2 
F-AGCGGCTCTACTGCAAGAAC 
R-TATGGCCTTCTGTCCAGGTC 
350 
mNGF Mouse nerve growth 
factor 
F-TGTGCCTCAAGCCAGTGAAATT   
R-TCCACAGTGATGTTGCGGGTCT 
463 
mGAPDH Mouse GAPDH F-CCCATCACCATCTTCCAGGAGC  
R-CCAGTGAGCTTCCCGTTCAGC 
450 
 
5.16. Statistical Analysis 
Statistical significance (P<0.05) between test groups was determined by one-way analysis of 
variance (ANOVA) and Tukey post-hoc test (SPSS v.17, Chicago, USA).  
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6. Effect of encapsulation on fibroblast viability, growth and 
catabolic activity 
Alginate hydrogel was used to encapsulate 3T3 fibroblasts to tissue engineer the dermis, in 
which the 3T3 murine fibroblasts serve as analogues for autologous dermal fibroblasts.  This 
alginate/ fibroblast graft will be implanted into the wound site to facilitate replacement of the 
lost dermis, and to act as a ‗feeder layer‘ to support the growth and differentiation of 
keratinocytes on the scaffold surface to form a new epidermis.  The effect that the alginate 
hydrogel scaffold has on the behaviour of cells is important for the success of the graft since 
scaffolds play an important part in controlling cell behaviour including growth (Brandl et al. 
2007; Discher et al. 2005; Kakisis et al. 2005).  It is desirable to limit proliferation of the 
encapsulated fibroblasts to prevent over-growth of keratinocytes and so that the viability of 
fibroblasts is maintained within the initially avascular scaffold.   
 
When a tissue engineered (TE) construct is delivered to the body, meeting the oxygen 
requirement of the cells is essential for the success of the treatment (Nomi et al. 2002), but 
also later to support various cellular mechanisms, including cell cycle, cell proliferation, 
glucose metabolism and cell differentiation (Mishra & Starly 2009).  This is more likely to be 
achieved if the early cell density, and therefore oxygen requirement of the avascular graft 
remains relatively low (Mishra & Starly 2009).   
 
For production of the TE skin a co-culture of keratinocytes and fibroblasts is used.  
Fibroblasts have a higher mitotic index than keratinocytes so to prevent overgrowth these 
cells are usually mitotically inhibited.  The growth of the fibroblasts can be inhibited by 
gamma irradiation or Mitomycin C treatment (Stanovic et al. 2000; Tseng et al. 1996).  These 
approaches are, however, only suitable for production of TE epidermal layers in vitro since 
they are lethal to the cells. The mitotically inhibited fibroblasts can be intermittently replaced 
to allow them to act as a feeder layer to support keratinocytes, in vitro.  Since the TE skin 
under development is, however, intended to be implanted and allow in vivo tissue 
development of both the epidermis and the dermis, it is essential that the fibroblasts remain 
both mitotically inhibited and viable to act both initially as a feeder layer for keratinocytes, 
and also, later to facilitate dermal repair. 
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Cell proliferation is known to be controlled by cell-cell contact (Wieser et al. 1990; Wieser & 
Oesch 1995).  Isolating cells to reduce cell-cell contact in both 2D and 3D culture has been 
shown to limit cell proliferation (Liu et al. 2006b; Mishra & Starly 2009).  Reducing cell 
density has also been shown to reduce catabolic activity and therefore the oxygen 
requirement of each cell (Guarino et al. 2004).  Limiting cell-cell contact in the 3D 
environment of the alginate hydrogels should achieve the same reduced proliferation and 
catabolic activity that is seen in monolayer culture, whilst maintaining cell viability.  In order 
to reduce cell-cell contact in the alginate hydrogels it is important to mechanically isolate the 
fibroblasts from one other as adherent cells tend to adhere to each other and form dense 
aggregates.  Such aggregates may develop central necrotic regions due to the relative 
inaccessibility of nutrients and oxygen to cells embedded in the core, or due to the build up of 
toxic products within the core (Guarino et al.  2004).    In this chapter the viability, growth, 
catabolic activity and change in cell distribution exhibited by fibroblasts encapsulated as 
uniformly dispersed entities in two concentrations of low viscosity calcium-alginate are 
described.   
 
6.1.  Results 
6.1.1. Live/ dead staining 
Calcein-AM/ PI Live/ dead staining was used to assess the long-term effect of alginate 
hydrogel encapsulation on cell viability.  In situ live/dead staining of fibroblasts encapsulated 
in 2% and 5% w/v alginate was performed at 3, 14, 28, 60 and 150 days.  The cells were seen 
to be homogeneously distributed throughout the alginate hydrogels as dispersed entities 
rather than aggregates at all time points in both 2% and 5% w/v alginate hydrogels.  Sections 
from the centre of alginate beads or discs of 3mm diameter are shown in Figure 6.1. The 
presence of mainly green and very few red cells illustrated that cell viability was maintained 
throughout the hydrogels for at least 150 days in vitro culture. 
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Figure 6.1: Alginate encapsulated fibroblasts stained with Calcein AM/ PI live/ dead 
stain in 2% w/v and 5% w/v alginate at 3, 14, 28, 60 and 150 days post encapsulation.  
No evidence of spheroid formation or cell proliferation is visible.  The viability of cells 
throughout the experiment was illustrated by the presence of mainly green cells and 
very few red cells.  This indicates that the diffusion of nutrients and waste products 
through the matrix was sufficient to maintain the cells’ viability. 
Day 3
Day 14
Day 28
Day 60
Day 150
2% w/v 5%w/v
250µm
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6.1.2. Effect of culture time on fibroblast distribution within the alginate hydrogels 
Histological evaluation of the encapsulated cells in 2% w/v and 5% w/v alginate using H&E 
(Figure 6.2) illustrated the architecture of the construct by staining the cytoplasm of cells 
pink due to eosin and the cell nuclei and alginate chains blue/black by the haematoxylin due 
to the negative charges of the nuclei and the alginate chains.  Sections of the tissue 
engineered construct were taken weekly from week one to week five.  This staining 
illustrated that the encapsulated cells remained present within the scaffold as discrete entities 
and not as aggregates throughout the duration of the study, mechanically confined from each 
other by the alginate hydrogel surrounding the individual cells in both 2% and 5% w/v 
alginate hydrogels (Figure 6.2).  
 
Figure 6.2: H&E staining of encapsulated fibroblasts up to five weeks post-
encapsulation in 2% w/v alginate and 5% w/v alginate.  Cell nuclei and alginate stain 
blue/ black and cytoplasm of cells stain pink.  The cells are shown to remain as 
dispersed entities mechanically confined by the alginate hydrogel throughout the 
experiment. 
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6.1.3. Effect of alginate encapsulation on fibroblast proliferation 
The effect that encapsulation in 2% and 5% w/v alginate hydrogels had on mitotic activity of 
cells both during their encapsulation and following their release from the degraded alginate 
hydrogels was investigated using the MTT assay.  This assay relies on mitochondrial activity 
of viable cells to covert MTT to formazan and can be used to quantitatively measure viable 
cell numbers encapsulated in alginate (Khattak et al. 2006).   
 
Fibroblasts encapsulated in 2% and 5% w/v alginate hydrogels were shown to remain viable 
but be mitotically inhibited by the encapsulation, as illustrated by the lack of change in viable 
cell number throughout the 33 days from the cell seeding number of 4.4×10
5
 cells (Figure 
6.3).    On release from 2% and 5% w/v alginate, the cells were shown to attach to tissue 
culture plastic and proliferate in monolayer culture after one and three weeks encapsulation in 
a similar manner to that seen before encapsulation (Figure 6.4).   The bell-shaped growth 
curve that is seen in these monolayer cultures is due to proliferation of the cells in the first 
few days to cover the surface of the culture dish to confluence, when the rate of cell 
proliferation decreases.  Cell number is then maintained as the cells enter the stationary phase 
(Freshney 2005).  Subsequently, cell death begins to occur at a higher rate than proliferation, 
as nutrients likely become limited (Hwang & Lee 2008) and toxic waste products likely begin 
to accumulate, since the medium was only refreshed three times weekly.  Dying cells release 
pro-apoptotic growth factors and cytokines (Burscha et al. 2008), and this would induce the 
death of surrounding cells.   
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Figure 6.3: Growth curves determined by the MTT growh assay of 3T3 fibroblasts 
encapsulated in a) 2% and b) 5% w/v alginate hydrogels, compared with non-
encapsulated 3T3s (control).  Mean values ± SD are shown (n=3).  The fibroblasts 
encapsulated in 2% and 5% w/v alginate remain at a constant cell number up to 33 
days post-encapsulation, rather than exhibiting the bell-shaped growth curve seen with 
monolayer cultured fibroblasts.  Significant differences (p<0.05) between encapsualed 
samples and the control were seen at all time points except day 0 and 1.  No significant 
differences were seen between samples encapsulated in 2% and 5% w/v alginate 
hydrogels. 
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Figure 6.4: Growth curves determined by the MTT growh assay of 3T3 fibroblasts 
released after one and three weeks encapsulation in a) 2% and b) 5% w/v alginate 
compared with non-encapsulated 3T3s (control).  Mean values ± SD are shown (n=3). 
Fibroblasts released from encapsulation in 2% and 5% w/v alginate generally displayed 
normal growth in monolayer culture after both one and three weeks encapsulation. 
Significant differences (p<0.05) between controls and released samples were only seen at 
days three (2% one and three week samples; 5% three week sample) and day 14 (2% 
and 5% at three week samples). 
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The possible causes of the reversible mitotic inhibition demonstrated by cells encapsulated in 
alginate hydrogel were investigated by examining the growth of fibroblasts in different 
conditions.  3T3 fibroblasts grown in monolayer culture in alginate hydrogel presence were 
shown to exhibit normal mitotic activity when compared with non-encapsulated control 
samples.   3T3 fibroblasts grown in monolayer culture after exposure to 100mM calcium 
chloride and 100mM tri-sodium citrate for a period of 2h also displayed normal mitotic 
behaviour (Figure 6.5). 
 
 
Figure 6.5: Growth curves determined by the MTT growh assay of non-encapsulated 
fibroblasts in the presence of 5% w/v alginate hydrogel, treated with CaCl2 and treated 
with tri-sodium citrate, compared with non-encapsulated control samples.  Mean values 
± SD are shown (n=3). The growth curves were seen to be very similar under all 
conditions showing that alginate presence, citrate treatment and CaCl2 treatment had 
no appreciable effect on cell proliferation.  Compared with the control, significant 
differences (p<0.5) were only seen at 3h for CaCl2 and alginate presence and for all 
samples at 12h. 
 
The reversible mitotic inhibition exhibited by cells encapsulated in alginate hydrogels was 
confirmed by staining for PCNA.  PCNA is a marker expressed primarily in the nuclei of 
cells in S phase of the cell cycle and thus can be used as a measure of mitotic activity (Foley 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
2.00
0 2 4 6 8 10 12 14 16
Ce
ll 
N
u
m
n
er
 (×
10
6)
Time (days)
control Calcium chloride Tri-sodium citrate alginate presence
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
2.00
0 5 10 15 20 25 30 35
V
ia
b
le
 c
e
ll
 n
u
m
b
e
r 
(x
1
0
6
)
Time (days)
c ntrol 2% encapsulated
69 
 
et al. 1991; Leong et al. 1995).  Before encapsulation in alginate, 3T3 fibroblasts were shown 
to express PCNA when grown in monolayer culture, as shown by the intense brown staining 
of cell nuclei (Figure 6.6a).  Fibroblasts are the main cell type present in the dermis of skin 
(MacNeil 2007) and the majority of cells encapsulated in the dermis of skin stained blue with 
the haematoxylin counter-stain, rather than brown and, therefore, were not dividing      
(Figure 6.6b).  PCNA staining of encapsulated fibroblasts in 2% and 5% w/v alginate 
confirmed that cells were not mitotically active at either week one or week three post-
encapsulation (Figure 6.7), like fibroblasts encapsulated in the ECM of normal rat dermis 
(Figure 6.6b).  PCNA staining also confirmed that when fibroblasts were released from the 
alginate hydrogels, normal mitotic activity was resumed, with nearly 100% of the cells 
staining positively for PCNA (Figure 6.7), as seen before encapsulation (Figure 6.6a). 
 
 
Figure 6.6:  PCNA expression in a) non-encapsulated (control) 3T3 fibroblasts and b) 
fibroblasts in the rat dermis.  Cells which express PCNA and are dividing have strongly 
stained brown nuclei, whereas cells which were not dividing and did not express PCNA 
stained blue due to the haematoxylin counter-stain.  The majority of fibroblasts in the 
dermis did not express PCNA whereas the fibroblasts in monolayer culture express 
PCNA. 
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Figure 6.7: PCNA expression of encapsulated 3T3 cells encapsulated and released from 
2% w/v and 5% w/v alginate after one and three weeks encapsulation.  All encapsulated 
fibroblasts were shown to have blue nuclei and therefore did not express PCNA and 
were not dividing and all released fibroblasts were shown to express PCNA and be 
proliferating. 
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6.1.4. Effect of alginate encapsulation on catabolic activity of cells 
The catabolic activity of fibroblasts were determined by measuring the amount of formazan 
that was produced (from reduction of MTT) with time.  Before encapsulation, 3.75×10
5
 
fibroblasts in monolayer culture were shown to produce 5.37±0.37µg of formazan from 
reduction of MTT in 5h, when no further formazan was produced (Figure 6.8a).  In 
comparison, the same number of cells encapsulated in 2% w/v alginate were shown to only 
produce 0.65±0.03µg of formazan in 5h after one week encapsulation and formazan 
continued to be produced between 5h and 11h (Figure 6.8a).  After three weeks encapsulation 
in 2% w/v alginate, the amount of formazan produced with time was not significantly 
different from that seen after one week encapsulation (p<0.05) (Figure 6.8a).  Fibroblasts 
encapsulated in 5% w/v alginate also exhibited a reduced ability to reduce MTT to formazan 
after both one and three weeks encapsulation when compared with non-encapsulated control 
fibroblasts (Figure 6.9b).  When fibroblasts were released form 2% w/v alginate (Figure 6.9a) 
and 5% w/v alginate (Figure 6.9b) after one and three weeks encapsulation, the cells were 
shown to reduce MTT to formazan at a similar rate to that seen before encapsulation showing 
that the catabolic inhibition seen during encapsulation was reversible.   
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Figure 6.8: Formazan produced with time from MTT for non-encapsulated (control) 
fibroblasts compared to fibroblasts encapsulated in a) 2% w/v and b) 5% w/v alginate 
hydrogel at one and three weeks post-encapsulation.  Mean values ± SD are shown 
(n=3). The rate at which the fibroblasts produce formazan was comparable for 
encapsulated cells at both one and three weeks post encapsulation.  The amount of 
formazan produced by both 5% w/v encapsulated fibroblast samples was significantly 
lower (p<0.05) than by control samples at all time points. 
 
 
0
1
2
3
4
5
6
7
0 2 4 6 8 10 12
F
o
rm
a
z
a
n
 (
µ
g
)
Time (hours)
control 2% encapsulated 1 week 2% encapsulated 3 weeks
0
1
2
3
4
5
6
7
0 2 4 6 8 10 12
F
o
rm
a
z
a
n
 (
µ
g
)
Time (hours)
control 5% 1 week encapsulated 5% 3 weeks encapsulated
A
B
73 
 
 
Figure 6.9:  Formazan produced with time from MTT for non-encapsulated (control) 
fibroblasts compared to fibroblasts released from a) 2% w/v and b) 5% w/v alginate 
hydrogels at one and three weeks post-encapsulation.  Mean values ± SD are shown 
(n=3). The rate at which the fibroblasts produce formazan was comparable for all 
samples showing that after release from encapsulation in 2% w/v and 5% w/v alginate 
the fibroblasts resumed normal catabolic activity.  Significant differences (compared 
with the control) (p<0.05) were only seen at 3h for 2% three week samples and 5% one 
and three week samples, and at 5h for 5% three week samples. 
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Calcium chloride treatment, tri-sodium citrate treatment and the presence of alginate hydrogel 
were shown to have no appreciable effect on the ability of fibroblasts in monolayer culture to 
reduce MTT to formazan (Figure 6.10).  This showed that these factors were not responsible 
for the reversible catabolic inhibition which is seen during encapsulation in 2% and 5% w/v 
alginate hydrogels. 
 
Figure 6.10: Formazan produced with time from MTT for non-encapsulated (control) 
fibroblasts compared with non-encapsulated cells exposed to calcium chloride or tri-
sodium citrate or cultured in the presence of 5% w/v alginate hydrogel.  Mean values ± 
SD are shown (n=3).  The rate of formazan production was comparible between all four 
samples, although the amount of formazan produced by all three samples at 2h and 3h, 
and alginate presence and citrate samples at 4h was significantly lower (p<0.05) than 
the control. 
 
The reversible catabolic inhibition by encapsulation was confirmed by staining the cells with 
JC-1, which gives a measure of mitochondrial membrane potential.  Fibroblasts encapsulated 
in both 2% and 5% w/v alginate after one and three weeks encapsulation were shown to 
exhibit reduced red fluorescence (Figure 6.11) when compared with control cells          
(Figure 6.12a) indicating that encapsulated cells had a lower mitochondrial activity than 
control samples.  The amount of red fluorescence was observed to be comparable for all 
encapsulated samples showing that incubation time and percentage alginate had no effect on 
the cells‘ catabolic activity.  Cells released from 2% and 5% w/v alginate after one and three 
weeks encapsulation (Figure 6.12b-e) were observed to exhibit a level of red fluorescence 
which was comparable with that which was seen before encapsulation (Figure 6.12a).  This 
showed that after release from encapsulation the fibroblasts resumed normal catabolic 
activity. 
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Figure 6.11: JC-1 staining of encapsulated fibroblasts in 2% and 5% w/v alginate one 
and three weeks post encapsulation.  Mitochondria with a high membrane potential 
stain red in catabolically active cells stain red.  There were very few cells with red 
staining present in any of the photomicrographs indicating that the cells were not very 
catabolically active when encapsulated in alginate hydrogels. 
 
Figure 6.12: JC-1 staining of fibroblast monolayers a) before encapsulation (control), b) 
released form 2% alginate after one week, c) released from 2% alginate after three 
weeks, d) released from 5% alginate after one week and e) released from 5% alginate 
after three weeks.  Mitochondria with a high membrane potential in catabolically active 
cells stain red.  In all samples the number of cells with some or complete red staining 
(catabolically active) was similar showing that after the cells are released from alginates 
they resume normal catabolic activity. 
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6.2.  Discussion 
The encapsulated fibroblasts were seen to be homogeneous distribution throughout the 
alginate hydrogels at all time points.  This contradicted the hypothesis made by Bienaime et 
al. (2003) that cell distribution would be more concentrated towards the periphery of the 
alginate hydrogels.  The authors proposed that this would happen due to the movement of 
alginate chains to the periphery during the gelling process, which would pull the cells toward 
the periphery.  Furthermore, the authors hypothesised that the effect would be especially 
evident when the concentration of alginate hydrocolloid was increased, and this was also not 
evident upon increasing the concentration from 2% to 5% w/v.    
 
Fibroblasts encapsulated in both 2% and 5% w/v alginate hydrogels were shown to be viable 
up to 150 days encapsulation  (Figure 6.1).  The long term viability of other encapsulated 
cells has been demonstrated, for example with chondrocytes (Schagemann et al. 2006) and 
human embryonic stem cells (Siti-Ismail et al. 2008) and two other fibroblast cell lines 
(Chang et al. 1994).  In the present study, the viability of cells in the centre of both 2% and 
5% w/v alginate hydrogel structures with a thickness of 3mm was observed.  This illustrated 
that there was no critical necrosis and that oxygen tension was high enough to support cell 
survival throughout the duration of the study, in contrast with what has been found with other 
alginate hydrogels and cell types (Khattak et al. 2007).  The cells remained as viable 
dispersed units and failed to form cell aggregates (Figures 6.1 and 6.2) in the alginate 
hydrogels throughout the duration of the study, in contrast with previous reports (Khattak et 
al. 2006; Schagemann et al. 2006; Siti-Ismail et al. 2008).   
 
Encapsulated cells in both 2% and 5% w/v alginate hydrogels were indicated to remain viable 
but not proliferate according to the MTT assay (Figure 6.3).  The lack of proliferation was 
further confirmed as the encapsulated cells failed to express PCNA in the nuclei, as shown by 
the blue rather than brown staining of all nuclei (Figure 6.7).  Following release of cells from 
the alginate hydrogels, normal mitotic activity was demonstrated (Figure 6.4), as was 
confirmed by positive staining for PCNA (Figure 6.7).  This indicated that cells encapsulated 
in both 2% and 5% w/v alginate were reversibly mitotically inhibited.  As the scaffold 
degrades in vivo by loss of calcium cross-links (Ikada 2006), the encapsulated cells will be 
released and should then proliferate to help to replace the lost dermal tissue at the wound site.   
Alginate constructs of different concentrations exhibit contrasting mechanical properties 
(Augst et al. 2006) and cell behaviour is known to be regulated by the mechanical properties 
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of the material on which they are cultured (Brandl et al. 2007;Discher et al. 2005).  
Decreasing the alginate hydrogel concentration from 5% to 2% w/v however, had no effect 
on the mitotic activity of encapsulated cells. This indicated that either gel would provide the 
reversible mitotic inhibition of encapsulated fibroblasts, which is desirable for the tissue 
engineering of skin in vivo. 
 
It has been suggested that alginate hydrogel may affect cell proliferation either due to the 
release of calcium ions or the presence of alginate monomers in the media (Doyle et al. 1996; 
Lansdown 2002), however no differences in cell growth were observed for non-encapsulated 
cells which were cultured in the presence or absence of alginate hydrogel (Figure 6.5).  This 
illustrated that the presence of calcium-alginate was not responsible for the lack of 
proliferation seen with encapsulated cells.  It also indicated that non-encapsulated cells could 
be co-transplanted with the encapsulated cells, so that the non-encapsulated cells can 
proliferate in vivo prior to release of the encapsulated cells.  It is therefore likely that the lack 
of mitotic activity that was exhibited by cells encapsulated in both 2% and 5% w/v alginate 
was due to the encapsulated cells remaining mechanically isolated from each other by the 
calcium cross-linked alginate hydrogel scaffold throughout the duration of the experiment 
(Figure 6.2).   This mechanical isolation prevented cell-cell contact, which is known to 
modulate growth in monolayer culture (Liu et al. 2006).  This is possibly also why the 
majority of fibroblasts encapsulated in the normal ECM of the dermis of skin, also failed to 
express PCNA (Figure 6.6b) and thus were in a quiescent state.   
 
This study illustrates that calcium-alginate hydrogel of 2% and 5% w/v concentration 
effectively simulates the ECM of soft tissue allowing for nutrients, waste products and 
signalling molecules to effectively perfuse the scaffold to maintain viability of encapsulated 
fibroblasts, as has been seen with other cell types (Tan & Takeuchi 2007; Bazou et al. 2008).  
The 3D environment is known to modulate cell behaviour (Pedersen & Swartz 2005) and 
here we have shown that 2% and 5% w/v alginate effectively modulate cell proliferation in a 
similar way to normal ECM.  The cell growth that has been seen in other studies (Bazou et al. 
2008; Khattak et al. 2006; McConell et al. 2004) is possibly due to a higher cell density being 
used which results in greater cell-cell contact.  The approach used allows for cells to remain 
as discrete entities within the scaffold so that no cell-cell agglomerations form.  This resulted 
in the viable cell number remaining constant throughout the initial culture period.  This 
should allow for sufficient proliferation of non-encapsulated co-cultured cells before the 
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release and subsequent proliferation of encapsulated cells.  The cell isolation (Figure 6.2) was 
also likely to be the reason for the reduced metabolic activity seen with encapsulated 
fibroblasts compared with non-encapsulated control fibroblasts (Figure 6.8 and 6.11).  This 
was assumed since alginate presence, citrate treatment and CaCl2 treatment had no effect on 
the ability of fibroblasts to reduce MTT to formazan (Figure 6.10) and after release from 
encapsulation in alginate hydrogels the cells resumed normal metabolic activity (Figure 6.9 
and 6.12).  The maintenance of a low cell number throughout the initial few weeks of culture 
and the reduced metabolic activity of the individual cells that were present should allow for 
the infiltration of blood vessels into the TE structure to maintain cell viability and support 
subsequent tissue development after scaffold degradation in vivo. 
 
6.3. Conclusion 
NIH 3T3 fibroblasts encapsulated in either 2% or 5% w/v alginate remained viable for at 
least 150 days in vitro and were effectively mitotically inhibited in the initial five weeks 
culture.  Normal cell proliferation in monolayer culture was observed after release of 
fibroblasts from the alginate hydrogel scaffolds.  The reversible mitotic activity was mirrored 
by reversible partial catabolic inhibition.  The growth and catabolic activity of fibroblasts was 
not influenced by the presence of the alginate hydrogel, treatment in calcium chloride or tri-
sodium citrate.  This indicated that the reversible growth and metabolic inhibition was due to 
the reversible mechanical confinement of cells.  The maintained viability and reversible 
mitotic and catabolic inhibition of fibroblasts by encapsulation as dispersed entities in 2% 
and 5% w/v alginate hydrogels makes these constructs potentially suitable dermal grafts.   
Since the fibroblasts remain viable but are mitotically inhibited, they should initially act as a 
feeder layer to support keratinocytes to form the epidermis during the initial few weeks after 
implantation.  Then, as the alginate hydrogel degrades, the fibroblasts should facilitate 
replacement of the dermal layer.  Furthermore, since the alginate itself does not inhibit the 
growth or catabolism of cells which are not encapsulated it should allow uninhibited growth 
of keratinocytes co-transplanted on the surface of the graft to restore of the epidermis at the 
wound site. 
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7. Replacement of alginate hydrogel scaffold with normal ECM 
In order that the tissue engineering approach is successful the rate of tissue growth should 
ideally occur at the rate of scaffold degradation (Mann et al. 2001b).  It is therefore important 
that the scaffold remains in situ for sufficient time to support new tissue formation (Alsberg 
et al. 2003).  Calcium cross-links are known to dissipate from Ca-alginate hydrogels over 
time during both in vivo and in vitro culture as a result of exposure of the hydrogels to ions 
such as sodium, potassium, magnesium and phosphate which cause the scaffold to degrade 
both in vitro and in vivo (Donati et al. 2009; Ikada 2006; Smidsrod & Skjakbraek 1990).  The 
effect that encapsulated mammalian cells have on the degradation of alginate hydrogel is 
largely unknown.   
 
Scaffold degradation results in changes in mechanical properties of hydrogel scaffolds 
(Boontheekul et al. 2005).  Mechanical properties of scaffolds have been shown to impact on 
the cell proliferation, cell phenotype, growth factor production, ECM deposition and tissue 
development (Boontheekul et al. 2007; Bryant et al. 2004; Discher et al. 2005).  Assessing 
the change in mechanical properties of scaffolds during culture is therefore important in 
determining the efficacy of a hydrogel as a cell encapsulating medium.  The mechanical 
properties of hydrogels can be measured in a number of ways including compression and 
tensile testing (Boontheekul et al. 2005; Kong et al. 2004).  When testing in compression, the 
sample‘s cross sectional area increases during the test and so it is difficult to obtain 
meaningful values for modulus and failure.  While testing in tension gives less disputable 
results and gross mechanical deformation has been used previously to measure the tensile 
strength and modulus of alginate gels in tissue engineering (Wang et al. 2003), this method is 
subject to high variability which can be attributed to difficulties associated with clamping the 
sample.   
 
Small deformation oscillatory rheology was used to measure changes in alginate hydrogel 
mechanical properties over time. Data collected using this technique can be analysed to 
precisely identify and discriminate between samples that are true gels (viscoelastic solids) or 
are concentrated polymer solutions which may appear gel like, but are actually viscoelastic 
liquids (Clark & Ross-Murphy 2009). The mechanical spectra of  alginate hydrogel (acellular 
and cell-encapsulating) samples were characterized by measurement of the storage modulus 
(G′), loss modulus (G′′) and complex viscosity (η*) as a function of angular frequency, to 
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quantify the effect of culture media and cell presence on gel degradation over a period of 28 
days in vitro.  The changes in mechanical properties of FCM-incubated samples were also 
compared with changes in gel morphology, the release of calcium ions from the structure and 
changes in the wet and dry mass of the samples during culture.   
 
The effect of gel degradation on the ECM production by the fibroblasts was also assessed.  
This was done by histological staining of fibroblasts encapsulated and released from both 2% 
and 5% w/v alginate hydrogels with HVG after three weeks encapsulation.  This allowed for 
assessment of collagen expression, which is the main component of the ECM of dermis.    
 
7.1. Results 
7.1.1. Gel morphology 
Visual evaluation of the acellular samples incubated in either water or FCM, and cell-
encapsulating samples incubated in FCM was performed after 28 days culture (Figure 7.1).  
The images illustrate that all the hydrogels retained disc shape morphology despite the 
significant degradation of samples incubated in FCM, which was apparent when handling the 
samples.  Acellular samples incubated in water showed no evidence of degradation upon 
handling.  Furthermore, the dimensions of the samples were very similar to that at day 0 for 
all samples, with no evidence of gel contraction. 
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Figure 7.1: Images of alginate gels at day 28.  Samples incubated in growth media were 
a) 2% w/v acellular b) 2% w/v cellular c) 5% w/v acellular d) 5% w/v cellular.  Samples 
incubated in water were e) 2% w/v acellular and f) 5% w/v acellular.  The appearance 
of the gels illustrates that all samples retained a solid gel structure.  The pink staining of 
the media incubated samples was due to the presence of phenol red pH indicator in the 
media.  The photos illustrate that after 28 days all samples retained self-supporting 
structures of disc-shaped morphology, and retained dimensions similar to day 0.  There 
was clear evidence of degradation in samples a-d but not in samples e-f. 
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7.1.2. Rheology 
Rheological measurements of G′, G′′ and η* were performed to evaluate the impact of cell 
encapsulation and the effect of culture media on the mechanical properties of 2% and 5% w/v  
alginate gels incubated at 37°C for up to 28 days.  Figure 7.2 shows the mechanical spectra 
for 5% and 2% w/v alginate samples at day one of the study.  Predictably, the 5% w/v 
alginate samples gave higher values of G′ and G′′ than the corresponding 2% w/v alginate 
samples.  The spectra illustrate that all alginate samples showed true gel properties for at day 
one with G′>> G′′ and no frequency dependence and a linear decrease in complex dynamic 
viscosity with increasing frequency.   
 
Figure 7.3 shows measurements of (a) G′ and (b) G′′ at 0.5% strain 1rad/sec for 5% w/v 
alginate samples over 28 day culture period. A dramatic reduction in G′ and G′′ is observed 
within 7 days of culture in the alginate sample containing encapsulated 3T3 fibroblasts, with 
G′ falling to only 5% of its original value.  A similar decrease in mechanical properties was 
also found with acellular alginate hydrogel, but the rate of reduction is much slower and at 
day 7 G′ for acellular samples were 30% the original value.  By day 21, however, there was 
no significant difference (p<0.05) between the cellular and acellular samples. The alginate 
samples incubated in water showed no change over the study period as expected.  
 
Similar trends were also witnessed in samples of 2% w/v alginate hydrogel (Figure 7.4) 
where G′ reduced in the cellular samples by 97% by day 7, whereas G′ of the acellular 
samples was found to be 40% of the original value and then reduced to 5% by day 21.  As 
with the 5% w/v alginate samples there was no variation in G′ or G′′ for the 2% w/v alginate 
samples incubated in water.  
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Figure 7.2:  Mechanical spectra (0.5% strain; 37°C), at day one showing variation of G′ 
(filled diamonds), G″ (open diamonds) and η* (filled triangles) with angular frequency 
for 5% w/v alginate hydrogel a) containing encapsulated 3T3 fibroblasts incubated in 
culture media, b) containing no cells incubated in culture media and c) containing no 
cells incubated in water, and 2% w/v alginate hydrogel d) containing encapsulated 3T3 
fibroblasts incubated in culture media, e) containing no cells incubated in culture media 
and f) containing no cells incubated in water.   
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Figure 7.3:  Changes in a) G′ and b) G″ (6rad s-1; 0.5% strain; 37°C), over 28 days 
incubation for 5% w/v alginate containing encapsulated 3T3 fibroblasts (filled circles), 
acellular alginate incubated in culture media (filled squares), and acellular alginate 
incubated in water (open triangles). Vertical error bars represent the standard 
deviation of the reported mean values (n=3).  G′ and G″ for both media-incubated 
samples were significantly lower (p<0.05) than water-incubated samples at all time 
points, except day 1.  G′ and G″ were significantly lower (p<0.05) for cell-encapsualting 
samples than acellular media-incuated samples at day 7. 
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Figure 7.4:  Changes in a) G′ and b) G″ (6rad s-1; 0.5% strain; 37°C), over 28 days 
incubation for 2% w/v alginate containing encapsulated 3T3 fibroblasts (filled circles), 
acellular alginate incubated in culture media (filled squares) and acellular alginate 
incubated in water (open triangles). Vertical error bars represent the standard 
deviation of the reported mean values (n=3).  G′ and G″ for both media-incubated 
samples were significantly lower (p<0.05) than water-incubated samples at all time 
points, except day 1.  G′ and G″ were significantly lower (p<0.05) for cell-encapsualting 
samples than acellular media-incuated samples at day 7 and 14. 
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Mechanical spectra, however, shown in Figure 7.5 indicate that all the 5% w/v alginate 
samples show ―true gel‖ properties (G′ >> G′′) at day 28 but values of G′ and G′′ are reduced 
by almost two decades compared with day one and at higher frequencies there is evidence of 
failure of the gels which does not occur at day one or in the sample incubated in water. The 
same trend is also observed in the 2% w/v alginate (Figure 7.7) samples, but failure of the 
gels occurs at lower frequency.   
 
Figure 7.5: Mechanical spectra (0.5% strain; 37°C), at day 28 showing variation of G′ 
(filled diamonds), G″ (open diamonds) and η* (filled triangles) with angular frequency 
for 5% w/v alginate a) containing encapsulated 3T3 fibroblasts incubated in culture 
media, b) containing no cells incubated in culture media and c) containing no cells 
incubated in water.   
87 
 
 
Figure 7.6:  Mechanical spectra (0.5% strain; 37°C), at day 28 showing variation of G′ 
(filled diamonds), G″ (open diamonds) and η* (filled triangles) with angular frequency 
for 2% w/v alginate a) containing encapsulated 3T3 fibroblasts incubated in culture 
media, b) containing no cells incubated in culture media and c) acellular incubated in 
water.   
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7.1.3. Calcium release 
The correlation of calcium ion release from constructs incubated in FCM with the changes in 
mechanical properties was assessed by measuring the change in calcium concentration of the 
media surrounding the alginates using ICP-MS (Figure 7.7).  The release of calcium from 
both 2% and 5% w/v alginate does not appear to be affected by the presence of cells since the 
values at all time points are comparable between acellular and cell-encapsulating samples of 
the same concentration.  For 2% w/v alginate hydrogel the greatest release of calcium into the 
media is seen within the first four days where the calcium concentration is around 7 times 
higher than at day 0, but at day six the calcium concentration of the media is still significantly 
higher (P<0.05) than at day 0.  By day 11 the calcium concentration is not significantly 
different (P>0.05) from day 0 and after day 11 no significant changes in calcium 
concentration are observed.  For 5% w/v alginate the release of calcium is seen to be highest 
in the first four days, where the calcium concentration becomes elevated by around 6.5 times 
that seen at day 0.  The calcium concentration then falls between day four and 13 where the 
calcium concentration is not significantly different (P>0.05) from day 0.  The changes in 
concentration of sodium, phosphate and potassium ion concentrations in the media over 25 
days were also measured for all four samples (Figure 7.8). Concentrations of sodium, 
phosphate and potassium ions were seen to fluctuate throughout the culture period, but no 
clear correlation between changes in calcium concentration and the other ions were observed.   
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Figure 7.7:  Change in relative calcium concentration over 25 days culture of media 
surrounding a) 2% w/v acellular and cell-encapsulating and b) 5% w/v acellular and 
cell-encapsulating alginate hydrogel bead samples.  Graphs show mean ± SD (n=3).  The 
results show that in all samples the calcium release was greatest within the first four 
days of culture for all samples.  Significant differences (p<0.05) between aceullar and 
cell-encapsulating hydrogels were only seen at day 11 for 5% w/v alginate hydrogels.  
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Figure 7.8: Change in a) sodium ion b) phosphate ion and c) potassium ion 
concentration over 25 days culture of media surrounding 2% and 5% w/v acellular and 
cell-encapsulating alginate hydrogel bead samples.  Graphs show mean ± SD (n=3).  
Fluctuations in all three ion concentrations was seen throughout the course of the 
experiment, but no clear correlation was observed. 
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7.1.4. Change in hydrogel mass 
The change in wet and dry mass of acellular and cell-encapsulating 2% and 5% w/v alginate 
hydrogel  beads cultured in FCM were assessed over 33 days (Figures 7.9 and 7.10).  The 
changes in hydrated and dry masses were very similar for corresponding acellular and cell-
encapsulating hydrogels.  The wet mass of 5% w/v hydrogels were seen to increase between 
day 0 and 18, and between day 0 and 14 for 2% w/v hydrogels.  Thereafter, the wet mass was 
seen to gradually decrease until day 33 for all samples.  The decrease in mass was seen to 
correlate with the formation of morphological defects such as cracks, and the breaking apart 
of beads. 
 
The dry masses of 5% w/v cell-encapsulating and acellular alginate hydrogel were shown to 
decrease over 33 days, so that by day 33 around 80% of the original mass remained.  It is 
evident that by reducing the alginate concentration to 2% w/v the rate of degradation was 
increased and that by day 33 only around 50% of the original alginate remained.  The cells 
appeared to play very little part in this degradation, as with both 2% and 5% w/v alginate 
hydrogels, the degradation profiles are extremely similar for both acellular and cell-seeded 
samples.  All four samples showed a significant decrease in dry mass between day 0 and 33 
(P<0.05).   
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Figure 7.9: Change in hydrated mass of a) 5% w/v and b) 2% w/v cell-encapsulating 
alginate hydrogel beads.  Mean values ± SD are shown (n=3). The hydrated mass 
increased between day 0 and day 18 for 5% w/v alginate and between day 0 and 13 for 
2% w/v alginate with alginate swelling then decreased as the alginate started to break 
apart and dissolve.  No significant differences between acellular and cell-encapsualting 
samples were observed at any time opint for either 2% or % w/v alginate hydrogels. 
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Figure 7.10: Change in dry mass of of acellular and cell-seeded 5% and 2% w/v alginate 
hydrogel beads.  Mean values ± SD are shown (n=3).  Encapsulation of cells in the 
scaffolds had no appreciable effect on the degradation profile.  It was also apparent that 
the 2% w/v alginate degrades faster than the 5% w/v alginate. 
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7.1.5. Collagen production 
To determine whether the encapsulated cells had deposited ECM histological sections of 
alginate encapsulated fibroblasts were stained with HVG after 21 days culture and compared 
with the normal dermis of rat skin (Figure 7.11).  In Figure 11a the distribution of cells and 
collagen in the dermis of normal rat skin can be seen.  The nuclei of cells stained blue-black 
due to the haematoxylin demonstrating the cell distribution, whilst the Van Gieson solution 
stains the collagen pink.  It can be seen that the dermis has a low cell content and that the 
cells are present in small clusters or individual units and the main component of the dermis is 
collagen, which is present in small bundles of around 10-35µm diameter.  The cells 
encapsulated within both 2% and 5% w/v alginate hydrogels (Figure 7.11b and 7.11c) 
remained as dispersed units within the hydrogel after 21 days of encapsulation and had not 
proliferated or migrated within the gel to form cell clusters as seen in the dermis of normal 
skin so the cell concentration was lower in the hydrogel than in normal rat skin.  The 
haematoxylin also stained the alginate fibres in the hydrogel blue-black due to their negative 
charge and the positive charge of the haematoxylin.  After 21 days there was no evidence of 
collagen presence in either 2% or 5% w/v alginate samples which indicated that the 
encapsulated fibroblasts failed to secrete ECM during this time period.  It was, however, 
observed that as the alginate degraded the encapsulated fibroblasts were released from the 
alginate matrix and attached to suitable substrates such as glass or tissue culture plastic in 
which the alginate encapsulated cells were being cultured.  Fibroblasts cultured on the glass 
slides for five days after release from both 2% and 5% w/v alginate hydrogels by degradation 
of the hydrogels in 100mM tri-sodium citrate were stained with HVG.  The staining indicated 
that the fibroblasts were able to secrete collagen on the surface of the glass slide to which the 
cells had attached, at a level which appeared comparable to before they were encapsulated 
(Figure 7.12).  
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Figure 7.11:  HVG staining of normal rat dermis (A), and fibroblasts encapsulated in 
2% w/v alginate (B) and 5% w/v alginate (C) after 21 days in vitro culture.  The 
haemotoxylin stains the cell nuclei blue/ black and the Van Gieson Solution stains the 
collagen pink.  In the dermis of skin there is a high collagen content, but after 21 days 
culture, there is no evidence of collagen presence within either 2% or 5% w/v alginate 
hydrogels. 
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Figure 7.12:  HVG staining of 3T3 monolayers cultured on glass slides for five days a) 
before encapsulation, b) after release from 2% w/v alginate hydrogel after 21 days 
encapsulation and c) after release from 5% w/v alginate hydrogel after 21 days 
encapsulation.  The Haematoxylin stains the cell nuclei blue/ black and the Van Gieson 
Solution stains the collagen pink.  The staining shows that cells released from both 2% 
and 5% w/v alginate retain the ability to secrete collagen, as before encapsulation.   
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7.2. Discussion 
Alginate hydrogel is known to degrade over time by dissipation of calcium ions that cross-
link the structure (Bajpai & Sharma 2004) as a result of exposure to monovalent cations such 
as sodium, potassium and phosphate which are present in cell culture media and the in vivo 
environment (Donati et al. 2009; Gombotz & Wee 1998; Ikada 2006; Smidsrod & Skjakbraek 
1990; Sutherland 1991), and this is associated with a reduction in mechanical properties.  
Indeed, the mechanical properties of alginate hydrogels were seen to decrease with time in 
the presence of cell culture media but not in the presence of Millipore water, in which these 
ions are not present (Figures 7.3 and 7.4).  The amount of calcium released from alginate 
hydrogels exposed to cell culture media was found to be very high within the first six days of 
culture for all alginates (Figure 7.7).  This release of calcium ions was seen to correlate with a 
steep decline in the G′ and G" of these gels between day one and day 7 (Figures 7.3 and 7.4).  
This drastic decrease in mechanical properties has also been seen to occur in acellular Ca-
alginate samples of 1-3% w/v in physiological saline during 7 days in culture conditions 
(Leroux et al. 1999).  It has been suggested that exchange of ions and reordering of the gelled 
network occurs within the first 7 days and stabilizes thereafter (Drury et al. 2004).    
 
It was expected that the movement of sodium, potassium ion and phosphate ions into the 
alginates would show a sharp drop in concentrations of these ions during the first 7 days in 
correlation with the sharp increase in calcium ions.  Since the concentration of these ions in 
the media surrounding alginate samples was not seen to decrease drastically with the increase 
in calcium ion concentration (Figure 7.8) it can be concluded that the release of calcium ions 
results from the presence of these ions rather than their movement into the gels.  Furthermore, 
it is possible that other ions present in the culture media such as lactate and citrate (Gombotz 
& Wee 1998; Sutherland 1991) influence the release of calcium cross-links from the alginate.  
Alternatively, the significant rise in calcium concentration of the media in the initial six days 
of culture may be due in part to the presence of excess un-bound calcium within the hydrogel 
which diffuses out the gel during this time period. 
 
The G′ and G′′ were seen to decrease more drastically in the first 7 days when cells were 
encapsulated in both 2% and 5% w/v gels.  The differences in mechanical properties between 
acellular and cell-encapsulating samples could not however be attributed to differences in the 
calcium release profiles between cell encapsulating and acellular samples.  It is possible that 
some of the calcium ions remaining within the alginates are used by the cells (Moore & 
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Dedman 1982) and thus not available for cross-linking of the alginate.  For example, calcium 
is utilised by cells in cell signalling (Berridge et al. 2000), cell proliferation and adhesion to 
culture substrates (Rouzaire-Dubois & Dubois 2004).   
 
The increased reduction of mechanical properties of the alginate hydrogels as a result of 
encapsulated fibroblasts in the initial week of culture may be of great importance for tissue 
engineering skin. The alginate hydrogel/ fibroblast dermal analogue will be seeded with 
keratinocytes after 7 days in vitro culture then implanted at the wound site.  5% w/v alginate 
hydrogel is preferable to 2% w/v alginate hydrogel, since the baseline properties of the 5% 
w/v alginate hydrogel are higher and there is therefore a reduced risk of gel disintegration 
upon implantation.   
 
Between day 7 and day 28 further reductions in the mechanical properties of the alginate 
hydrogels incubated in FCM were observed.  After 28 days the mechanical properties of cell-
encapsulating and acellular samples of the same concentration in media were not significantly 
different (P>0.05) (Figures 7.4 and 7.5) and both the cell-encapsulating alginate hydrogels 
and their acellular counterparts were seen to remain as self supporting gels with similar 
dimensions to those seen at day 0 (Figure 7.6), and were seen to maintain gel-like mechanical 
spectra (Figures 7.7 and 7.8).  Approximately 80% of the alginate remained in the 5% w/v 
alginate after 33 days culture and around 50% in the 2% w/v alginate, as confirmed by 
analysis of dehydrated mass of alginate hydrogel samples (Figure 7.10).  It has been shown 
that the presence of a scaffold material to fill the wound space results in reduced scar 
formation (Heimbach et al. 1988; Wang et al. 2004).  Alginate hydrogel is, therefore a 
preferable scaffold material compared with collagen and fibrin based scaffold materials, since 
these materials show increased degradation and contraction compared with both 2% and 5% 
w/v alginate hydrogels (Chun et al. 2003; Souren et al. 1989).  In addition, the use of 5% w/v 
alginate hydrogel may be preferable to 2% w/v alginate hydrogel, since it shows a slower 
degradation profile in terms of mass change with culture time up to 33 days (Figure 7.10). 
 
The long term stability of the gels should allow the encapsulated cells to be retained at the 
desired implantation location until sufficient ECM has accumulated (Kim & Mooney 1998; 
Koh & Atala 2004).  Eventually, the alginate hydrogel implanted at a desired location should 
completely degrade and be resorbed (Smidsrod & Skjakbraek 1990) to leave behind new 
tissue which resembles the native host tissue.  At three weeks encapsulation there was no 
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evidence of collagen presence within the alginate hydrogels (Figure 7.11) but when cells 
were released from the alginate hydrogel ECM production was evident (Figure 7.12).  With 
the increased degradation that occurs with time increased ECM accumulation should occur, 
to facilitate tissue regeneration, as was seen with 1.95% w/v alginate hydrogel samples 
implanted into rats (Nunamaker et al. 2007).  The inhibition of collagen production during 
encapsulation may have been due to the fibroblasts sensing the confinement of the 3D 
environment through cytoskeletal arrangement (Discher et al. 2005) which is known to alter 
cell behaviour in comparison with that exhibited in the 2D environment (Pedersen & Swartz 
2005).  This hypothesis is supported by the fact that in the body, fibroblasts only begin to 
secrete large quantities of ECM after injury (Welch et al. 1990), when the cells are released 
from the 3D confinement of the damaged ECM.   
 
7.3. Conclusion 
In this chapter it has been shown that alginate hydrogel may be a suitable scaffold material 
for the production of tissue engineered skin since it degrades relatively slowly over time in 
culture.  This should allow for encapsulated fibroblasts to remain immobilised at the wound 
site upon implantation for extended periods where they will gradually be released from the 
scaffold as it degrades and secrete ECM to facilitate dermal repair. It has been demonstrated 
that 5% w/v alginate hydrogel may be preferable to 2% w/v alginate hydrogel since 5% w/v 
alginate hydrogel has higher baseline mechanical properties.  The risk of gel disintegration 
upon implantation is therefore reduced if 5% w/v alginate hydrogel is used, compared with 
2% w/v alginate hydrogel.  Furthermore, since the dry mass of 5% w/v alginate hydrogel was 
seen to decrease less rapidly over time compared with 2% w/v alginate hydrogel, 
significantly more scaffold material should remain present at the wound site with time when 
5% w/v alginate hydrogel is used for production of the dermal analogue.  The alginate 
hydrogel acts as a filler material, and therefore, use of 5% w/v alginate hydrogel as the 
scaffold material may result in reduced scar formation compared with 2% w/v alginate 
hydrogel.  
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8. Angiogenesis 
A problem with tissue engineered skin, as with other tissues, is clinical failure due to delays 
in vascularisation (Kaully et al. 2009; Sahota et al. 2004).   It is generally accepted that the 
diffusion of nutrients and oxygen is limited to 100μm to 200μm (Rouwkema et al. 2008).  
Vascularisation is, therefore, essential to ensure adequate supply of nutrients to the 
transplanted cells.  In addition, this vascular network acts as a transport system for hormones, 
waste products, and growth factors (Grellier et al. 2009).  Inadequate vascularisation 
following implantation can result in cell death in tissue-engineered constructs (Rouwkema et 
al. 2008; Smith et al. 2004) and ineffective tissue development and integration (Malda et al. 
2004; Yu et al. 2009).  
 
Tissue engineering relies on angiogenesis for the vascularisation of new grafts (Cassell et al. 
2002), which is the formation of new blood vessels by the growth and sprouting of existing 
vessels (Rouwkema et al. 2008).  A range of growth factors and cytokines are known to be 
involved in angiogenesis, which stimulate different stages of blood vessel formation.  The 
initiation of angiogenesis is known to be accelerated by the increased proliferation and 
migration of endothelial cells (ECs) (Bos et al. 2005; Egginton 2009) as a result of 
angiogenic factors such as VEGF (Bao et al. 2009; Keck et al. 1989; Leung et al. 1989; Noiri 
et al. 1998; Plouet et al. 1989; Yancopoulos et al. 2000; Yoshida et al. 1996), IL-6 (Fee et al. 
2000; Jee et al. 2004; Nilsson et al. 2005; Yao et al. 2006), FGF-2 (Jansen et al. 2009; 
Yoshida,  et al. 1996) and NGF (Cantarella et al. 2002; Emanueli et al. 2002; Nico et al. 
2008; Zeng et al. 2010).  VEGF is thought to be an especially important angiogenic factor 
(Ferrara 2009), and in addition to its mitogenic and chemotactic effect on ECs, it also 
increases vascular permeability to enhance angiogenesis (Ferrara 1999; Gavard & Gutkind 
2006; Griffioen & Molema 2000; Senger et al. 1983; Senger et al. 1990; Yamagishi et al. 
1999).   
 
The direct application of VEGF to the wound site has been investigated as a possible 
approach to improve angiogenesis, but little success has been achieved (Lazarous et al. 
1996), likely as a result of rapidly depleting and poorly controlled VEGF levels in the local 
tissue (Brem et al. 2009; Khurana et al. 2005).  Sustained release of VEGF from grafts or 
dressings has been demonstrated to be more beneficial than direct application of VEGF.  For 
example, VEGF has been incorporated into synthetic polymer scaffolds such as poly(lactide-
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coglycolide) (PLG) (Chen et al. 2007), collagen scaffolds (Chiu & Radisic 2010) and alginate 
hydrogel beads (Gu et al. 2004) to provide sustained localised release.   The sustained release 
of other angiogenic factors incorporated into scaffolds have also been shown to enhance 
angiogenesis (Moon & West 2008; Shi et al. 2008).  Another approach to providing sustained 
release of growth factors is to incorporate cells which secrete angiogenic factors into the 
construct (Keshaw et al. 2005; Pinney et al. 2000).   
 
Fibroblasts are known to produce angiogenic factors (Brenneisen et al. 2003; Detmar et al. 
1997; Trompezinski et al. 2002; Tunyogi-Csapo et al. 2007), and the application of dermal 
fibroblasts to wound beds has been reported to accelerate angiogenesis (Chen et al. 2004).  It 
was, therefore, hypothesised that fibroblasts encapsulated in alginate hydrogel scaffolds used 
in this thesis, may provide sustained release of angiogenic factors to promote vascularisation 
of the graft.  In this chapter the transcription of genes encoding NGF, FGF-2, VEGF and IL-6 
by fibroblasts following encapsulation ion 2% and 5% w/v alginate hydrogels was assessed.  
Since VEGF is of such importance in the stimulation of angiogenesis, the expression of 
VEGF protein by encapsulated cells was also assessed by ELISA, and compared with the 
level of expression seen in fibroblasts monolayer cultures.  
 
To determine whether the angiogenic factors secreted by encapsulated fibroblasts were 
sufficient to induce angiogenesis, the recruitment and proliferation of ECs in the presence of 
alginate encapsulated fibroblasts was determined.  This was compared with the proliferation 
and migration of ECs on transwell inserts in the presence of acellular samples of alginate 
hydrogels, or in plates which contained no alginate hydrogel or fibroblasts.  These control 
samples allowed the effect of alginate hydrogel on proliferation and migration of endothelial 
cells to be determined. 
 
8.1. Results 
8.1.1. RT-PCR analysis of VEGF, FGF-2, NGF and IL-6 expression by fibroblasts 
The potential of fibroblasts encapsulated in both 5% w/v and 2% w/v alginate hydrogels to 
induce vascularisation of the scaffolds was assessed by RT-PCR analysis of VEGF, FGF-2, 
IL-6 and NGF expression, compared with GAPDH expression (Figures 8.1 and 8.2).  The 
expression of these genes was assessed at one and three weeks post encapsulation, while still 
encapsulated, or following release from encapsulation by degradation of the alginate hydrogel 
in citrate, followed by 48h of monolayer culture on tissue culture plastic.  Control samples 
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were monolayer cultures of fibroblasts which had not been previously encapsulated in 
alginate hydrogel.  Visual examination shows that VEGF and NGF were expressed by 
fibroblasts both during encapsulation and following release from 5% and 2% w/v alginate 
hydrogels.    In contrast, FGF-2 transcription was not evident following encapsulation in 5% 
w/v alginate, and was only evident at week one encapsulation in 2% w/v alginate, and not in 
other conditions.  The relative expression of VEGF, FGF-2, NGF and IL-6 according to band 
intensity were determined and are represented in Figures 8.3-8.6.   
 
 
Figure 8.1:  RT-PCR analysis of GAPDH, VEGF, FGF-2, NGF and IL-6 expression by 
3T3 fibroblasts following encapsulation in 5% w/v alginate for one or three weeks, 
compared with before encapsulation (control).  Transcription of the genes was analysed 
either during encapsulation or following release from encapsulation and monolayer 
culture for 48h.  
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Figure 8.2: RT-PCR analysis of GAPDH, VEGF, FGF-2, NGF and IL-6 expression by 
3T3 fibroblasts following encapsulation in 2% w/v alginate for one or three weeks, 
compared with before encapsulation (control).  Transcription of the genes was analysed 
either during encapsulation, or following release from encapsulation and monolayer 
culture for 48h.  
 
Variations in the expression of the three different VEGF isoforms were seen following 
encapsulation in 5% w/v alginate hydrogel (Figure 8.3a), but generally, VEGF transcription 
was down-regulated at week one following encapsulation, but was comparable with the 
control after three weeks encapsulation.  After release from encapsulation at week one, the 
transcription of VEGF was seen to increase compared with during encapsulation, to a level 
comparable with the control.  The transcription of VEGF at week three after release was also 
comparable with the control. 
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The expression of the three different VEGF isoforms by fibroblasts following encapsulation 
in 2% w/v alginate was at different levels in each condition (Figure 8.3b), as following 
encapsulation in 5% w/v alginate hydrogel (Figure 8.3a).   The transcription of VEGF was 
down-regulated following one week encapsulation in 2% w/v compared with the control, as 
in 5% w/v alginate.  This down-regulation was, however, less extensive than following 
encapsulation in 5% w/v alginate.  The expression of VEGF increased after three weeks 
encapsulation compared with one week encapsulation, to a level comparable with the control, 
as was observed following encapsulation in 5% w/v alginate hydrogel.  Following release 
from encapsulation in 2% w/v alginate hydrogel the expression of VEGF at week one was 
seen to be up-regulated compared with sustained encapsulation, to a level comparable with 
the control.  At week three, however, the fibroblasts released from 2% w/v alginate showed 
reduced transcription of VEGF both compared with the control and the encapsulated samples 
at week three. 
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Figure 8.3:  Relative transcription of VEGF isoforms 121, 165 and 189 by fibroblasts 
following encapsulation in a) 5% w/v alginate hydrogel or b) 2% w/v alginate hydrogel, 
compared with before encapsulation (control).   Transcription of VEGF was analysed 
either during encapsulation or following release from encapsulation and monolayer 
culture for 48h.  Expression of all three VEGF isoforms is seen in all five conditions, 
although the level of expression varies with differing conditions. 
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Quantification of band intensity revealed that FGF-2 transcription by fibroblasts encapsulated 
and released from 5% w/v alginate hydrogel was reduced to less than 10% of that seen before 
encapsulation (Figure 8.4a).  This severe reduction in FGF-2 transcription was also observed 
at week three encapsulation and weeks one and three after release form encapsulation in 2% 
w/v alginate hydrogel (Figure 8.4b).  The expression of FGF-2 at week one encapsulation in 
2% w/v alginate was, however, comparable with the control. 
 
Following encapsulation in 5% w/v alginate, the transcription of NGF was seen to be reduced 
to approximately 35% and 40% of that seen before encapsulation at week one and week 
three, respectively.  Following release from encapsulation, the level of NGF expression was 
seen to more than double after one week encapsulation, to approximately 75% of that seen in 
the control sample.  After three weeks encapsulation the level of NGF expression was only 
seen to be approximately 30% of that seen in the control (Figure 8.5a).  The transcription of 
NGF by fibroblasts encapsulated in 2% w/v alginate was seen to be comparable with the 
control at week one encapsulation, and was seen to be up-regulated compared with the 
control at three weeks encapsulation.  Following release from 2% w/v alginate, the level of 
NGF transcription at one week was seen to be approximately 10% higher than the control, 
and at three weeks, approximately 15% lower than the control (Figure 8.5b). 
 
IL-6 transcription during encapsulation in 5% w/v alginate hydrogel was comparable with the 
control at week one and was up-regulated when compared with the control at week three. 
Following release from encapsulation, the fibroblasts continued transcribing IL-6, but at 
week one, this expression was down-regulated by ~50% compared with the control.  
Transcription of IL-6 at week three following release was, however, at a level comparable 
with the control (Figure 8.6a).  In comparison, the expression of IL-6 by fibroblasts following 
encapsulation in 2% w/v alginate was seen to fluctuate by only ~15% compared with the 
control (Figure 8.6b).   
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Figure 8.4:  Relative transcription of FGF-2 by fibroblasts following encapsulation in a) 
5% w/v alginate hydrogel or b) 2% w/v alginate hydrogel, compared with before 
encapsulation (control).   Transcription of FGF-2 was analysed either during 
encapsulation or following release from encapsulation and monolayer culture for 48h.  
Expression of FGF-2 was reduced to less than 5% of that seen before encapsulation 
both during encapsulation and after release from 5% w/v alginate hydrogel.  Extensive 
down-regulation of FGF-2 transcription was also observed following encapsulation in 
2% w/v alginate hydrogel, although to a lesser degree. 
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Figure 8.5: Relative transcription of NGF by fibroblasts following encapsulation in a) 
5% w/v alginate hydrogel or b) 2% w/v alginate hydrogel, compared with before 
encapsulation (control).   Transcription of NGF was analysed either during 
encapsulation or following release from encapsulation and monolayer culture for 48h.  
Expression of NGF was observed to be maintained following encapsulation in both 5% 
and 2% w/v alginate hydrogel.  Transcription during encapsulation in 5% w/v alginate 
was down-regulated compared with the control, which was reversed after release at one 
week, but not after release at three weeks.  Transcription of NGF was less effected by 
encapsulation in 2% w/v alginate hydrogel. 
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Figure 8.6:  Relative transcription of IL-6 by fibroblasts following encapsulation in a) 
5% w/v alginate hydrogel or b) 2% w/v alginate hydrogel, compared with before 
encapsulation (control).   Transcription of IL-6 was analysed either during 
encapsulation or following release from encapsulation and monolayer culture for 48h.  
Expression of IL-6 was observed to be maintained following encapsulation in both 5% 
and 2% w/v alginate hydrogel, although a ~50% down-regulation of transcription was 
evident at day 7 after release from encapsulation.  In comparison, the fluctuation in IL-
6 transcription following encapsulation in 2% w/v alginate was seen to only be ~15%. 
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8.1.2. VEGF ELISA 
Since VEGF is thought to be the main cell signalling molecule involved in the induction of 
angiogenesis, the level of VEGF protein expression by encapsulated fibroblasts was assessed 
by ELISA, and compared with VEGF expression by fibroblast monolayers.  Figure 8.7 shows 
the expression of VEGF by fibroblasts encapsulated in 2% and 5% w/v alginate hydrogels up 
to three weeks post-encapsulation.  The level of VEGF expression remained relatively 
constant throughout the course of the study, and a million encapsulated cells secreted 
approximately 1400pg of VEGF within the three days prior to sampling at all time points for 
both 2% and 5% w/v encapsulated fibroblasts.  The amount of VEGF protein expressed by 
monolayer cultures of fibroblasts before encapsulation was also assessed by VEGF ELISA 
and found to be 5481±588.5pg/million cells.  This demonstrated that VEGF protein 
expression by encapsulated fibroblasts was reduced by approximately 75% compared with 
before encapsulation. 
 
Figure 8.7:  Amount of VEGF protein secreted by fibroblasts encapsulated in 2% or 5% 
w/v alginate hydrogels as determined by VEGF ELISA up to 21 days post-
encapsulation.  Mean values ± SD are shown (n=3).  The expression of VEGF protein 
was seen to be constant throughout the course of the study at approximately 1400pg/ 
million fibroblasts for both 2% and 5% w/v alginate encapsulated fibroblasts.  The 
expression of VEGF protein was seen to be significantly (p<0.05) reduced by 
encapsulation in alginate since before encapsulation, fibroblasts monolayers were seen 
to express 5481±588.5pg VEGF/ million cells.  No significant differences (p<0.05) 
between the amount of VEGF produced by 2% and 5% w/v encapsulated cells were 
seen at any time point. 
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8.1.3. EC migration and proliferation 
In order to assess whether fibroblasts encapsulated in 5% and 2% w/v alginate hydrogel 
would induce angiogenesis, the migration and proliferation of ECs co-cultured with the 
encapsulated fibroblasts were assessed and compared with control samples of acellular 5% 
and 2% w/v alginate hydrogels, respectively.  Figure 8.8 shows the growth of ECs in the 
presence of acellular and fibroblast-encapsulating samples of 5% w/v and 2% w/v alginate 
hydrogels.  It was evident that proliferation of ECs occurred in the presence of all four 
alginate hydrogel samples and the growth of ECs was not affected by the presence of 
encapsulated fibroblasts in either 5% or 2% w/v alginate hydrogels.  Figure 8.9 shows the 
number of ECs that migrated toward 5% and 2% w/v fibroblast-encapsulating and acellular 
alginate hydrogels with time.  It was evident that ECs migrated toward all four samples, and 
that the presence of fibroblasts within both 5% and 2% w/v alginate had no significant effect 
on the rate of migration. 
 
 
Figure 8.8:  Number of viable ECs present on membrane supports up to four days 
culture in the presence of acellular and fibroblast-encapsulating samples of 2% and 5% 
w/v alginate hydrogels.    Mean values ± SD are shown (n=3).  Presence of fibroblasts 
within the alginate hydrogels, or changing the alginate hydrgogel concentration had no 
significant (p>0.05) effect on the proliferation of ECs. 
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Figure 8.9:  Number of ECs which had migrated through the culture membrane 
towards acellular or fibroblast-encapsulating samples of 2% and 5% w/v alginate, with 
time.   Mean values ± SD are shown (n=3).  The migration of ECs towards all four 
samples was relatively similar. Significant differences in the number of ECs on the 
underside of membranes were only seen at day two between 5% acellular and 2% 
acellular or 2% cell-encapsulating samples.  
 
8.2. Discussion 
Angiogenesis is a key requirement for successful tissue engineering of skin.  Although 
fibroblasts are known to secrete angiogenic factors (Chen et al. 2004; Tunyogi-Csapo et al. 
2007), this appears to be the first study evaluating the effect of encapsulation on the secretion 
of angiogenic factors.  RT-PCR analysis indicated that fibroblasts encapsulated in both 5% 
and 2% w/v alginate should provide sustained release of VEGF, IL-6 and NGF, to support 
vascularisation of the dermal analogue.   Conversely, the transcription of FGF-2 was not seen 
to be sustained by fibroblasts following encapsulation in the alginate hydrogels (Figure 8.1).   
 
The VEGF ELISA (Figure 8.7), showed that fibroblasts encapsulated in 2% and 5% w/v 
alginate expressed a constant level of VEGF protein, which was detected in the culture 
medium surrounding the samples.   The level of VEGF expression was, however, 
approximately four times lower than that seen before encapsulation.   The difference in 
VEGF transcription and expression profiles may be due to the VEGF mRNA not being 
0
2
4
6
8
10
12
14
16
18
0 1 2 3 4
N
u
m
b
er
 o
f m
ig
ra
te
d
 E
Cs
 (×
10
5 )
Time (days)
2% cell-encapsulating 2% acellular 5% cell-encapsulating 5% acellular
113 
 
stabilized as much as in control samples after transcription in the encapsulated samples.  A 
number of factors are known to be involved in the stabilization of VEGF mRNA, including 
hypoxia-inducible factor-1alpha (HIF-1α) (White et al. 1995) and Bcl-2 (Iervolino et al. 
2002).  Down-regulation of expression of these proteins may be the reason for decreased 
translation of VEGF following encapsulation, which may occur as a result of the reduced 
metabolic activity (Adair 2005; Adair et al.1990) of the encapsulated fibroblasts (Figures 6.8 
and 6.11).    
 
In order to assess whether the combined levels of angiogenic factors secreted by encapsulated 
fibroblasts were sufficient to induce angiogenesis, the effect of the encapsulated cells on the 
migration and proliferation of endothelial cells were assessed.  It was seen that the fibroblasts 
encapsulated in both 2% and 5% w/v alginate had no significant effect (p>0.05) on the 
proliferation or migration of the endothelial cells (Figures 8.8 and 8.9), suggesting that the 
level of angiogenic factors secreted was too low to induce angiogenesis.   Further work 
should therefore seek to increase the level of angiogenic factor expression by encapsulated 
fibroblasts.   
 
It is, however, possible that the apparent lack of angiogenic response to the encapsulated 
fibroblasts in vitro is not representative of the in vivo response (Egginton 2009).  VEGF 
(Breen 2007) and IL-6 (Egginton 2009) are also known to induce leukocyte recruitment 
which also secrete VEGF (Nogami et al. 2007) to induce angiogenesis (Sidky & Auerbach 
1975; Sidky & Auerbach 1976).  Further work should therefore seek to assess whether the 
level of VEGF and IL-6 expression are sufficient to induce leukocyte proliferation and 
migration.  In addition, the levels of expression of these proteins may be sufficient to 
facilitate other aspects of wound healing.  For example, VEGF and NGF can promote the 
regeneration of peripheral nerve as well as contraction and re-epithelisation of wound (Hu et 
al. 2007). 
 
Furthermore, only the angiogenic potential of fibroblasts in the dermal analogue have been 
assessed.  Keratinocytes are also known to secrete angiogenic factors including VEGF 
(Detmar et al. 1995; Detmar 2000).  VEGF expression by keratinocytes is seen to occur at 
increasing levels with increased stratification (Shirakata et al. 2003). Proliferating 
keratinocytes in the basal layer of the epidermis also secrete TGF-alpha (Werner et al. 2007) 
which is known to stimulate endothelial cell migration (Grotendorst et al. 1989) and to up-
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regulate VEGF expression by keratinocytes (Detmar et al. 1995), and thus also promotes 
enhanced vascularisation.  Further work should seek to evaluate the potential of keratinocytes 
in the tissue engineered epidermal layer to induce angiogenesis. 
 
8.3. Conclusions 
In this chapter it has been demonstrated that fibroblasts encapsulated in alginate hydrogel can 
provide sustained release of VEGF, although at a level lower than before encapsulation.  
Since sustained IL-6 and NGF expression were also recognised following encapsulation in 
alginate hydrogels, sustained release of these proteins may also be achieved.  Although the 
level of angiogenic factor expression was not seen to be sufficient to induce proliferation and 
migration of endothelial cells in vitro, this may be achieved in vivo due to recruitment of 
VEGF-secreting leucocytes.  In addition, since VEGF and NGF are also known to enhance 
other aspects of wound healing, such as epithelialisation, collagen deposition and innervation, 
the results indicate that many aspects of wound healing may be enhanced by fibroblasts 
encapsulated in alginate hydrogel.   
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9. Re-epithelialisation 
In addition to the restoration of the ECM of the dermal matrix, and the vascularisation of the 
dermal layer, it is essential that the wound site becomes re-epithelialised to prevent 
penetration of foreign materials and prevent heat and water loss from the body (Gibbs & 
Ponec 2000; Liu et al. 2007).   Re-epithelialisation occurs by the proliferation of keratinocyte 
basal cells and their progressive differentiation to form the suprabasal layers and finally the 
stratum corneum (SC).  The differentiation of the keratinocytes can be evidenced by 
examining the expression of various cytokeratins (Ks) and other proteins expressed in the 
specific strata of the epidermis (Fuchs 2007).  The cells in the basal layer express K5, K14 
and ki67 (Gibbs & Ponec 2000; Nelson & Sun 1983), whilst the spinous layer cells express 
K1 and K10 (Fuchs 2008). Involucrin (INV) and fillagrin (FGN) are expressed in the upper 
most region of the suprabasal layers shortly before the cells lose their nuclei and form the SC, 
and can be used as an indication of SC presence (Fuchs 2008; Gibbs & Ponec 2000).  The 
proliferation and differentiation of keratinocytes is controlled by paracrine interactions with 
the fibroblasts of the dermis.   
 
The fibroblasts secrete various growth factors which stimulate re-epithelialisation including 
keratinocyte growth factor (KGF), granular macrophage colony stimulating factor (GM-
CSF), pleiotrophin (PTN), transforming growth factor β (TGFβ), interleukin-6, vascular 
endothelial growth factor (IL-6), vascular endothelial growth factor (VEGF) and stromal cell-
derived factor (SDF-1) (Braunstein et al. 1994; Finch & Rubin 2004; Florin et al. 2005; 
Grossman et al. 1989; Singer & Clark 1999; Werner et al. 2007).  In Chapter 8 the expression 
of IL-6 and VEGF by encapsulated fibroblasts was demonstrated, indicating that the alginate 
encapsulated fibroblasts should support epithelialisation. 
 
In this chapter the potential of the bi-layered tissue engineered skin to support re-
epithelialisation of a wound site was further assessed. The ability of the fibroblasts in the 
dermal analogue to support keratinocyte proliferation and differentiation on the surface to 
produce a stratified epidermal layer was assessed by semi quantitative RT-PCR analysis of 
KGF expression, compared with the expression of these factors by fibroblast monolayers. 
The formation of multi-layered epidermal layer on the surface of the alginate/ fibroblast 
dermal analogue was assessed and compared with normal skin and keratinocytes grown at the 
air/liquid interface (A/L) on Thincert polystyrene polymer membranes in the presence of a 
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fibroblast feeder layer.  The differentiation of keratinocytes was assessed by RT-PCR 
analysis of keratins (Ks) 1, 5, 14 and involucucrin.  Histological staining of the epidermal 
layers with H&E allowed tissue architecture to be assessed and IHC staining for Pan 
cytokeratin (PanK) was performed to confirm that the stratified layers were formed of 
keratinocytes, since co-cultures of fibroblasts and keratinocytes were used and primary 
keratinocytes were isolated from rats, and therefore contamination with other cells was 
possible. 
 
9.1. Results 
9.1.1. RT-PCR analysis of KGF expression by fibroblasts following encapsulation 
The potential of fibroblasts in the dermal analogue to support the growth and differentiation 
of keratinocytes on the surface was assessed by RT-PCR analysis of KGF expression, 
compared with GAPDH expression (Figure 9.1).  The expression of KGF was assessed at one 
and three weeks post encapsulation, while still encapsulated, or following release from 
encapsulation.  Control samples were monolayer cultures of fibroblasts which had not been 
previously encapsulated in alginate hydrogel.  Visual examination showed that KGF was 
expressed by fibroblasts in all five conditions.  The relative transcription KGF under the 
different conditions was determined and is represented in Figure 9.2.  
 
 
Figure 9.1:  RT-PCR analysis of GAPDH and KGF expression by 3T3 fibroblasts 
encapsulated in 5% w/v alginate hydrogel for one and three weeks.  Expression is shown 
for encapsulated cells and those which are released and grown as monolayers for 48h, 
compared with culture as monolayers for 48h before encapsulation (control).   KGF was 
expressed at week one and three while encapsulated and following release from alginate 
hydrogel encapsulation. 
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Figure 9.2:  Relative KGF transcription by 3T3 fibroblasts encapsulated and released 
from 5% w/v alginate hydrogel after one and three weeks compared with monolayer 
cultures of fibroblasts which had not been encapsulated (control).  Cells which were 
released from the alginate were grown for 48h in monolayer culture before RT-PCR 
analysis.  KGF transcription was maintained following encapsulation in 5% w/v 
alginate hydrogel, although the level of transcription was reduced by at least 50% 
during encapsulation and by ~20-35% after release from encapsulation. 
 
KGF transcription was down regulated by more than 50% during encapsulation when 
compared with the control (Figure 9.2).  Following release from the alginate hydrogel at 
weeks one and three the transcription of KGF increased considerably when compared with 
that during encapsulation, but was still ~20-35% lower than in control samples. 
 
9.1.2. Formation of the epidermis by keratinocytes 
The growth and stratification of keratinocytes on the surface of the dermal analogue was 
assessed by RT-PCR, histological analysis and IHC.   
 
9.1.2.1. Histology and Immunochemistry 
After two weeks of keratinocyte growth at the A/L sections of the TE epidermis formed on 
the surface of the alginate/ fibroblast dermal analogue were stained with H&E and compared 
with sections of normal rat skin and TE epidermis formed on the surface of Thincert™ 
membranes (Figure 9.3).  The results indicate that after two weeks of culture at the A/L, 
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keratinocytes on both the dermal analogue and the Thincert™ membrane had formed multi-
layered structures.  The TE epidermis formed on the dermal analogue, however displayed no 
evidence of a SC, where as the tissue engineered epidermis formed on the surface of the 
membrane appeared to be fully stratified with presence of a SC, and closely resembled the 
epidermis of normal skin (9.3a).  The multi-layered epidermal layers formed on the surface of 
the dermal analogue and the membrane were confirmed to be formed from keratinocytes 
rather than fibroblasts or other contaminating cell types by IHC staining for PanK (Figure 
9.4).  The presence of PanK in the tissue engineered epidermal layers (Figures 9.4b and 9.4c) 
was indicated by the brown staining of the cells, as was seen in the epidermis of normal skin 
(Figure 9.4a).  The cells in the dermal layer did not stain positive for PanK, since the cells in 
this layer are mainly fibroblasts and not keratinocytes.   
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Figure 9.3:  H&E staining of a) normal skin showing epidermal architecture, and TE 
epidermis grown at the A/L for 14 days on the surface of b) a Thincert™ polystyrene 
polymer membrane in the presence of a 3T3 feeder layer and c) 5% w/v alginate/ 3T3 
dermal analogue.  A muli-layered structure was formed on the surface of the dermal 
analogue, but after 14 days there was no evidence of a SC.  A SC was present in the 
control TE epidermis, which closely resembled the epidermis of normal rat skin. 
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Figure 9.4:  PanK staining of a) normal rat skin and the TE epidermis formed on the 
surface of the b) dermal analogue and c) Thincert membrane after 14 days culture at 
the A/L interface.  Positive staining for PanK is indicated by brown staining of the cells, 
as can be seen for the majority of cells in the epidermis of normal skin (a), in which the 
main cell type is the keratinocyte.  No brown staining is seen in the dermis of normal 
skin (a), where keratinocytes are not present.  The positive staining for PanK in (b) and 
(c) indicated that the cell layers formed are indeed composed of keratinocytes and not 
other contaminating cell types such as fibroblasts. 
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9.1.2.2. RT-PCR analyisis of keratinocyte differentiation markers 
In order to determine the presence of distinct epidermal sub-layers in the TE epidermal 
layers, expression of K5, K14, K1 and involucrin by keratinocytes in the TE epidermal layers 
was assessed by RT-PCR and compared with the expression of GAPDH after four, 7, 11 and 
14 days culture at the A/L.  Monolayer cultures of fibroblasts were used as a negative control 
to show the primers were specific to the target proteins which are only expressed by 
keratinocytes and not by fibroblasts (Figure 9.5).  The relative expression of K5, K14, K1 and 
involucrin were determined by measuring the relative band intensities.   
 
Figure 9.5:  GAPDH, Keratin 1, 5, 14 and Involucrin expression by keratinocytes grown 
at the A/L for 4, 7, 11 and 14 days.  Keratinocytes were either grown on alginate/ 3T3 
dermal analogue (with no feeder layer) or Thincert™ polymer membrane in the 
presence of a feeder layer. No expression of Keratin 1, 5, 14 and Involucrin by 3T3 
fibroblasts demonstrated that the primers were specific to these keratinocyte-expressed 
genes. 
GAPDH
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K5 is a marker of the basal layers of the epidermis, and this gene was expressed at all time 
points in both the epidermal tissue formed on the Thincert™ membrane and on the dermal 
analogue (Figure 9.6).  On the surface of the dermal analogue, the level of K5 expression 
increased between days four and seven, before dropping between days 7 and 11, then 
increasing again between days 11 and 14.  The expression of K5 was constant between day 
four and day 7 then doubled between day 7 and day 14.  K14 is also a basal cell marker, and 
as expected, the pattern of K14 expression (Figure 9.7) was very similar to that of K5 (Figure 
9. 6). 
 
The presence of suprabasal layers in the samples was identified by detection of K1 expression 
(Figure 9.8).  K1 expression at day four and 7 for the dermal analogue samples was 
comparable with the transcription patterns seen for K5 and K14.  For the membrane-cultured 
samples, the expression of K1 was strong at all four time points indicating presence of 
suprabasal layers at all four time points. 
 
Involucrin expression at day four was not evident with the dermal analogue samples but was 
strong at day 7 indicating the presence of cells which had terminally differentiated (Figure 
9.9).  The expression of involucrin was then not detected at day 11 but was detected at day 
14, although at a level which was only approximately 50% of that at day 7.  Involucrin 
expression for keratinocytes cultured on Thincerts was detected at all four time points, 
although it increased between day four and 14 illustrating that more cells were terminally 
differentiating with time, as would be expected as stratification occurs.  A decrease in 
involucrin expression was, however, seen between day 7 and day 11.  
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Figure 9.6:  Relative expression of K5 by keratinocytes grown at the A/L for 4, 7, 11 and 
14 days.  Keratinocytes were either grown on the alginate/ 3T3 dermal analogue (with 
no feeder layer) or Thincert™ polymer membrane in the presence of a feeder layer.  
3T3 fibroblasts were used as a negative control.  K5 expression indicated presence of 
basal layer keratinocytes. 
 
Figure 9.7:  Relative expression of K14 by keratinocytes grown at the A/L for 4, 7, 11 
and 14 days.  Keratinocytes were either grown on the alginate/ 3T3 dermal analogue 
(with no feeder layer) or Thincert™ polymer membrane in the presence of a feeder 
layer.  3T3 fibroblasts were used as a negative control.  K14 expression indicated the 
presence of basal layer keratinocytes. 
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Figure 9.8:  Relative expression of K1 by keratinocytes grown at the A/L for 4, 7, 11 and 
14 days.  Keratinocytes were either grown on the alginate/ 3T3 dermal analogue (with 
no feeder layer) or Thincert™ polymer membrane in the presence of a feeder layer.  
3T3 fibroblasts were used as a negative control.  K1 expression indicated presence of 
suprabasal layer keratinocytes. 
 
Figure 9.9:  Relative expression of Involucrin by keratinocytes grown at the A/L for 4, 
7, 11 and 14 days.  Keratinocytes were either grown on the alginate/ 3T3 dermal 
analogue (with no feeder layer) or Thincert™ polymer membrane in the presence of a 
feeder layer.  3T3 fibroblasts were used as a negative control.  Involucrin is a 
component of the cornified envelope and expression of involucrin indicated the presence 
of terminally differentiated keratinocytes of the suprabasal layers, progressing toward 
the SC. 
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9.2. Discussion 
A key requirement of skin healing is the effective re-epithelialisation of the wound site (Brem 
et al. 2009; Stojadinovic et al. 2007).  The epidermis forms by the proliferation of basal stem 
cells to cover the wound surface and the progressive differentiation of these basal cells to 
form the cells of the suprabasal layer, which later terminally differentiate to form the SC 
(MacNeil 2007).  Effective restoration of the epidermis, however, requires the presence of 
both keratinocytes and fibroblasts (Fuchs 1990; Fuchs 2008).  For this reason, when tissue 
engineered epidermis is produced in vitro, mitomycin-treated or lethally irradiated post-
mitotic cultures of fibroblasts are often used as feeder layers (Maas-Szabowski et al. 
2000;Werner et al. 2007; Witte & Kao 2005) to provide growth factors and cytokines to 
support epithelial regeneration.  For this reason a mitomycin-treated fibroblast feeder layer 
was used to support epithelial development in control samples of keratinocytes grown on 
Thincert™ polymer membranes.    
 
For the production of the TE epidermis on the surface of the dermal analogue, the fibroblast 
feeder layer was eliminated since fibroblasts were present in the dermal analogue and normal 
fibroblasts encapsulated in fibrin have previously been shown to act as an effective feeder 
layer for the production of tissue engineered epidermis (Panacchia et al. 2010; Rheinwald & 
Green 1975b).  Therefore, it was proposed that the alginate encapsulated fibroblasts should 
also act as an effective feeder layer, especially since the alginate encapsulated fibroblasts in 
the dermal analogue have been shown to be mitotically inhibited (Figures 6.3 and 6.7), and 
therefore should not overgrow the keratinocytes in the co-culture, and remain viable for at 
least 150 days encapsulation (Figure 6.1).  The potential of the fibroblasts in the dermal 
analogue to act as feeder layers was further demonstrated by their sustained transcription of 
IL-6, VEGF (Figures 8.1, 8.3 and 8.6) and KGF (Figures 9.1 and 9.2) following 
encapsulation in 5% w/v alginate hydrogel, relative to control samples of monolayer cultured 
fibroblasts.  Continued transcription of these factors was seen following encapsulation in the 
alginate hydrogel, as has been shown for fibroblasts cultured in collagen-based dermal 
analogues (Panacchia et al. 2010). This indicated that the dermal analogue should support 
keratinocyte growth and differentiation to restore the epidermis (Froget et al. 2003; Sun et al. 
2009).  Alginate hydrogel may, therefore, be a suitable alternative scaffold material to the 
collagen-based scaffolds commonly used in dermal TE (Finch & Rubin 2004; Grossman et 
al. 1989; Werner et al. 2007).   
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The keratinocytes which were cultivated on the surface of the dermal analogue were seen to 
form a multi-layered epidermal layer after 14 days A/L culture (Figures 9.3 and 9.4).  The 
epidermal layer, however, lacked a SC and was seen loosely packed in comparison with the 
TE epidermis formed after 14 days culture at the A/L on the surface of the Thincert™ 
membrane and the epidermis of normal rat skin.   In addition, the epidermal layer formed of 
the TE bi-layer was not seen to cover the entire surface of the dermal analogue and RT-PCR 
analysis of these differentiation markers indicated that keratinocytes grown at the A/L on the 
surface of the dermal analogue proliferated and differentiated more extensively within the 
first 7 days than keratinocytes grown on the Thincert
TM
 membrane.  In the following 7 days 
culture, the keratinocytes grown on the dermal analogues showed decreased expression of all 
markers, compared with the control samples (Figures 9.5-9.9).    
 
Keratinocyte adhesion to the growth substrate regulates differentiation of the keratinocytes to 
form a stratified epidermis (Jensen & Wheelock 1996).  The altered expression pattern of 
keratinocyte differentiation markers, and epidermal architecture, in comparison with the 
membrane-cultures TE epidermis is, therefore, likely due to the limited cell adhesiveness of 
the alginate hydrogel (Braunstein et al. 2004; Florin et al. 2005; Grossman et al. 1989; Singer 
& Clark 1999; Werner et al. 2007).  
 
9.3. Conclusion 
The potential of fibroblasts in the dermal analogues to act as a feeder layer to support 
epidermal regeneration has been demonstrated by the sustained transcription of VEGF, IL-6 
and KGF following encapsulation in 5% w/v alginate hydrogel.  Keratinocytes cultured on 
the surface of the dermal analogue produced multi-layered epidermal layers.  The 
differentiation pattern of the keratinocytes and the morphology of the TE epidermis of the bi-
layer construct was altered compared with TE epidermis grown on Thincert™ membranes in 
the presence of mitomycin-treated feeder layers.  This may result from the limited adhesion 
of keratinocytes to the alginate surface. 
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10. Conclusions and future work 
10.1. Conclusions 
In this thesis, a TE skin bi-layer consisting of fibroblasts encapsulated in calcium-alginate 
hydrogel and keratinocytes seeded on the surface has been developed and characterised. The 
effectiveness of the TE skin bi-layer to promote dermal regeneration, re-epithelialisation and 
vascularisation has been assessed in vitro.  The main conclusions of each results chapter are 
described below. 
 
10.1.1. Effect of encapsulation on fibroblast viability, growth and catabolic activity 
Fibroblasts encapsulated in 5% and 2% w/v alginate hydrogels were shown to remain viable 
for at least 150 days encapsulation.  This is essential to ensuring that these fibroblasts can 
secrete factors to support keratinocyte growth and differentiation to promote re-
epithelialisation, secrete ECM to provide dermal repair and secrete factors to support 
endothelial recruitment to facilitate vascularisation of the tissue.   
 
Alginate encapsulation was also shown to cause mitotic inhibition. This mitotic inhibition 
was seen to be reversed by degradation of the alginate hydrogel scaffolds to release the 
encapsulated fibroblasts, confirming that viability of encapsulated fibroblasts was 
maintained.  The mitotic inhibition indicated that the encapsulated fibroblasts should not 
over-grow the keratinocytes in the co-culture, without the need for gamma-irradiation or 
Mitomycin C treatment of the fibroblasts. 
 
The reversible mitotic inhibition of fibroblasts encapsulated in alginate hydrogels was 
accompanied by reversible catabolic inhibition of the cells.  This catabolic inhibition was 
likely the reason that the viability of the cells was maintained for at least 150 days 
encapsulation in the avascular scaffold.  The reversible nature of the metabolic inhibition 
again confirmed that the viability of the cells was maintained following encapsulation.  It also 
demonstrated that as the scaffold degraded in vivo the metabolic demand of the tissue would 
increase and, therefore, it is essential that the scaffold should become vascularised. 
 
10.1.2. Replacement of alginate hydrogel scaffold with normal ECM 
During encapsulation, histological evaluation displayed no evidence of ECM accumulation, 
but following degradation of the alginate hydrogels, encapsulated fibroblasts were seen to 
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secrete collagen.  The alginate hydrogel scaffold should, therefore, be replaced with normal 
ECM to facilitate dermal repair.  The degradation of acellular and fibroblast-encapsulating 
2% and 5% w/v alginate hydrogels were assessed by measuring release of cross-linking 
calcium cations by inductively coupled plasma mass spectroscopy (ICP-MS), and changes in 
rheological properties, morphology and mass.  The results indicated that the alginate 
hydrogels degraded slowly over time and retained gel-like morphology and mechanical 
properties for at least 28 days culture.  There was a steep decline in mechanical properties of 
all alginate hydrogels within the first 7 days, followed by a slower decline throughout the 
following 21 days.  The decline in mechanical properties during the first 7 days was increased 
by the inclusion of cells in the scaffolds, but the differences in mechanical properties between 
acellular and cell-encapsulating samples could not be attributed to differences in the calcium 
release profiles between cell encapsulating and acellular samples.  Overall, the results of 
degradation analysis indicated that 5% w/v alginate hydrogel degraded more slowly than 2% 
w/v alginate hydrogel, and retained higher mechanical properties over the culture period.  5% 
w/v alginate hydrogel should, therefore, better support the regeneration of the dermal and 
epidermal layers and was, therefore, chosen as the scaffold material for construction of the bi-
layer skin replacement. 
 
10.1.3.  Angiogenesis 
Scaffold vascularisation is essential to maintaining the viability and normal function of 
transplanted cells, to support tissue development.  Graft vascularisation is known to be 
achieved by angiogenesis, which is promoted by angiogenic factors such as FGF-2, VEGF, 
IL-6 and NGF.  RT-PCR analysis demonstrated that sustained transcription of VEGF, IL-6 
and NGF were maintained by fibroblasts following encapsulation in both 2% and 5% w/v 
alginate hydrogels.  The transcription of FGF-2, however, was not maintained.  Since VEGF 
is the main factor responsible for promotion of angiogenesis, the level of VEGF expression 
by encapsulated fibroblasts was also assessed by ELISA.  The level of VEGF protein 
expression by fibroblasts encapsulated in both 2% and 5% w/v alginate hydrogels was shown 
to be comparable, but approximately four times lower than the level of expression in 
monolayer fibroblast cultures.  As expected, the level of expression of angiogenic factors was 
not high enough to cause enhanced endothelial cell recruitment or migration toward the 
alginate hydrogel scaffolds.   
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10.1.4. Re-epithelialisation 
Fibroblasts encapsulated in 5% w/v alginate hydrogel were shown by RT-PCR to maintain 
transcription of KGF, which in addition to IL-6 and NGF, which were shown to be 
transcribed in Chapter 8, is known to support the proliferation and differentiation of 
keratinocytes to achieve epidermal replacement.  The formation of a multi-layered epidermal 
layer by keratinocytes seeded on the surface of the alginate hydrogel was compared with that 
of keratinocytes seeded onto a Thincert
TM
 membrane in the presence of a Mitomycin C-
treated feeder layer.  Histological analysis and PanK staining at day 14 after A/L culture 
indicated that the keratinocytes formed multi-layered epidermal layers on the surface of the 
alginate hydrogel.  The layers, however, were not continuous, and appeared to lack a stratum 
corneum. In addition, RT-PCR of differentiation markers indicated that keratinocytes grown 
on the surface of the alginate had an altered differentiation pattern compared with 
keratinocytes grown on Thincert
TM
 membranes.  This was likely due to the limited adhesion 
of keratinocytes to the surface of the alginate hydrogel, since adhesion is a key regulator of 
epidermal development. 
 
10.2. Future work 
Although the potential of the bi-layer to enhance wound healing has been illustrated, it is 
clear that further assessment of this potential should be assessed.  Further work should seek to 
quantify the level of KGF, NGF and IL-6 protein expression by alginate encapsulated 
fibroblasts, to assess whether it corresponds with the transcription of these genes. The 
expression of GM-CSF, PTN, TGFβ, and SDF-1, (Mansbridge 2008) should also be 
quantified in order that the potential of alginate-encapsulated fibroblasts to promote re-
epithelialisation can be better understood.  The effect of the TE skin when seeded with 
autologous keratinocytes and fibroblasts, on wound healing in vivo should be studied.  This 
should include analysis of the inflammatory response, scaffold degradation, ECM 
accumulation in the dermal layer, vascularisation, cell viability, cell migration, epidermal 
development, wound contraction, scar formation and innervation of the wound site (Babensee 
et al. 2003).   
 
The results also seem to indicate that further improvements should be made to the TE skin to 
enhance wound healing.  In particular, efforts should be made to enhance keratinocyte 
adhesion to the surface of the dermal analogue to improve epidermal regeneration, as well as 
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to increase ECM accumulation in the alginate hydrogel by fibroblasts and enhance 
angiogenic gene expression by the encapsulated fibroblasts. 
 
10.2.1. Increasing keratinocyte adhesion to the dermal analogue 
Promoting better adhesion of keratinocytes to the dermal analogue surface would possibly 
improve the potential for the formation of a full-thickness epidermis, since keratinocyte 
adhesion to the growth substrate regulates differentiation of the keratinocytes to form a 
stratified epidermis (Jensen & Wheelock 1996).    It has been shown that a higher G:M ratio 
alginate promotes increased cell adhesion (Wang et al. 2003) but cell adhesion and growth 
even on high G:M alginate hydrogel cross-linked with calcium without any modifications 
seems to be limited.  It is possible that a fibrin-rich blood clot would form around the scaffold 
in vivo to promote better adhesion (Wilshaw et al. 2009) of keratinocytes to the surface.  
Alginate can also be coated with Poly-L-lysine (PLL) (Lu et al. 2009; Wittmer et al. 2008) or 
chitosan (Majima et al. 2005) to promote cell adhesion of keratinocytes to the surface of the 
dermal analogue by immersion of alginate hydrogel in a solution of PLL or chitosan, since 
both PLL and chitosan are positively charged (Semenov et al. 2009) and alginate is 
negatively charged (Rinaudo 2008).    
 
Increased keratinocyte adhesion may also be achieved by increased adhesion throughout the 
scaffold, which may be achieved in a number of ways, including cross-linking alginate 
hydrogel with iron (hida-Sano et al. 2009) rather than calcium or using a blended 
biolpolymer gel of alginate and chitosan (Li et al. 2005; Majima et al. 2005), or covalently 
modifying the alginate with RGD (Alsberg et al. 2001; Augst et al. 2006; Kong et al. 2003; 
Rowley et al. 1999).    
 
10.2.2. Mechanical conditioning 
All cells are able to convert inputs from mechanical forces into chemical signals that alter cell 
migration, proliferation, orientation, metabolism and survival (Cukierman et al. 2001).  
Integrin receptors have been shown to transmit mechanical signals from the ECM to the cell 
cytoskeleton at structures known as focal adhesions (Nishimura et al. 2009).  Increasing 
adhesiveness throughout the alginate hydrogel scaffold would increase the adhesion of 
fibroblasts and ECs in the dermal layer.   This would allow the fibroblasts and ECs to show a 
greater response to mechanical stimulation (Discher et al. 2005), in order that dermal matrix 
accumulation and angiogenesis may be enhanced. Mechanical conditioning of the TE skin 
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may therefore increase neo-tissue formation.   Mechanical stimulation can be applied in 
compression (Villanueva et al. 2009; Waldman et al. 2007), shear (Cassell et al. 2002; 
Steward et al. 2010), tensile straining (Deng et al. 2009), but ultrasound may be particularly 
beneficial.   
 
Ultrasound is known to be effective in stimulating fracture (ter Haar 2007), muscle (Piedade 
et al. 2008), skin wound (Altomare et al. 2009) and cartilage repair (Speed 2001) and 
therefore, has been investigated as a method for mechanically conditioning engineered tissues 
(Bilodeau & Mantovani 2006).  Pulsed low intensity ultrasound has been shown to increase 
matrix synthesis by bovine invertebral disc cells encapsulated in alginate beads (Miyamoto et 
al. 2005), and has been proposed as an effective method for stimulating dentine repair 
(Scheven et al. 2007; Scheven et al. 2009b).  Ultrasound treatment has also been shown to 
up-regulate VEGF expression in monolayer cultures of cells (Kobayashi et al. 2009; Scheven 
et al. 2009a), and has been shown to enhance the formation of new blood vessels in full-
thickness excised lesions (Emsen 2007) and therefore, may enhance the production of 
angiogenic factors by encapsulated fibroblasts, to expedite vascularisation of the construct.  
Ultrasound treatment may therefore prove an effective method for improving 
epithelialisation, matrix accumulation and vascularisation of the tissue engineered skin bi-
layer. 
 
10.2.3. Chemical stimulation of collagen production 
Collagen accumulation can also be enhanced by addition of interferon-gamma, ascorbic acid 
(Chung et al. 1997), TGF-β (Chan et al. 2005) and proline (Barbul 2008), which are 
promoters of the collagen synthesis pathway.  The effectiveness of addition of these 
molecules to culture media to enhance dermal and epidermal repair should be investigated, 
both in the presence and absence of mechanical stimulation.   
 
10.2.4. Angiogenesis  
Further work should also seek to analyse whether down-regulation of VEGF protein 
expression resulted from down-regulation of HIF-1 and Bcl-2 expression.  Approaches to 
enhancing angiogenic gene expression, in addition to mechanical stimulation, should also be 
investigated.  For example, since copper is known to enhance angiogenesis (Barralet et al. 
2009; Gerard et al. 2010) by promoting the transcription of angiogenic factors such as VEGF 
(Xie & Kang 2009) and IL-8 (Bar-Or et al. 2003), and promoting the expression and 
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stabilizing HIF-1 (Martin et al. 2005), enhanced angiogenic gene expression by alginate 
encapsulated fibroblasts may be achieved by cross-linking some of the alginate with copper 
rather than calcium.  In order to better understand the angiogenic potential of the bi-layer skin 
graft, the effect of keratinocytes on angiogenesis should be investigated, including the 
expression of VEGF, and the effect of the keratinocytes on endothelial recruitment. 
 
10.3. Summary 
This thesis has investigated the use of alginate hydrogel as a scaffold material for the co-
culture of fibroblasts and keratinocytes to produce TE skin.  The potential of the construct to 
enhance dermal and epidermal regeneration at wound sites has been shown, and indicates that 
alginate hydrogel may prove to be an effective scaffold material for the tissue engineering of 
skin.  Further assessment and optimisation of the tissue engineering technique should now be 
sought in order that clinical application may be achieved. 
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Abstract 
Tactile sensation is important for the performance of daily tasks 
and prevention of injury.  Full thickness wounds of greater than 
4cm diameter will not spontaneously heal.  Tissue engineering 
can be used to replace the lost skin, but this skin will often fail to 
be reinnervated.  This results in loss of tactile sensations.  Here 
we have developed a novel, silicon based 
MicroElectroMechanical Systems (MEMS) sensor array that is 
capable of detecting tactile experiences of the tissue engineered 
skin.   Tissue engineered skin with tactile experiences can also be 
useful in the replacement of animal testing in the pharmaceutical 
industry. 
Key words:  tissue engineering, skin, MEMS tactile sensors, 
regenerative medicine, pharmaceutical testing. 
I. INTRODUCTION 
Biological tactile sensors of the fingertip play an important 
role in exploration of surfaces and tactile sensation is important 
for performance of daily tasks and prevention of injury.   The 
body has a limited capacity to regenerate nerves [1] and 
although advances have been made in the regeneration of 
neurons in vitro in recent years [2-4], at present fully 
functional tissue engineered neurons and are not available.  
Researchers have explored neural interface devices leading to 
the possibility of re-creating sensory experiences by linking 
artificial sensing devices with the nervous system [5]. 
Mechanical tactile sensors have been developed that emulate 
the performance of mechanoreceptors, i.e. biological touch 
sensors and there is a general trend towards bio-inspired 
designs of sensors [6-8].  
MEMS technology allows the realization of an array of 
such sensors that can be incorporated within a small area 
allowing high spatial resolution and a robust design which is 
highly desirable in robotics, medical and industrial fields. For 
packaging such sensors, the general trend has been towards 
materials mimicking the mechanical properties of skin. To 
date, materials such as silicone elastomers have been used for 
packaging sensors [9, 10]. Incorporation of sensors into tissue 
engineered skin has not been previously explored but is 
important both within regenerative medicine, in the context of 
implantable sensors and biohybrid systems [11, 12]. It is also 
relevant in the pharmaceutical industry for applications where 
it is important to mimic the contact conditions generated when 
human skin comes into contact with textured stimuli for 
characterisation of surfaces. This paper explores the integration 
of designed silicon based MEMS sensors with tissue 
engineered skin.  
II. METHODS AND MATERIALS 
A. MEMS Tactile Sensors 
A 4 x 1 linear sensor array was developed to measure the 
distribution of contact forces produced when the tactile device 
comes into contact with a surface. The main sensing unit 
consists of a clamped highly doped silicon membrane which, 
on application of pressure deflects towards a silicon substrate, 
thereby changing the electrical capacitance between the two 
plates (Figure 1). The subsequent change in capacitance is 
measured using a detection circuit.  The capacitance as a 
function of applied force C(F) can be expressed as: 
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   (1) 
where w(x,y) is the membrane deflection as a function of x 
and y coordinates of the sensing membrane, a and b are the 
dimensions of the sensing area, d0 is the initial gap between the 
two silicon plates and ε is the permittivity of air. 
Sensors were fabricated using standard MEMs fabrication 
techniques and simple process steps involving 
photolithography, Deep Reactive Ion Etching (DRIE), 
Hydrofluoric acid release etching and thermal evaporation of 
gold. For connection to an electrical measurement system, the 
fabricated sensors (figure 2) were mounted onto standard DIP 
chip carriers (figure 3) and wire bonded (using 25 µm 
aluminium wires).  The wires were protected with a coating of 
epoxy resin. The readout electronics for the tactile sensor array 
was implemented on a Printed Circuit Board (PCB) and 
included high resolution capacitance-to-digital converters 
(AD7747, Analog Devices) having a nominal resolution down 
to 20 aF. This allowed highly sensitive responses to be 
measured. 
 
  
 
 
 
 
 
Figure 1.  Cross sectional schematic of a single capacitive sensor. On 
application of pressure, the sensor diaphragm deforms resulting in a change in 
electrical capacitance between the diaphragm and substrate layer which can be 
measured using capacitance sensing electronics 
 
 
 
 
 
 
 
 
 
Figure 2.  Left – Scanning Electron Micrograph (SEM)  image of a single 
sensor (membrane dimensions 500 µm x 200 µm), Right – cross section of 
device showing two highly doped Silicon layers separated by an airgap. 
 
 
Figure 3.  Bare sensor array chip mounted onto standard DIP package. Wires 
are coated with epoxy to prevent their dislocation during sensor operation. 
B. Production of  tissue engineered (TE) skin 
Keratinocytes were obtained from a neonatal rat sacrificed 
by cervical dislocation.  The keratinocytes were isolated using 
0.25% trypsin–0.02% EDTA and mechanical dissociation and 
cultured in 3:1 DMEM:Ham’s F12 supplemented with 50mM 
hydrocortisone, 10 µg/ml insulin, 25 ng/ml EGF, 10% v/v FBS 
(PAA), 1% v/v P/S, 2.25% v/v HEPES, 2% v/v L-glutamine as 
monolayers, with the support of a fibroblast feeder layer 
prepared by treatment with 4mM Mitomycin C for 2h at 37ºC, 
until a sufficient number of keratinocytes were obtained, as 
determined by counting using a haemocytometer.  The 
keratinocytes were seeded at a density of 0.2×10
6 
cells/cm
2 
onto Thincert TM membranes and grown in the presence of a 
Mitomycin-treated feeder layer.  The keratinocytes were 
cultured for a further 7 days on the alginate scaffold before 
being raised to the air-liquid (A/L) interface for 14 days to 
allow for stratification of the keratinocytes.  All keratinocyte 
cultures were maintained at 37ºC with 5% CO2 and 100% 
relative humidity. 
Thincert TM polymer membranes were seeded with 
primary neonatal keratinocytes and after 7 days the 
keratinocyte culture was raised to the A/L interface for 14 days 
to promote keratinocyte differentiation in order to produce a 
full thickness epidermis. 
C. Characterisation of skin and TE skin by histology 
An adult rat was humanely sacrificed by cervical 
dislocation before removal of the hairy skin. Tissue engineered 
epidermis and normal hairy skin samples were fixed in 
formalin buffer for 24h before progressive dehydration in 
cassettes (Thermo Shandon, Citadel 1000, Cheshire, UK).  The 
dehydrated samples were then embedded in paraffin wax 
(Sakura, Tissue Tek, TEC) and stored at room temperature.  
Samples were then cooled to 5°C and 5µm sections were taken 
using a microtome (Leica RM 2035), which were attached to 
glass slides and dried at 60°C in an oven for 1h before removal 
of the wax in xylene and staining with  Haematoxylin and 
Eosin (H&E) (Surgipath Europe Ltd, Peterborough, UK) to 
demonstrate tissue architecture.  The haematoxylin stained cell 
nuclei blue/ black whilst the eosin stained the cytoplasm and all 
extracellular matrix components shades of pink.   Coverslips 
were then applied to the slides using XAM (BDH Laboratory 
Supplies, Poole, UK) and images of the slides obtained with a 
light microscope (Carl Zeiss Ltd, Axiolab, Herefordshire, UK) 
and captured (Canon Powershot GS, Surrey, UK).  The images 
were then corrected using Image J software (NIH, Maryland, 
USA) to remove any uneven illumination from the image.  
Figure 4.  H&E staining of a) normal hairy skin and b) tissue engineered 
epidermis on Thincert TM polymer membrane.  The nuclei of the cells stain 
blue due to the haematoxylin and cytoplasm and extracellular matrix stain 
shades of pink due to the eosin.  The staining shows that the tissue engineered 
epidermis is similar in architecture to the epidermis of normal skin with 
stratification and a stratum corneum. 
III. RESULTS AND DISCUSSION 
The fabricated tactile sensors were characterised using 
load-unload indentation experiments. Controlled normal loads 
were applied on the surface of the sensor using a loading 
station with precise position control of a spherical probe. The 
resulting change in capacitance was simultaneously recorded. 
Bare sensors were found to be able to resolve forces in the sub 
mN range as seen in Figure 5.  
In robotics sensors are often packaged using materials such 
as silicone elastomers which are used to simulate skin.  To 
explore performance of the fabricated MEMS sensors with 
50µm
A B
 
Sensor array 
mounted on chip 
carrier 
Al wires coated with 
epoxy resin 
 
 
Au 
n
+
Si 
n
+
Si airgap 
Sensor 
membrane 
Reference 
sensor 
such packaging, they were they were coated with a layer of 
Dragon Skin™ Q (Smooth-On, PA, USA).  Indentation testing 
of the sensors coated with this material (Figure 6) indicated 
that the packaging material reduced the sensitivity of sensors to 
loading stimulus.   
A tissue engineered skin has been produced which was 
shown by histological staining to be structurally similar in 
composition to the epidermis of normal skin (Figure 4).  The 
H&E staining illustrated that the keratinocytes had fully 
stratified to form a 3-5 cell thick epidermis with a stratum 
corneum.  The mechanical properties of skin, tissue engineered 
skin and Dragon Skin™ Q were compared tribologically and 
by indentation testing and atomic force microscopy.  The 
mechanical properties of the tissue engineered skin are, in 
contrast with Dragon Skin™ Q, mechanically similar to normal 
skin (results not shown).  It is therefore thought that coating the 
sensors with tissue engineered skin rather than Dragon Skin™ 
Q should allow for the detection and discrimination of tactile 
stimulation by the MEMS sensors to be more similar to those 
which would be experienced when the epidermis of normal 
skin is applied to the surface of the sensors. 
Currently work is underway adhering tissue engineered 
skin and normal skin epidermis directly to the surface of the 
sensors and carrying out further indentation and 
characterisation experiments.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Response of sensors to load - steady state - unload cycles of 
indentation for bare sensor. Upper trace shows the capacitance change 
measured during two load-steady state-unload indentation cycles. Bottom 
trace shows data from commercial load cell ((ATI NANO 17 F/T, Apex, NC, 
USA). The sensor response is coherent with applied loading conditions. For 
an applied load of 10 mN there is an approximate capacitance change of 500 
fF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Response of sensors to load- steady state- unload cycle of 
indentation for sensor packaged with Dragon Skin™ Q . Overall decreased 
sensitivity and drift of response can be observed during a steady state 
indentation 
IV. CONCLUSIONS 
 
In this paper, the development and characterization of a silicon 
based MEMS sensor has been shown, which is capable of 
detecting forces in the sub mN range.  Tissue engineered 
epidermis has also been developed that can be applied to the 
surface of these sensors.  Tactile stimulation experiments are 
currently being conducted on MEMS sensors incorporated into 
tissue engineered epidermis, and the results of these 
experiments will follow shortly. 
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Abstract: Alginate has been used as a biomaterial for around 20 years.  It has been used to 
encapsulate mammalian cells for immunoisolation and tissue engineering applications.  In 
the present study the effectiveness of alginate hydrogel as a delivery vehicle and scaffold for 
wound healing has been evaluated.  Encapsulation of fibroblasts within the alginate hydrogel 
was shown to cause mitotic inhibition, allowing for keratinocytes seeded on the gel surface 
to form a stratified epidermal layer that could assist in wound closure.  The alginate was 
shown to degrade over time and in doing so released the encapsulated fibroblasts.  The 
fibroblasts were shown to resume normal growth upon release from the alginate hydrogel 
which could facilitate the repair of damage to the dermal layer.  The release of calcium from 
the alginate was shown not to affect keratinocyte maturation, which allowed the 
keratinocytes to form a stratified layer in which the cells did not all terminally differentiate 
and remained viable.  The keratinocytes could therefore repopulate the wound site in clinical 
application and provide wound closure.  Alginate hydrogel is potentially an effective scaffold 
for the co-culture and delivery of keratinocytes and fibroblasts to a wound bed to provide 
wound closure and expedite the healing process. 
 
Keywords: Alginate, Tissue Regeneration, Wound Healing, Keratinocytes, Fibroblasts. 
 
 
1. INTRODUCTION 
 
1.1 Skin and Wound Healing  
 
Skin consists of two main layers known as the epidermis and the dermis, in which the main cell types are the 
fibroblast and the keratinocyte.  Chronic wounds are wounds that do not heal in an orderly set of stages and in a 
predictable amount of time the way most wounds do (Supp and Boyce, 2005).  These wounds are usually full-
thickness and therefore lack both a dermal and epidermal component.  The paracrine interactions between the 
fibroblasts and keratinocytes  have been found to be essential for effective wound healing, and therefore it is 
important that both cell types are present within the tissue engineered skin (Spiekstra et al., 2007).  Although a 
number of tissue engineered skin constructs exist, some simply aim to replace the epidermal layer and thus only 
provide wound closure but not necessarily structural integrity.  The constructs that aim to replace the dermal layer 
generally contain animal derived components such as collagen or de-epidermalised dermis (DED) which can present 
risks of disease transmission and immunological rejection.  There is a significant need for a tissue engineered bilayer 
which contains no animal derived components (MacNeil, 2007). 
 
1.2 Tissue Engineering  
 
There is a considerable demand for the development of novel methods to replace diseased or damaged tissues.  
Synthetic materials have been used as tissue replacements for many centuries, but issues remain surrounding the 
integration of these materials into the body.  Tissue engineers seek to produce and condition tissues in vitro with the 
intention of implanting the resulting construct into the body (Langer and Vacanti, 1993).  In order to mimic the 3D 
organisation of cells in a range of tissues they are typically seeded onto a scaffold composed of a macro-porous 
sponge-like material.  Although such structures provide a certain amount of 3D organisation, the cells are still 
adhering to a 2D surface.  It has been demonstrated that cells that cultured on 2D substrates exhibit distinct 
phenotypes when compared with cells in the extracellular matrix (Pedersen and Swartz, 2005).  In order to produce a 
tissue representative of that found in vivo it is therefore desirable to culture the cells in an environment that mimics 
both the structure and spatial resolution of the extracellular matrix (ECM).  Hydrogels represent a class of 
biomaterials which provide such a 3D environment to encapsulated cells (Boontheekul et al., 2005). 
 
1.3 Alginate 
 
Alginate is a polysaccharide isolated from sea weed which can be crosslinked with calcium to form a hydrogel.  The 
highly porous structure of alginate hydrogel allows for good mass transport properties so that nutrients, waste 
products and signalling molecules can effectively perfuse the scaffold to maintain cell viability (Rowley et al., 
1999).  Alginate has been used for medical applications such as for drug encapsulation for slow and sustained 
release of drugs, microencapsulation of cells to protect them from immunological responses when implanted in the 
body, as a filler to provide bulk to areas where tissue has been lost and in wound dressings (Augst et al., 2006; 
Boateng et al., 2008).  In addition it has been investigated as a material for tissue engineering bone, cartilage and 
other materials due to its mild gelling reaction, lack of toxicity and its approval for medical applications (Drury and 
Mooney, 2003; Smith et al., 2007).   
 
In the present study alginate hydrogel was investigated as the scaffold for delivery of a fibroblast/ keratinocyte co-
culture to the wound bed to facilitate replacement of the dermis and epidermis.  3T3 fibroblasts and primary rat 
keratinocytes were used as models for autologous fibroblasts and keratinocytes. 
 
 
2. METHODS AND MATERIALS 
 
2.1 Materials and Chemicals 
 
All chemicals were purchased from Sigma Aldrich (UK) unless otherwise specified.   
 
2.2 Fibroblast Encapsulation 
 
5% w/v low viscosity alginate (20-40 centipoise (cps) for 2% w/v at 25°C) was sterilised by autoclave then used to 
encapsulate NIH 3T3 cells (LGC, Middlesex, UK) at density of 7.5x105cells/ml.  The alginate/3T3 dispersion was 
added dropwise into a bath of 100mM CaCl2 and left to incubate at 37ºC for 2h to form cross linked spheres of 
3.0±0.2 mm diameter, then washed three times in non-supplemented DMEM.  Acellular samples for ICP-MS were 
prepared in the same manner.  To form an alginate encapsulating cell sheet, the suspension was used to cover the 
surface of a petri-dish and immersed in 100mM CaCl2 for 2h to allow for complete cross-linking of the alginate.  
The displacement of alginate by calcium chloride was prevented by covering the alginate hydrocolloid with a layer 
of filter paper impregnated with 100mM CaCl2.  Cells were grown and maintained in high glucose DMEM 
supplemented with 10% foetal bovine serum (FBS) (PAA, Somerset, UK), 1% penicillin-streptomycin (P/S), 2.25% 
HEPES and 2% L-glutamine.  All cultures were maintained at 37ºC with 5% CO2 and 100% relative humidity and 
media was changed three times weekly.   
 
2.3 Keratinocyte cultures 
 
Keratinocytes were obtained from neonatal rat sacrificed by cervical dislocation.  The keratinocytes were isolated 
using 0.25% trypsin  –         ( ’ 7 $   D Q G   P H F K D Q L F D O   G L V V R F L D W L R Q   D Q G   F X O W X U H G   L Q         ’ 0 ( 0  + D P ¶ V   )   
supplemented with 50mM hydrocortisone, 10µg/ml insulin, 25ng/ml EGF, 10% FBS (PAA), 1% P/S, 2.25% 
HEPES, 2% L-glutamine as monolayers, with the support of a 3T3 feeder layer prepared by treatment with 4mM 
Mitomycin C for 2h at 37ºC, until sufficient number of keratinocyte cells were obtained, as determined by counting 
using a haemocytometer.  The keratinocytes were seeded at a density of 0.2×106 cells/cm2 onto the surface of 
alginate/ fibroblast cell sheet or Thincert TM cell culture inserts, in the presence of a feeder layer (control).    After 7 
days submerged culture, the keratinocytes were raised to the air/liquid (A/L) interface for 7 days for evaluation by 
immunohistochemistry (IHC) and 4 days at the A/L interface for evaluation by the reverse-transcription polymerase 
chain reaction (RT-PCR) and live/ dead staining.   All keratinocyte cultures were maintained at 37ºC with 5% CO2 
and 100% relative humidity and media was changed three times weekly.   
 
 
 
2.4 Fibroblast Growth  
 
A stock solution of 5mg/ml MTT in phosphate buffered saline was added to supplemented DMEM at a 
concentration of 10% (v/v).  Samples of alginate/ 3T3 beads were removed from the media, washed in DMEM and 
immersed in the resulting 10% solution of MTT for 18hrs for growth analysis.  The MTT solution was then removed 
and replaced with HCl-isopropanol and left for 2.5hrs to allow the formazan produced to dissolve and diffuse out of 
the alginate.  The optical absorbance of the solution at 620nm was measured using a spectrophotometer (Cecil, 
Cambridge, UK).  This amount of formazan produced by cellular reduction of MTT was determined from the 
absorbance at 620nm according to a calibration of different cell concentrations in alginate, as determined by 
counting on a haemocytometer, and the absorbance at 620nm after application of the MTT assay. 
 
2.5 Inductively coupled plasma - mass spectroscopy (ICP-MS) 
 
1ml samples of 5% w/v alginate beads were prepared and immersed in 4ml supplemented DMEM.  The samples 
were prepared and maintained according to the method described for encapsulated fibroblasts.  Before assaying the 
calcium concentration the media was unchanged for 4 days.  The calcium ion concentrations in the culture medium 
was determined using ICP-MS (Varian,Darmstadt, Germany) against standard solutions of 50 ppm and 100 ppm 
(Merck, Darmstadt, Germany).  Samples were performed in triplicate at days 0, 6, 8 and 20 and the mean±SD is 
shown at each time point. 
 
2.6 Immunohisochemistry (IHC) 
 
Samples were fixed in formalin buffer for 24 h before progressive dehydration in cassettes (Thermo Shandon, 
Citadel 1000, Cheshire, UK).  The dehydrated samples were then embedded in paraffin wax (Sakura, Tissue Tek, 
TEC) and store G   D W   U R R P   W H P S H U D W X U H      6 D P S O H V   Z H U H   W K H Q   F R R O H G   W R      &   D Q G     P   V H F W L R Q V   Z H U H cut using a 
microtome (Leica RM 2035) before attachment to Superfrost glass slides (Laboratory Sales (UK) Limited, 
Rochdale, UK) and dried at 56°C for 2h before removal of the wax in xylene and staining with Pan Cytokeratin (Pan 
K) labelled with diaminobenzidine (DAB) and Mayers Haematoxylin (Surgipath Europe Ltd, Peterborough, UK) 
according to the manufacturers instructions to label cytokeratins brown and cell nuclei blue black, respectively.  
Coverslips were then applied to the slides using XAM (BDH Laboratory Supplies, Poole, UK) and viewed with a 
light microscope. 
 
2.7 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
Keratinocyte layers were removed from the alginate/ fibroblast dermal analogue and control scaffolds using 0.25% 
trypsin  –0.02% EDTA. The trypsin was inactivated by addition of supplemented media before centrifugation to form 
cell pellets.  mRNA was isolated from the cell pellets using a RNeasy Mini Kit (Qiagen, Crawley, UK).  Reverse 
transcription of RNA to cDNA was performed using an Omniscript RT Kit (Qiagen, Crawley, UK). Polymerase 
chain reactions were performed using a red TAQ ready mix PCR mix and resulting products were detected by 
agarose gel electrophoresis, stained with ethidium bromide and visualised under UV illumination.  GAPDH 
expression was used for normalisation (Invitrogen, Paisley, UK) and the target genes analysed were involucrin and 
keratin 1, 5 and 13 (Invitrogen, Paisley, UK).   
 
2.8 Live/ dead staining 
 
Sections of 1mm thickness were taken from the centre of alginate beads containing 3T3 cells 4 days post 
encapsulation, using a razor blade and keratinocytes were stained in situ on the surface of the alginate/ 3T3 dermal 
analogue.  Samples were immersed in 0.2µg/ml Calcein acetoxymethylester for 15 mins and 2.5µg/ml Propidium 
Iodide (Invitrogen, Paisley, UK) for 5 mins in DMEM at 37ºC to stain live cells green and dead cells red, 
respectively, when visualised with a fluorescence microscope. 
 
 
3. RESULTS 
 
Encapsulated fibroblasts were shown to be evenly dispersed and remain viable throughout the 3mm diameter of the 
alginate hydrogel bead after 4 days encapsulation (Fig. 1A).  The effect of long term encapsulation of fibroblasts in 
5% w/v alginate hydrogel on growth was assessed over an 18 day period by cell counting using the MTT assay (Fig. 
1B).  The number of viable fibroblasts present within the alginate hydrogel did not deviate significantly from 
0.44×106 cells over the duration of the study, demonstrating that the fibroblasts were in a quiescent state within the 
hydrogel matrix.   
 
0.00
0.50
1.00
1.50
2.00
2.50
0 5 10 15 20
C
e
ll
 n
u
m
b
e
r 
(x
1
0
6
)
Time (days)
                 
    
Fig. 1.  A. Encapsulated fibroblasts (black squares) were shown to remain at a constant cell number for 18 days.  
When keratinocytes were released from alginate (grey triangles) these cells were shown to return to normal growth, 
as seen before the fibroblasts were encapsulated (open diamonds).  B. Live/ Dead stained encapsulated fibroblasts 
(day 4) showed that cells remain viable throughout the diameter of the bead and the cells were evenly dispersed.  
 
The alginate hydrogel scaffold degraded over time by the release of calcium cations which cross-link the structure 
into the culture medium (Fig. 2). The concentration of calcium in the medium increased between day 0 and 6 then 
gradually fell between day 6 and 20, indicating that the rate of degradation decreases with time (Fig. 2). The calcium 
release profiles for acellular and fibroblast encapsulating samples were shown to be very similar, indicating that the 
cells had very little effect on the degradation of the scaffold.  Fibroblasts were observed on the surface of the culture 
dish in which the alginate was incubated, illustrating that the degradation resulted in the release of encapsulated 
fibroblasts.  Fibroblasts that were released from the alginate hydrogel matrix were shown to resume mitotic activity, 
and demonstrated the normal growth characteristics that are observed with 2D culture (Fig. 1B). 
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Fig. 2.  Change in calcium concentration of cell-culture media with time due release of calcium cations cross-linking 
the 5% w/v alginate hydrogel.  Fibroblast encapsulating samples (closed diamonds) and acellular samples (open 
squares) show similar calcium release profiles. 
  
A stratified epidermal layer was shown to form on the surface of the alginate after 7 days submerged culture 
followed by 7 days culture at the A/L interface, as indicated by positive staining for PanK (Fig. 3A).  Expression of 
various proteins specific to different sublayers of the epidermis were assayed by RT-PCR after 4 days culture at the 
A B 
A/L interface (Table 1).  The keratinocyes were shown to express keratin 5, a marker of basal cell lineage, indicating 
the presence of a basal layer.  Expression of keratin 1 and 13 which are specific to the suprabasal epidermal layers 
was also detected, indicating that some cells had differentiated to form suprabasal layers.  Expression of involucrin, 
a marker of terminal differentiation to form the cornified layer of the epidermis, was not detected indicating that the 
keratinocytes had not terminally differentiated. The keratinocytes were confirmed to remain viable by the presence 
of mainly green staining in Fig. 3B. The same pattern of expression of the four proteins was observed for control 
epidermal layer and the epidermal layer formed upon the surface of the alginate/ fibroblast dermal analogue. 
       
A B
 
Figure 3. A.  A stratified layer formed upon the surface of the alginate/ fibroblast dermal analogue and stained 
positively with Pan Cytokeratin, indicating that it was formed of keratinocytes and not fibroblasts.  B.  Live/dead 
staining of the stratified layer on the alginate/ fibroblast surface showed keratinocytes remained viable. 
Table 1.  Expression of keratin 5, 13 and 1 and involucrin after 7 days submerged culture and 4 days culture at the 
air-liquid interface.  The keratinocytes grown upon the surface of alginate/ fibroblast dermal analogue expressed 
keratin 5, 13 and 1 but not involucrin.  The same expression pattern was observed for keratinocytes cultured on 
polymer membranes in the presence of a feeder layer (control). 
 Control Alginate  
Keratin 5 Expressed Expressed 
Keratin 13 Expressed Expressed 
Keratin 1 Expressed Expressed 
Involucrin Absent Absent 
 
 
4. DISCUSSION 
 
Fibroblast presence is essential to the formation of a full-thickness epidermis (Werner et al., 2007), but the 
fibroblasts must be mitotically inhibited to prevent over-growth of the keratinocyte/ fibroblast co-culture (Clark et 
al., 2007).  Encapsulation of fibroblasts within the 5% w/v alginate hydrogel matrix was found to effectively inhibit 
their growth (Fig. 1) in contrast to what has been found for HepG2 liver cells encapsulated at a higher cell density in 
a lower concentration alginate (Khattak et al., 2006).  It is therefore proposed that the lack of cell proliferation in our 
study is due to the cells being mechanically confined from each other by the alginate scaffold.  This growth 
inhibition allowed for keratinocytes to form a stratified epidermal layer upon the surface (Fig. 2).   
 
Calcium is a key regulator of keratinocyte maturation, and in excess can cause all keratinocytes to terminally 
differentiate and die (Lansdown, 2002).  The alginate hydrogel degraded over time by the release of cross-linking 
calcium cations into the culture medium (Fig. 2) in a similar manner to that which has previously been observed 
with other alginate hydrogels (Boontheekul et al., 2005). The release of calcium from the scaffold was found to have 
no effect on the expression profile of keratinocytes after 4 days at the A/L interface indicating that the release of 
calcium from the alginate was not significant enough to alter the normal course of keratinocyte maturation (Table 1).  
After 7 days at the A/L interface the keratinocytes were shown to be viable by live/ dead staining, again illustrating 
that the keratinocytes had not terminally differentiated due to the calcium released from the alginate hydrogel (Fig.  
2b). The keratinocytes should therefore be able to undergo further proliferation and differentiation at the wound site 
to produce a full thickness epidermis to provide wound closure. 
 
As the alginate scaffold degraded, fibroblasts were observed to be released from the scaffold and attached to the 
tissue culture plastic of the petri-dish in which the alginate was cultured.  The growth of released fibroblasts 
appeared very similar to that seen before encapsulation (Fig. 1) and therefore the fibroblasts should be capable of 
replacing the lost dermis at the wound site, after the closure of the wound by the keratinocytes.  As the scaffold 
degrades at the wound site other cell types which are involved in wound healing may also be able to migrate into the 
scaffold to facilitate wound healing and integration of the tissue engineered scaffold into the body.   
 
 
5. CONCLUSIONS 
 
Alginate hydrogel is a promising scaffold and delivery vehicle for a co-culture of keratinocytes and fibroblast to the 
wound bed to facilitate the healing of full thickness skin wounds.  The keratinocytes could provide wound closure to 
restore the barrier function of skin.  The alginate should degrade with time to release the encapsulated fibroblasts to 
facilitate replacement of the dermal layer.  Further work will seek to evaluate the behaviour of the scaffold in vivo 
when seeded with autologous fibroblasts and keratinocytes, after cultivation in serum-free media to avoid 
immunological responses. 
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1  IN TRO DUC T IO N  
The increasin gl y a gin g population and lack of donor ti ssue has pushed ti ssue re gene rati on  
to the fore front of mode r n biom edical res ear ch  an d b iopol ymers tr adit ionall y found  in th e  
food and ph arma ceuti cal  indus tr y are  i ncr easin gl y b eing used  in ti ss ue  e ngine erin g . The  
developm ent of ti ssue en gine erin g provides the  op portunit y to t ake a sampl e of c ell s from a  
pati ent  which ar e then c ult ured in vit ro  to organi se int o functi onal ti ssue that can then b e  
im planted back int o the pati ent , u lt im atel y ,  over co mi ng problems of ti ssue rejecti on and  
the need fo r donor  ti ss ue .  To grow replac eme nt ti ssue requires a suit able subst rate  o r 
scaffold  for cell s to att a ch, proli fer ate and or ga nise int o viable ti ssue t hat can b e sa fel y 
im planted int o the bod y . Biopol ymers  a nd h yd r ogel  formi n g biopol yme rs in pa rticular,  
have been shown to be a promi sing scaffold mate rial due having prope rtie s that resembl e 
the environment of the mammalian ex tracell ular matrix  (EC M ). In addit ion properties such  
as mi ld gelation condit i ons, pot enti al for good  mass transport  of nutr ients  and w aste  
mol ecules, nontox ic na ture and  biol ogi cal co mpatibi li t y p rovide an  advanta ge ov er 
s ynthetic  pol ym ers and c erami c  and m etalli c mate rials which  have  also b ee n used as ti ssue  
engin eerin g sc affolds.  
 
As  we ll  as supportin g c ell  growth and proli fe rati o n, the scaf fold must  have  the mechani cal  
chara cterist ics n eed ed to  retain  it s structur e fo r a s long as  it  is ne eded
 1
.   Id eall y  gels used  
as scaf folds for ti ssue  en gine erin g  would hav e a mi ld sol - gel re acti on th at  can be  controll ed  
at 37°C  and at ph ysiol o gical pH, have rapid gelati on kinetics and be robust enough for 3D  
cult ure and im plantati on. This ex plains  wh y mu ch of the resea rch on b iopol ym ers for  
ti ssue engin eerin g h as been pe rformed  on ma terials such as al ginate
2
 and chit osan
3
 
coll agen
4
 a garos e
5  
and f ibrin
6
. The relative su cc ess  of the  cell  cult ure o f the mentione d  
biopol ym ers  has gener at ed int erest in other gel f ormi ng biopol ym ers suc h a s gell an gum
7
 
and chemi c all y modi fie d gels  such as R GD al ginate
8
. P erf o rmanc e of  the cell s when  
encapsul ated in these bi opol ymers va ries due to the cell ular int era cti on with  the pol ym er  
chemi str y and gel netwo r k st ructure .  
 
In thi s stud y we hav e investi gated th e use of carr a ge enan as a  3D  ti ssue en ginee rin g 
scaffold for mam malian cell s  and looked at  the i mpact of structu ral diff e rences  betwe en  
kappa and iot a carr a geen an has on the att achment, survival and proli ferati on of fibroblasts 
and in compa rison  with alginat e which ,  is widel y used in ti ssue r e gen erati on.  C arra geen an 
ha s  been used in bacteria l cult ure
9
 and has been evaluated as a  deli ver y ve hicle for growth  
factors fo r mammalian ti ssue engine erin g  appli cati ons
1 0
 however there  have been no  
reports of c arr a ge enan be ing used ex clusi vel y for t he 3D cult ure o f mamma li an cell s .    
 
 
 
 
2 METHODS  AND RES U LTS  
Unless ot herwise spe cifie d all  rea gents w ere obt ained form S igma Aldrich (Pool e, UK).  
 
2.1 . For mation  of  h yd rogel scaf f olds f or en cap su lation  of  f ib rob lasts  
N IH 3T3 murine fibrobla sts  were added to 2% (w/ v) Na - al ginate  at a densi ty of 0.75 x  10
6
 
cell s/m l .  The c ell - gel su spension was th en  add ed  drop wise  int o a  bath o f 100mM  C aC l 2  
and left t o incubate at 37ºC  for 2h to form  cross - li nked spheres o f 3.0±0.2 mm  diameter.  
 
1% kappa  and  2% Iota  c arra geen an  discs we re fo rmed usi ng 3ml  a utoclav ed gel which was 
cooled to 40°C  before a 0.75 x  10
6  
NIH 3T3 mur ine fibroblast cell  suspen sion was added  
and pippetted re peatedl y to ensure homo genisati o n. No ex tra cati ons w ere added to the gel  
solut ion as there w ere  sufficient salt s pr esent with in the suppl emented med ia added to cell  
suspensions t o cause the gel t o c ross - li nk.  
 
All sampl es w ere  cult ure d in hi gh glucose  Dulbecco’s Modified Eagle’s Media (DMEM )  
suppl emented with 10%  v/v foet al bovine s eru m (FBS ) (PAA, S omers et, UK),  1%  v/v  
penicill in - streptom ycin ( P /S ), 2.25% v/ v HEPES  and 2% v/v L - glut ami ne  and maintained  
at 37ºC with 5% C O 2  and 100% relative  humi dit y and medi a was chan ged  three  ti mes  
weekl y.  C ontrol samples without  cell  seeding wer e also prep ared for de gra dati on st udies .  
 
2.2  For m ation  of  h yd rogel scaf f olds f or su rf ace seed in g  
Alginate discs wer e pre pared usin g steril e 2 % low viscosit y Na - al ginate . The discs wer e  
formed b y cov erin g  3ml  Na - al ginate with  100  mM C aC l 2  for 2h  in 6 - well  ti ssue cult ure 
plates. Foll owin g crossli nking,  N IH  3T3 murine fibroblasts  wer e seed ed on the surfa ce o f  
the algin ate at a d ensit y o f  0 . 4 4×10
6
 cell s/m l  
  
Iota  and K appa  c arr a geenan gel c yli nd ers we re formed usin g steril e  2%  (w/v) iot a -
carr a ge enan and 1% (w/v) kappa  carra geen an in 12 - well  cult ure plates co ntaining 3ml  of  
the gel sol uti on pe r w ell  before  addit ion of  1  m l  2 00 mM KC l.  Th e c ross - l inked kappa  and 
iot a - carr a geen an discs were then seed ed at a cell  densit y of 0.75 × 10
6
. The gel discs wer e  
topped wit h suppl emente d DMEM and maintaine d at 37ºC  with 5%  C O 2  and 100% relative  
humi dit y .  
 
2.3  Anal ysis  of  cell  mor p h ology and  su rvival   
Foll owing 10  da ys  in c ult ure,  sampl es of the gels we re remov ed and  the cell s were 
anal ys ed usin g a  Live/ Dead
®
 Viabil it y/C ytot ox icit y Kit . This procedu r e, based on the  
uptake of calc ein AM and conve rsion to fluor escent c alcein ( gre en) b y int r acell ula r  
esterases in li ve  cell s and the uptake of propidium  iodi de  (red) b y cell s with damaged  
plasma membran es ,  wa s used in conjunction with fluorescen ce mi c ro scop y to  assess  
cell ular  re sponses to the alginat e  and car ra geenan sc affolds .  The r esult s for the 
encapsul ated  sampl es sh ow ed  that > 95% o f c ell s remained vi able in algin a te .   The  rounded  
morpholog y, h owev er, al so  indi cate that the y w e r e  not well  att ached to the gel ( Fi g. 1 A).   
S im il arl y cell s enc apsul ated in kappa - car ra ge en an ar e rounded in appea rance  on da y 10  
(Fi g 1 B)  with > 95 %  of  the c ell s remainin g li ve .  S ampl es of  iot a - c arr a geenan  (Fi g.  1C )  
also had a  > 95%  survival ,  however , the appe aranc e of thi n projecti ons and overall  
elonga ti on of th e c ell s s uggests  att achment  of th e c ell s to the h yd ro gel. It is h ypoth esis ed  
that the lack of ioni call y bound junction z ones within the structure of iot a - carra geen an  gels  
provides  spa ces b etween  the pol ymer  ch ains tha t  are  suffici ent in all ow ing the  c ell s to  
gro w and proli f erat e sim il ar to the findings of J eon et. al. (2007 )
1 1
.   For surfa ce se ede d  
sampl es  o nl y a f ew cell s were se en to be att ached to alginate and iot a - car ra ge enan aft er  10  
spont aneousl y re form below their melti n g p oint  following me chan ical disrupti on
1 2
 
all owing cell s to mi grat e throughout the gel without  disrupti ng the network, unli ke in 
kappa - c arr a ge enan and a lginate  wh ere th e cell s a re confin ed withi n a more ti ghtl y b ound  
gel n etwork.  Afte r 5 d a ys in c ult ure, thi s numbe r  reduce d  (f rom 4.9 × 10
6  
to 1.1 × 10
6
 b y da y 
12). P roliferati on  was als o seen in kappa - c arr a gee nan ,  howeve r ,  not at the same rate as in  
iot a - carr a geen an  a nd it  was not unti l da y 10 tha t the c ell s in kapp a c arr ageen an w ere  o f  
comparable  numb er to th ose in the iot a - ca rra geen an .  
 
Num ber of cells calculated fr om  absorb ance of for m azan for  encapsulated cells.
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Fig. 3 : Nu mb e r of  viab le cell s calcul ated  f rom the ab sorban ce of  for mazan  of  the  
en cap su lated  cell s. Ve rtical e rro r b ars rep r esen t the  stand ard  d e viation  of  the 
re p orted  mean  valu es (n=3).  
 
2.4  Degrad ation  
The chan ges in mass of gels with and without  cell s was determi ned b y m easurin g the dr y  
mass of the sampl es  (b y slow vacuum dr yin g) o n a dail y basis  in a vac uum freez e - dri er  
(Edwa rds, EF03, S ussex , UK) for 16h.  Thi s wa s to quanti f y  an y fluctu ati ons in mass 
withi n the sa mpl es which ma y o ccu r as a conse quence of pol ym er de gr adati on, protein  
absorption from t he cult u re media or formation of ex tracell ular matrix .    
 
Chang e in ma ss for K -car ra gee nan  with and without cells.
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Fig. 4 : Chan ges in  the mass f or  K appa - carrag een an  w ith an d without cell s.  Vertica l  
erro r b ars rep r esen t th e stand ard  d eviation  of  the rep ort ed  mean  valu es (n=3).  
 Chang e in ma ss for I -car ra gee nan  with and without cells.
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Fig. 5 : Chan ges in  the mass f or Iota - ca rrag e en an  w ith an d  w ithou t cell s.  Ver tical 
erro r b ars rep r esen t  th e stand ard  d eviation  of  the rep ort ed  mean  valu es (n=3).  
 
The de grad ati on rates of the three gels we re foun d to var y consi derabl y, with no statis ti cal 
differen ce  seen  betwe en the cell ular  and a c ell ular  sampl es of  al ginate ( P  > 0.05)  ( result s  
not shown ) .  Th e acell ul ar sampl es  of  kappa - ca rra ge enan  rem ained un c hanged for th e 
durati on of the stud y, ho wever, the addit ion of ce ll s withi n the gel caused a gradual loss  in 
tot al mass suggesti ng d e gr adati on of th e pol ym e r. The gel mass of  ac ell ular sampl es of  
iot a - carr a geen an incr eas ed  b y a tot al  of 3. 9% 2  da ys post  en capsul ati o n indi cati ng the 
possi bil it y of p rotein abs orpti on from the cult ure  media  to the ca rra geen a n,  enabli ng cell  
att achment. This supports the findings from the proliferati on  assa y and the  observa ti ons of 
cell  att achment. Th e iot a - car ra ge enan containing c ell s showed a  3.5 % r educti on in  mass  
which, is thought to be due to degrad ati on of the gel which was visuall y appa rent when  
sampl es wer e bein g tr ansfer red to the fre ez e dr ye r  for measu reme nts . T he kapp a  
carr a ge enan sampl e s  wh ere obse rved to be mor e robust than the iot a - ca rra ge enan how eve r  
the gel int e grit y of  bot h t ypes  did redu ce  thro ugh the  durati on o f the  stud y.  Kappa -
carr a ge enan w as ini ti all y observ ed to be a s tronge r gel in compari son with iot a -
carr a ge enan  and int erest ingl y, t hese ph ysic al properties ma y be the c au se of ini ti al cell 
proli ferati on observed i n iot a - carr a geen an which were not seen in the kappa form.  
Eventual diss olut ion of iot a - ca rra geenan l ead to difficult y in quanti f yin g the prol ifer ati on 
of enc apsul ated cell s wi thi n the pol ymer  at da y 12 which a ccounts  fo r the reducti on in  
cell ular p roliferati on  m e asured  usin g th e MTT  assa y. The  gel n etwork  of the  kappa -
carr a ge enan s ampl es als o be gan  to lose  it s int egr it y ,  how ever ,  thi s was  n ot a ppar ent unti l 
da y 10 of the stud y  w hich correlates  with a dramatic incre ase in the proli ferati on  of 
encapsul ated  cell s . This is in contrast to the al gi nate sampl es which app eared  unchan ged 
throughout. T his d emons trates the n ec essi t y o f in vesti gati n g the  me ch anic al properties  of  
h ydro gel scaf folds  in rela ti on t o cell ular behaviour .       
 
3 .0  CONCL USIO N  
In conclusi on we h ave shown that cell s can b e  encapsul ated and r emain viable in both 
kappa and iot a carr a geen an  for up to 12 da ys which is comparable with alg inate which is a  
widel y used ti ssue en gineerin g subst rate. Th ere was no evidenc e of att a c hment of cell s to  
the alginat e or the kapp a  carr a geen an howev er so me att achment was evid ent when using  
iot a carr a geen an as the s caffold fo r both enc apsul ated cell s and  sur fac e see ded cell s. It wa s  
also shown that proli fer ati on  of the cell s withi n the scaffolds oc cur s  a t different rat es 
possi bl y due to the mechanic al properties and network archit e ctu re of the  gels.  
Fluctuati ons in mass w er e  also me asured  in the s c affolds  which  cor relat e d  with chan ges  in 
cell ular prolife rati on.    
 
S ubsequentl y, t his stud y has hi ghli ghted  the ne e d for investi gati ons int o  the mech anical 
pr o perties of h yd ro gels  when appli ed as cell  scaffolds. The potential for uti li sing 
biopol ym ers and mi x tu res of  biopol ym ers tradit ionall y us ed in the food and  
pharmac euti cal indus tr y for thi s purpose  is apparent  as  the  subt le dif feren ces in gel  
archit ectu re can  have  a  d ramatic eff ect on  cell  cul ture. This pr eli mi nar y stu d y su ggests  that 
both kappa and iot a - c a rr ageen an ma y be suit able  h ydro gel s  for use as a scaffold fo r ti ssue  
engin eerin g pu rposes a nd as a tool  fo r ex ami ning c ell s as proli f erati on occurs . Iota -
carr a ge enan in p articula r , ma y hav e appli c ati ons  a s a c ell  deli ver y vehicle  due to the ini ti al 
proli fe rati on and subseq uent diss olut ion . Furthermore, chemi c al modi ficati ons , and the 
developm ent of pol ymer  blends to chan ge the  str ucture  and  gelation beh a viour ma y be o f  
use to tailor the  scaf fold s  further.   
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